anno_start	anno_end	anno_text	entity_type	sentence	section
40	64	autocatalytic activation	ptm	A unified mechanism for proteolysis and autocatalytic activation in the 20S proteasome	TITLE
72	86	20S proteasome	complex_assembly	A unified mechanism for proteolysis and autocatalytic activation in the 20S proteasome	TITLE
18	32	20S proteasome	complex_assembly	Biogenesis of the 20S proteasome is tightly regulated.	ABSTRACT
15	26	propeptides	structure_element	The N-terminal propeptides protecting the active-site threonines are autocatalytically released only on completion of assembly.	ABSTRACT
42	53	active-site	site	The N-terminal propeptides protecting the active-site threonines are autocatalytically released only on completion of assembly.	ABSTRACT
54	64	threonines	residue_name	The N-terminal propeptides protecting the active-site threonines are autocatalytically released only on completion of assembly.	ABSTRACT
69	86	autocatalytically	ptm	The N-terminal propeptides protecting the active-site threonines are autocatalytically released only on completion of assembly.	ABSTRACT
68	87	strict conservation	protein_state	However, the trigger for the self-activation and the reason for the strict conservation of threonine as the active site nucleophile remain enigmatic.	ABSTRACT
91	100	threonine	residue_name	However, the trigger for the self-activation and the reason for the strict conservation of threonine as the active site nucleophile remain enigmatic.	ABSTRACT
12	23	mutagenesis	experimental_method	Here we use mutagenesis, X-ray crystallography and biochemical assays to suggest that Lys33 initiates nucleophilic attack of the propeptide by deprotonating the Thr1 hydroxyl group and that both residues together with Asp17 are part of a catalytic triad.	ABSTRACT
25	46	X-ray crystallography	experimental_method	Here we use mutagenesis, X-ray crystallography and biochemical assays to suggest that Lys33 initiates nucleophilic attack of the propeptide by deprotonating the Thr1 hydroxyl group and that both residues together with Asp17 are part of a catalytic triad.	ABSTRACT
51	69	biochemical assays	experimental_method	Here we use mutagenesis, X-ray crystallography and biochemical assays to suggest that Lys33 initiates nucleophilic attack of the propeptide by deprotonating the Thr1 hydroxyl group and that both residues together with Asp17 are part of a catalytic triad.	ABSTRACT
86	91	Lys33	residue_name_number	Here we use mutagenesis, X-ray crystallography and biochemical assays to suggest that Lys33 initiates nucleophilic attack of the propeptide by deprotonating the Thr1 hydroxyl group and that both residues together with Asp17 are part of a catalytic triad.	ABSTRACT
129	139	propeptide	structure_element	Here we use mutagenesis, X-ray crystallography and biochemical assays to suggest that Lys33 initiates nucleophilic attack of the propeptide by deprotonating the Thr1 hydroxyl group and that both residues together with Asp17 are part of a catalytic triad.	ABSTRACT
161	165	Thr1	residue_name_number	Here we use mutagenesis, X-ray crystallography and biochemical assays to suggest that Lys33 initiates nucleophilic attack of the propeptide by deprotonating the Thr1 hydroxyl group and that both residues together with Asp17 are part of a catalytic triad.	ABSTRACT
218	223	Asp17	residue_name_number	Here we use mutagenesis, X-ray crystallography and biochemical assays to suggest that Lys33 initiates nucleophilic attack of the propeptide by deprotonating the Thr1 hydroxyl group and that both residues together with Asp17 are part of a catalytic triad.	ABSTRACT
238	253	catalytic triad	site	Here we use mutagenesis, X-ray crystallography and biochemical assays to suggest that Lys33 initiates nucleophilic attack of the propeptide by deprotonating the Thr1 hydroxyl group and that both residues together with Asp17 are part of a catalytic triad.	ABSTRACT
0	12	Substitution	experimental_method	Substitution of Thr1 by Cys disrupts the interaction with Lys33 and inactivates the proteasome.	ABSTRACT
16	20	Thr1	residue_name_number	Substitution of Thr1 by Cys disrupts the interaction with Lys33 and inactivates the proteasome.	ABSTRACT
24	27	Cys	residue_name	Substitution of Thr1 by Cys disrupts the interaction with Lys33 and inactivates the proteasome.	ABSTRACT
58	63	Lys33	residue_name_number	Substitution of Thr1 by Cys disrupts the interaction with Lys33 and inactivates the proteasome.	ABSTRACT
68	79	inactivates	protein_state	Substitution of Thr1 by Cys disrupts the interaction with Lys33 and inactivates the proteasome.	ABSTRACT
84	94	proteasome	complex_assembly	Substitution of Thr1 by Cys disrupts the interaction with Lys33 and inactivates the proteasome.	ABSTRACT
11	18	Thr1Ser	mutant	Although a Thr1Ser mutant is active, it is less efficient compared with wild type because of the unfavourable orientation of Ser1 towards incoming substrates.	ABSTRACT
19	25	mutant	protein_state	Although a Thr1Ser mutant is active, it is less efficient compared with wild type because of the unfavourable orientation of Ser1 towards incoming substrates.	ABSTRACT
29	35	active	protein_state	Although a Thr1Ser mutant is active, it is less efficient compared with wild type because of the unfavourable orientation of Ser1 towards incoming substrates.	ABSTRACT
72	81	wild type	protein_state	Although a Thr1Ser mutant is active, it is less efficient compared with wild type because of the unfavourable orientation of Ser1 towards incoming substrates.	ABSTRACT
125	129	Ser1	residue_name_number	Although a Thr1Ser mutant is active, it is less efficient compared with wild type because of the unfavourable orientation of Ser1 towards incoming substrates.	ABSTRACT
72	92	propeptide autolysis	ptm	This work provides insights into the basic mechanism of proteolysis and propeptide autolysis, as well as the evolutionary pressures that drove the proteasome to become a threonine protease.	ABSTRACT
147	157	proteasome	complex_assembly	This work provides insights into the basic mechanism of proteolysis and propeptide autolysis, as well as the evolutionary pressures that drove the proteasome to become a threonine protease.	ABSTRACT
170	188	threonine protease	protein_type	This work provides insights into the basic mechanism of proteolysis and propeptide autolysis, as well as the evolutionary pressures that drove the proteasome to become a threonine protease.	ABSTRACT
5	15	proteasome	complex_assembly	 The proteasome, an essential molecular machine, is a threonine protease, but the evolution and the components of its proteolytic centre are unclear.	ABSTRACT
54	72	threonine protease	protein_type	 The proteasome, an essential molecular machine, is a threonine protease, but the evolution and the components of its proteolytic centre are unclear.	ABSTRACT
85	95	proteasome	complex_assembly	Here, the authors use structural biology and biochemistry to investigate the role of proteasome active site residues on maturation and activity.	ABSTRACT
96	107	active site	site	Here, the authors use structural biology and biochemistry to investigate the role of proteasome active site residues on maturation and activity.	ABSTRACT
4	32	20S proteasome core particle	complex_assembly	The 20S proteasome core particle (CP) is the key non-lysosomal protease of eukaryotic cells.	INTRO
34	36	CP	complex_assembly	The 20S proteasome core particle (CP) is the key non-lysosomal protease of eukaryotic cells.	INTRO
49	71	non-lysosomal protease	protein_type	The 20S proteasome core particle (CP) is the key non-lysosomal protease of eukaryotic cells.	INTRO
75	85	eukaryotic	taxonomy_domain	The 20S proteasome core particle (CP) is the key non-lysosomal protease of eukaryotic cells.	INTRO
20	21	α	protein	Its seven different α and seven different β subunits assemble into four heptameric rings that are stacked on each other to form a hollow cylinder.	INTRO
42	52	β subunits	protein	Its seven different α and seven different β subunits assemble into four heptameric rings that are stacked on each other to form a hollow cylinder.	INTRO
72	82	heptameric	oligomeric_state	Its seven different α and seven different β subunits assemble into four heptameric rings that are stacked on each other to form a hollow cylinder.	INTRO
83	88	rings	structure_element	Its seven different α and seven different β subunits assemble into four heptameric rings that are stacked on each other to form a hollow cylinder.	INTRO
130	145	hollow cylinder	structure_element	Its seven different α and seven different β subunits assemble into four heptameric rings that are stacked on each other to form a hollow cylinder.	INTRO
10	18	inactive	protein_state	While the inactive α subunits build the two outer rings, the β subunits form the inner rings.	INTRO
19	29	α subunits	protein	While the inactive α subunits build the two outer rings, the β subunits form the inner rings.	INTRO
50	55	rings	structure_element	While the inactive α subunits build the two outer rings, the β subunits form the inner rings.	INTRO
61	71	β subunits	protein	While the inactive α subunits build the two outer rings, the β subunits form the inner rings.	INTRO
87	92	rings	structure_element	While the inactive α subunits build the two outer rings, the β subunits form the inner rings.	INTRO
38	48	β subunits	protein	Only three out of the seven different β subunits, namely β1, β2 and β5, bear N-terminal proteolytic active centres, and before CP maturation these are protected by propeptides.	INTRO
57	59	β1	protein	Only three out of the seven different β subunits, namely β1, β2 and β5, bear N-terminal proteolytic active centres, and before CP maturation these are protected by propeptides.	INTRO
61	63	β2	protein	Only three out of the seven different β subunits, namely β1, β2 and β5, bear N-terminal proteolytic active centres, and before CP maturation these are protected by propeptides.	INTRO
68	70	β5	protein	Only three out of the seven different β subunits, namely β1, β2 and β5, bear N-terminal proteolytic active centres, and before CP maturation these are protected by propeptides.	INTRO
88	114	proteolytic active centres	site	Only three out of the seven different β subunits, namely β1, β2 and β5, bear N-terminal proteolytic active centres, and before CP maturation these are protected by propeptides.	INTRO
127	129	CP	complex_assembly	Only three out of the seven different β subunits, namely β1, β2 and β5, bear N-terminal proteolytic active centres, and before CP maturation these are protected by propeptides.	INTRO
164	175	propeptides	structure_element	Only three out of the seven different β subunits, namely β1, β2 and β5, bear N-terminal proteolytic active centres, and before CP maturation these are protected by propeptides.	INTRO
21	23	CP	complex_assembly	In the last stage of CP biogenesis, the prosegments are autocatalytically removed through nucleophilic attack by the active site residue Thr1 on the preceding peptide bond involving Gly(-1).	INTRO
40	51	prosegments	structure_element	In the last stage of CP biogenesis, the prosegments are autocatalytically removed through nucleophilic attack by the active site residue Thr1 on the preceding peptide bond involving Gly(-1).	INTRO
56	81	autocatalytically removed	ptm	In the last stage of CP biogenesis, the prosegments are autocatalytically removed through nucleophilic attack by the active site residue Thr1 on the preceding peptide bond involving Gly(-1).	INTRO
117	136	active site residue	site	In the last stage of CP biogenesis, the prosegments are autocatalytically removed through nucleophilic attack by the active site residue Thr1 on the preceding peptide bond involving Gly(-1).	INTRO
137	141	Thr1	residue_name_number	In the last stage of CP biogenesis, the prosegments are autocatalytically removed through nucleophilic attack by the active site residue Thr1 on the preceding peptide bond involving Gly(-1).	INTRO
182	189	Gly(-1)	residue_name_number	In the last stage of CP biogenesis, the prosegments are autocatalytically removed through nucleophilic attack by the active site residue Thr1 on the preceding peptide bond involving Gly(-1).	INTRO
15	26	propeptides	structure_element	Release of the propeptides creates a functionally active CP that cleaves proteins into short peptides.	INTRO
50	56	active	protein_state	Release of the propeptides creates a functionally active CP that cleaves proteins into short peptides.	INTRO
57	59	CP	complex_assembly	Release of the propeptides creates a functionally active CP that cleaves proteins into short peptides.	INTRO
36	61	substrate-binding channel	site	Although the chemical nature of the substrate-binding channel and hence substrate preferences are unique to each of the distinct active β subunits, all active sites employ an identical reaction mechanism to hydrolyse peptide bonds.	INTRO
129	135	active	protein_state	Although the chemical nature of the substrate-binding channel and hence substrate preferences are unique to each of the distinct active β subunits, all active sites employ an identical reaction mechanism to hydrolyse peptide bonds.	INTRO
136	146	β subunits	protein	Although the chemical nature of the substrate-binding channel and hence substrate preferences are unique to each of the distinct active β subunits, all active sites employ an identical reaction mechanism to hydrolyse peptide bonds.	INTRO
152	164	active sites	site	Although the chemical nature of the substrate-binding channel and hence substrate preferences are unique to each of the distinct active β subunits, all active sites employ an identical reaction mechanism to hydrolyse peptide bonds.	INTRO
23	27	Thr1	residue_name_number	Nucleophilic attack of Thr1Oγ on the carbonyl carbon atom of the scissile peptide bond creates a first cleavage product and a covalent acyl-enzyme intermediate.	INTRO
19	26	complex	complex_assembly	Hydrolysis of this complex by the addition of a nucleophilic water molecule regenerates the enzyme and releases the second peptide fragment.	INTRO
61	66	water	chemical	Hydrolysis of this complex by the addition of a nucleophilic water molecule regenerates the enzyme and releases the second peptide fragment.	INTRO
92	98	enzyme	complex_assembly	Hydrolysis of this complex by the addition of a nucleophilic water molecule regenerates the enzyme and releases the second peptide fragment.	INTRO
123	130	peptide	chemical	Hydrolysis of this complex by the addition of a nucleophilic water molecule regenerates the enzyme and releases the second peptide fragment.	INTRO
4	14	proteasome	complex_assembly	The proteasome belongs to the family of N-terminal nucleophilic (Ntn) hydrolases, and the free N-terminal amine group of Thr1 was proposed to deprotonate the Thr1 hydroxyl group to generate a nucleophilic Thr1Oγ for peptide-bond cleavage.	INTRO
40	80	N-terminal nucleophilic (Ntn) hydrolases	protein_type	The proteasome belongs to the family of N-terminal nucleophilic (Ntn) hydrolases, and the free N-terminal amine group of Thr1 was proposed to deprotonate the Thr1 hydroxyl group to generate a nucleophilic Thr1Oγ for peptide-bond cleavage.	INTRO
90	94	free	protein_state	The proteasome belongs to the family of N-terminal nucleophilic (Ntn) hydrolases, and the free N-terminal amine group of Thr1 was proposed to deprotonate the Thr1 hydroxyl group to generate a nucleophilic Thr1Oγ for peptide-bond cleavage.	INTRO
121	125	Thr1	residue_name_number	The proteasome belongs to the family of N-terminal nucleophilic (Ntn) hydrolases, and the free N-terminal amine group of Thr1 was proposed to deprotonate the Thr1 hydroxyl group to generate a nucleophilic Thr1Oγ for peptide-bond cleavage.	INTRO
158	162	Thr1	residue_name_number	The proteasome belongs to the family of N-terminal nucleophilic (Ntn) hydrolases, and the free N-terminal amine group of Thr1 was proposed to deprotonate the Thr1 hydroxyl group to generate a nucleophilic Thr1Oγ for peptide-bond cleavage.	INTRO
205	209	Thr1	residue_name_number	The proteasome belongs to the family of N-terminal nucleophilic (Ntn) hydrolases, and the free N-terminal amine group of Thr1 was proposed to deprotonate the Thr1 hydroxyl group to generate a nucleophilic Thr1Oγ for peptide-bond cleavage.	INTRO
40	74	autocatalytic precursor processing	ptm	This mechanism, however, cannot explain autocatalytic precursor processing because in the immature active sites, Thr1N is part of the peptide bond with Gly(-1), the bond that needs to be hydrolysed.	INTRO
90	98	immature	protein_state	This mechanism, however, cannot explain autocatalytic precursor processing because in the immature active sites, Thr1N is part of the peptide bond with Gly(-1), the bond that needs to be hydrolysed.	INTRO
99	111	active sites	site	This mechanism, however, cannot explain autocatalytic precursor processing because in the immature active sites, Thr1N is part of the peptide bond with Gly(-1), the bond that needs to be hydrolysed.	INTRO
113	117	Thr1	residue_name_number	This mechanism, however, cannot explain autocatalytic precursor processing because in the immature active sites, Thr1N is part of the peptide bond with Gly(-1), the bond that needs to be hydrolysed.	INTRO
152	159	Gly(-1)	residue_name_number	This mechanism, however, cannot explain autocatalytic precursor processing because in the immature active sites, Thr1N is part of the peptide bond with Gly(-1), the bond that needs to be hydrolysed.	INTRO
47	51	Thr1	residue_name_number	An alternative candidate for deprotonating the Thr1 hydroxyl group is the side chain of Lys33 as it is within hydrogen-bonding distance to Thr1OH (2.7 Å).	INTRO
88	93	Lys33	residue_name_number	An alternative candidate for deprotonating the Thr1 hydroxyl group is the side chain of Lys33 as it is within hydrogen-bonding distance to Thr1OH (2.7 Å).	INTRO
139	143	Thr1	residue_name_number	An alternative candidate for deprotonating the Thr1 hydroxyl group is the side chain of Lys33 as it is within hydrogen-bonding distance to Thr1OH (2.7 Å).	INTRO
63	84	autocatalytic removal	ptm	In principle it could function as the general base during both autocatalytic removal of the propeptide and protein substrate cleavage.	INTRO
92	102	propeptide	structure_element	In principle it could function as the general base during both autocatalytic removal of the propeptide and protein substrate cleavage.	INTRO
69	79	proteasome	complex_assembly	Here we provide experimental evidences for this distinct view of the proteasome active-site mechanism.	INTRO
80	91	active-site	site	Here we provide experimental evidences for this distinct view of the proteasome active-site mechanism.	INTRO
10	45	biochemical and structural analyses	experimental_method	Data from biochemical and structural analyses of proteasome variants with mutations in the β5 propeptide and the active site strongly support the model and deliver novel insights into the structural constraints required for the autocatalytic activation of the proteasome.	INTRO
91	93	β5	protein	Data from biochemical and structural analyses of proteasome variants with mutations in the β5 propeptide and the active site strongly support the model and deliver novel insights into the structural constraints required for the autocatalytic activation of the proteasome.	INTRO
94	104	propeptide	structure_element	Data from biochemical and structural analyses of proteasome variants with mutations in the β5 propeptide and the active site strongly support the model and deliver novel insights into the structural constraints required for the autocatalytic activation of the proteasome.	INTRO
113	124	active site	site	Data from biochemical and structural analyses of proteasome variants with mutations in the β5 propeptide and the active site strongly support the model and deliver novel insights into the structural constraints required for the autocatalytic activation of the proteasome.	INTRO
228	252	autocatalytic activation	ptm	Data from biochemical and structural analyses of proteasome variants with mutations in the β5 propeptide and the active site strongly support the model and deliver novel insights into the structural constraints required for the autocatalytic activation of the proteasome.	INTRO
260	270	proteasome	complex_assembly	Data from biochemical and structural analyses of proteasome variants with mutations in the β5 propeptide and the active site strongly support the model and deliver novel insights into the structural constraints required for the autocatalytic activation of the proteasome.	INTRO
44	47	Thr	residue_name	Furthermore, we determine the advantages of Thr over Cys or Ser as the active-site nucleophile using X-ray crystallography together with activity and inhibition assays.	INTRO
53	56	Cys	residue_name	Furthermore, we determine the advantages of Thr over Cys or Ser as the active-site nucleophile using X-ray crystallography together with activity and inhibition assays.	INTRO
60	63	Ser	residue_name	Furthermore, we determine the advantages of Thr over Cys or Ser as the active-site nucleophile using X-ray crystallography together with activity and inhibition assays.	INTRO
101	122	X-ray crystallography	experimental_method	Furthermore, we determine the advantages of Thr over Cys or Ser as the active-site nucleophile using X-ray crystallography together with activity and inhibition assays.	INTRO
137	167	activity and inhibition assays	experimental_method	Furthermore, we determine the advantages of Thr over Cys or Ser as the active-site nucleophile using X-ray crystallography together with activity and inhibition assays.	INTRO
16	26	proteasome	complex_assembly	Inactivation of proteasome subunits by T1A mutations	RESULTS
27	35	subunits	protein	Inactivation of proteasome subunits by T1A mutations	RESULTS
39	42	T1A	mutant	Inactivation of proteasome subunits by T1A mutations	RESULTS
43	52	mutations	experimental_method	Inactivation of proteasome subunits by T1A mutations	RESULTS
0	10	Proteasome	complex_assembly	Proteasome-mediated degradation of cell-cycle regulators and potentially toxic misfolded proteins is required for the viability of eukaryotic cells.	RESULTS
131	141	eukaryotic	taxonomy_domain	Proteasome-mediated degradation of cell-cycle regulators and potentially toxic misfolded proteins is required for the viability of eukaryotic cells.	RESULTS
20	31	active site	site	Inactivation of the active site Thr1 by mutation to Ala has been used to study substrate specificity and the hierarchy of the proteasome active sites.	RESULTS
32	36	Thr1	residue_name_number	Inactivation of the active site Thr1 by mutation to Ala has been used to study substrate specificity and the hierarchy of the proteasome active sites.	RESULTS
40	51	mutation to	experimental_method	Inactivation of the active site Thr1 by mutation to Ala has been used to study substrate specificity and the hierarchy of the proteasome active sites.	RESULTS
52	55	Ala	residue_name	Inactivation of the active site Thr1 by mutation to Ala has been used to study substrate specificity and the hierarchy of the proteasome active sites.	RESULTS
126	136	proteasome	complex_assembly	Inactivation of the active site Thr1 by mutation to Ala has been used to study substrate specificity and the hierarchy of the proteasome active sites.	RESULTS
137	149	active sites	site	Inactivation of the active site Thr1 by mutation to Ala has been used to study substrate specificity and the hierarchy of the proteasome active sites.	RESULTS
0	5	Yeast	taxonomy_domain	Yeast strains carrying the single mutations β1-T1A or β2-T1A, or both, are viable, even though one or two of the three distinct catalytic β subunits are disabled and carry remnants of their N-terminal propeptides (Table 1).	RESULTS
44	50	β1-T1A	mutant	Yeast strains carrying the single mutations β1-T1A or β2-T1A, or both, are viable, even though one or two of the three distinct catalytic β subunits are disabled and carry remnants of their N-terminal propeptides (Table 1).	RESULTS
54	60	β2-T1A	mutant	Yeast strains carrying the single mutations β1-T1A or β2-T1A, or both, are viable, even though one or two of the three distinct catalytic β subunits are disabled and carry remnants of their N-terminal propeptides (Table 1).	RESULTS
128	137	catalytic	protein_state	Yeast strains carrying the single mutations β1-T1A or β2-T1A, or both, are viable, even though one or two of the three distinct catalytic β subunits are disabled and carry remnants of their N-terminal propeptides (Table 1).	RESULTS
138	148	β subunits	protein	Yeast strains carrying the single mutations β1-T1A or β2-T1A, or both, are viable, even though one or two of the three distinct catalytic β subunits are disabled and carry remnants of their N-terminal propeptides (Table 1).	RESULTS
153	161	disabled	protein_state	Yeast strains carrying the single mutations β1-T1A or β2-T1A, or both, are viable, even though one or two of the three distinct catalytic β subunits are disabled and carry remnants of their N-terminal propeptides (Table 1).	RESULTS
166	183	carry remnants of	protein_state	Yeast strains carrying the single mutations β1-T1A or β2-T1A, or both, are viable, even though one or two of the three distinct catalytic β subunits are disabled and carry remnants of their N-terminal propeptides (Table 1).	RESULTS
201	212	propeptides	structure_element	Yeast strains carrying the single mutations β1-T1A or β2-T1A, or both, are viable, even though one or two of the three distinct catalytic β subunits are disabled and carry remnants of their N-terminal propeptides (Table 1).	RESULTS
32	34	β1	protein	These results indicate that the β1 and β2 proteolytic activities are not essential for cell survival.	RESULTS
39	41	β2	protein	These results indicate that the β1 and β2 proteolytic activities are not essential for cell survival.	RESULTS
17	20	T1A	mutant	By contrast, the T1A mutation in subunit β5 has been reported to be lethal or nearly so.	RESULTS
41	43	β5	protein	By contrast, the T1A mutation in subunit β5 has been reported to be lethal or nearly so.	RESULTS
29	35	β5-T1A	mutant	Viability is restored if the β5-T1A subunit has its propeptide (pp) deleted but expressed separately in trans (β5-T1A pp trans), although substantial phenotypic impairment remains (Table 1).	RESULTS
52	62	propeptide	structure_element	Viability is restored if the β5-T1A subunit has its propeptide (pp) deleted but expressed separately in trans (β5-T1A pp trans), although substantial phenotypic impairment remains (Table 1).	RESULTS
64	66	pp	chemical	Viability is restored if the β5-T1A subunit has its propeptide (pp) deleted but expressed separately in trans (β5-T1A pp trans), although substantial phenotypic impairment remains (Table 1).	RESULTS
68	100	deleted but expressed separately	experimental_method	Viability is restored if the β5-T1A subunit has its propeptide (pp) deleted but expressed separately in trans (β5-T1A pp trans), although substantial phenotypic impairment remains (Table 1).	RESULTS
104	109	trans	protein_state	Viability is restored if the β5-T1A subunit has its propeptide (pp) deleted but expressed separately in trans (β5-T1A pp trans), although substantial phenotypic impairment remains (Table 1).	RESULTS
111	117	β5-T1A	mutant	Viability is restored if the β5-T1A subunit has its propeptide (pp) deleted but expressed separately in trans (β5-T1A pp trans), although substantial phenotypic impairment remains (Table 1).	RESULTS
118	120	pp	chemical	Viability is restored if the β5-T1A subunit has its propeptide (pp) deleted but expressed separately in trans (β5-T1A pp trans), although substantial phenotypic impairment remains (Table 1).	RESULTS
121	126	trans	protein_state	Viability is restored if the β5-T1A subunit has its propeptide (pp) deleted but expressed separately in trans (β5-T1A pp trans), although substantial phenotypic impairment remains (Table 1).	RESULTS
12	37	crystallographic analysis	experimental_method	Our present crystallographic analysis of the β5-T1A pp trans mutant demonstrates that the mutation per se does not structurally alter the catalytic active site and that the trans-expressed β5 propeptide is not bound in the β5 substrate-binding channel (Supplementary Fig. 1a).	RESULTS
45	51	β5-T1A	mutant	Our present crystallographic analysis of the β5-T1A pp trans mutant demonstrates that the mutation per se does not structurally alter the catalytic active site and that the trans-expressed β5 propeptide is not bound in the β5 substrate-binding channel (Supplementary Fig. 1a).	RESULTS
52	54	pp	chemical	Our present crystallographic analysis of the β5-T1A pp trans mutant demonstrates that the mutation per se does not structurally alter the catalytic active site and that the trans-expressed β5 propeptide is not bound in the β5 substrate-binding channel (Supplementary Fig. 1a).	RESULTS
55	60	trans	protein_state	Our present crystallographic analysis of the β5-T1A pp trans mutant demonstrates that the mutation per se does not structurally alter the catalytic active site and that the trans-expressed β5 propeptide is not bound in the β5 substrate-binding channel (Supplementary Fig. 1a).	RESULTS
61	67	mutant	protein_state	Our present crystallographic analysis of the β5-T1A pp trans mutant demonstrates that the mutation per se does not structurally alter the catalytic active site and that the trans-expressed β5 propeptide is not bound in the β5 substrate-binding channel (Supplementary Fig. 1a).	RESULTS
90	98	mutation	experimental_method	Our present crystallographic analysis of the β5-T1A pp trans mutant demonstrates that the mutation per se does not structurally alter the catalytic active site and that the trans-expressed β5 propeptide is not bound in the β5 substrate-binding channel (Supplementary Fig. 1a).	RESULTS
138	159	catalytic active site	site	Our present crystallographic analysis of the β5-T1A pp trans mutant demonstrates that the mutation per se does not structurally alter the catalytic active site and that the trans-expressed β5 propeptide is not bound in the β5 substrate-binding channel (Supplementary Fig. 1a).	RESULTS
173	188	trans-expressed	experimental_method	Our present crystallographic analysis of the β5-T1A pp trans mutant demonstrates that the mutation per se does not structurally alter the catalytic active site and that the trans-expressed β5 propeptide is not bound in the β5 substrate-binding channel (Supplementary Fig. 1a).	RESULTS
189	191	β5	protein	Our present crystallographic analysis of the β5-T1A pp trans mutant demonstrates that the mutation per se does not structurally alter the catalytic active site and that the trans-expressed β5 propeptide is not bound in the β5 substrate-binding channel (Supplementary Fig. 1a).	RESULTS
192	202	propeptide	structure_element	Our present crystallographic analysis of the β5-T1A pp trans mutant demonstrates that the mutation per se does not structurally alter the catalytic active site and that the trans-expressed β5 propeptide is not bound in the β5 substrate-binding channel (Supplementary Fig. 1a).	RESULTS
206	215	not bound	protein_state	Our present crystallographic analysis of the β5-T1A pp trans mutant demonstrates that the mutation per se does not structurally alter the catalytic active site and that the trans-expressed β5 propeptide is not bound in the β5 substrate-binding channel (Supplementary Fig. 1a).	RESULTS
223	225	β5	protein	Our present crystallographic analysis of the β5-T1A pp trans mutant demonstrates that the mutation per se does not structurally alter the catalytic active site and that the trans-expressed β5 propeptide is not bound in the β5 substrate-binding channel (Supplementary Fig. 1a).	RESULTS
226	251	substrate-binding channel	site	Our present crystallographic analysis of the β5-T1A pp trans mutant demonstrates that the mutation per se does not structurally alter the catalytic active site and that the trans-expressed β5 propeptide is not bound in the β5 substrate-binding channel (Supplementary Fig. 1a).	RESULTS
33	39	β5-T1A	mutant	The extremely weak growth of the β5-T1A mutant pp cis described by Chen and Hochstrasser compared with the inviability reported by Heinemeyer et al. prompted us to analyse this discrepancy.	RESULTS
40	46	mutant	protein_state	The extremely weak growth of the β5-T1A mutant pp cis described by Chen and Hochstrasser compared with the inviability reported by Heinemeyer et al. prompted us to analyse this discrepancy.	RESULTS
47	49	pp	chemical	The extremely weak growth of the β5-T1A mutant pp cis described by Chen and Hochstrasser compared with the inviability reported by Heinemeyer et al. prompted us to analyse this discrepancy.	RESULTS
50	53	cis	protein_state	The extremely weak growth of the β5-T1A mutant pp cis described by Chen and Hochstrasser compared with the inviability reported by Heinemeyer et al. prompted us to analyse this discrepancy.	RESULTS
0	26	Sequencing of the plasmids	experimental_method	Sequencing of the plasmids, testing them in both published yeast strain backgrounds and site-directed mutagenesis revealed that the β5-T1A mutant pp cis is viable, but suffers from a marked growth defect that requires extended incubation of 4–5 days for initial colony formation (Table 1 and Supplementary Methods).	RESULTS
59	64	yeast	taxonomy_domain	Sequencing of the plasmids, testing them in both published yeast strain backgrounds and site-directed mutagenesis revealed that the β5-T1A mutant pp cis is viable, but suffers from a marked growth defect that requires extended incubation of 4–5 days for initial colony formation (Table 1 and Supplementary Methods).	RESULTS
88	113	site-directed mutagenesis	experimental_method	Sequencing of the plasmids, testing them in both published yeast strain backgrounds and site-directed mutagenesis revealed that the β5-T1A mutant pp cis is viable, but suffers from a marked growth defect that requires extended incubation of 4–5 days for initial colony formation (Table 1 and Supplementary Methods).	RESULTS
132	138	β5-T1A	mutant	Sequencing of the plasmids, testing them in both published yeast strain backgrounds and site-directed mutagenesis revealed that the β5-T1A mutant pp cis is viable, but suffers from a marked growth defect that requires extended incubation of 4–5 days for initial colony formation (Table 1 and Supplementary Methods).	RESULTS
139	145	mutant	protein_state	Sequencing of the plasmids, testing them in both published yeast strain backgrounds and site-directed mutagenesis revealed that the β5-T1A mutant pp cis is viable, but suffers from a marked growth defect that requires extended incubation of 4–5 days for initial colony formation (Table 1 and Supplementary Methods).	RESULTS
146	148	pp	chemical	Sequencing of the plasmids, testing them in both published yeast strain backgrounds and site-directed mutagenesis revealed that the β5-T1A mutant pp cis is viable, but suffers from a marked growth defect that requires extended incubation of 4–5 days for initial colony formation (Table 1 and Supplementary Methods).	RESULTS
149	152	cis	protein_state	Sequencing of the plasmids, testing them in both published yeast strain backgrounds and site-directed mutagenesis revealed that the β5-T1A mutant pp cis is viable, but suffers from a marked growth defect that requires extended incubation of 4–5 days for initial colony formation (Table 1 and Supplementary Methods).	RESULTS
48	52	K81R	mutant	We also identified an additional point mutation K81R in subunit β5 that was present in the allele used in ref.. This single amino-acid exchange is located at the interface of the subunits α4, β4 and β5 (Supplementary Fig. 1b) and might weakly promote CP assembly by enhancing inter-subunit contacts.	RESULTS
64	66	β5	protein	We also identified an additional point mutation K81R in subunit β5 that was present in the allele used in ref.. This single amino-acid exchange is located at the interface of the subunits α4, β4 and β5 (Supplementary Fig. 1b) and might weakly promote CP assembly by enhancing inter-subunit contacts.	RESULTS
112	143	This single amino-acid exchange	experimental_method	We also identified an additional point mutation K81R in subunit β5 that was present in the allele used in ref.. This single amino-acid exchange is located at the interface of the subunits α4, β4 and β5 (Supplementary Fig. 1b) and might weakly promote CP assembly by enhancing inter-subunit contacts.	RESULTS
162	171	interface	site	We also identified an additional point mutation K81R in subunit β5 that was present in the allele used in ref.. This single amino-acid exchange is located at the interface of the subunits α4, β4 and β5 (Supplementary Fig. 1b) and might weakly promote CP assembly by enhancing inter-subunit contacts.	RESULTS
188	190	α4	protein	We also identified an additional point mutation K81R in subunit β5 that was present in the allele used in ref.. This single amino-acid exchange is located at the interface of the subunits α4, β4 and β5 (Supplementary Fig. 1b) and might weakly promote CP assembly by enhancing inter-subunit contacts.	RESULTS
192	194	β4	protein	We also identified an additional point mutation K81R in subunit β5 that was present in the allele used in ref.. This single amino-acid exchange is located at the interface of the subunits α4, β4 and β5 (Supplementary Fig. 1b) and might weakly promote CP assembly by enhancing inter-subunit contacts.	RESULTS
199	201	β5	protein	We also identified an additional point mutation K81R in subunit β5 that was present in the allele used in ref.. This single amino-acid exchange is located at the interface of the subunits α4, β4 and β5 (Supplementary Fig. 1b) and might weakly promote CP assembly by enhancing inter-subunit contacts.	RESULTS
251	253	CP	complex_assembly	We also identified an additional point mutation K81R in subunit β5 that was present in the allele used in ref.. This single amino-acid exchange is located at the interface of the subunits α4, β4 and β5 (Supplementary Fig. 1b) and might weakly promote CP assembly by enhancing inter-subunit contacts.	RESULTS
34	45	β5-T1A-K81R	mutant	The slightly better growth of the β5-T1A-K81R mutant allowed us to solve the crystal structure of a yeast proteasome (yCP) with the β5-T1A mutation, which is discussed in the following section (for details see Supplementary Note 1).	RESULTS
46	52	mutant	protein_state	The slightly better growth of the β5-T1A-K81R mutant allowed us to solve the crystal structure of a yeast proteasome (yCP) with the β5-T1A mutation, which is discussed in the following section (for details see Supplementary Note 1).	RESULTS
77	94	crystal structure	evidence	The slightly better growth of the β5-T1A-K81R mutant allowed us to solve the crystal structure of a yeast proteasome (yCP) with the β5-T1A mutation, which is discussed in the following section (for details see Supplementary Note 1).	RESULTS
100	105	yeast	taxonomy_domain	The slightly better growth of the β5-T1A-K81R mutant allowed us to solve the crystal structure of a yeast proteasome (yCP) with the β5-T1A mutation, which is discussed in the following section (for details see Supplementary Note 1).	RESULTS
106	116	proteasome	complex_assembly	The slightly better growth of the β5-T1A-K81R mutant allowed us to solve the crystal structure of a yeast proteasome (yCP) with the β5-T1A mutation, which is discussed in the following section (for details see Supplementary Note 1).	RESULTS
118	121	yCP	complex_assembly	The slightly better growth of the β5-T1A-K81R mutant allowed us to solve the crystal structure of a yeast proteasome (yCP) with the β5-T1A mutation, which is discussed in the following section (for details see Supplementary Note 1).	RESULTS
132	138	β5-T1A	mutant	The slightly better growth of the β5-T1A-K81R mutant allowed us to solve the crystal structure of a yeast proteasome (yCP) with the β5-T1A mutation, which is discussed in the following section (for details see Supplementary Note 1).	RESULTS
0	10	Propeptide	structure_element	Propeptide conformation and triggering of autolysis	RESULTS
42	51	autolysis	ptm	Propeptide conformation and triggering of autolysis	RESULTS
22	32	proteasome	complex_assembly	In the final steps of proteasome biogenesis, the propeptides are autocatalytically cleaved from the mature β-subunit domains.	RESULTS
49	60	propeptides	structure_element	In the final steps of proteasome biogenesis, the propeptides are autocatalytically cleaved from the mature β-subunit domains.	RESULTS
65	90	autocatalytically cleaved	ptm	In the final steps of proteasome biogenesis, the propeptides are autocatalytically cleaved from the mature β-subunit domains.	RESULTS
100	106	mature	protein_state	In the final steps of proteasome biogenesis, the propeptides are autocatalytically cleaved from the mature β-subunit domains.	RESULTS
107	124	β-subunit domains	protein	In the final steps of proteasome biogenesis, the propeptides are autocatalytically cleaved from the mature β-subunit domains.	RESULTS
12	14	β1	protein	For subunit β1, this process was previously inferred to require that the propeptide residue at position (-2) of the subunit precursor occupies the S1 specificity pocket of the substrate-binding channel formed by amino acid 45 (for details see Supplementary Note 2).	RESULTS
73	83	propeptide	structure_element	For subunit β1, this process was previously inferred to require that the propeptide residue at position (-2) of the subunit precursor occupies the S1 specificity pocket of the substrate-binding channel formed by amino acid 45 (for details see Supplementary Note 2).	RESULTS
104	108	(-2)	residue_number	For subunit β1, this process was previously inferred to require that the propeptide residue at position (-2) of the subunit precursor occupies the S1 specificity pocket of the substrate-binding channel formed by amino acid 45 (for details see Supplementary Note 2).	RESULTS
147	168	S1 specificity pocket	site	For subunit β1, this process was previously inferred to require that the propeptide residue at position (-2) of the subunit precursor occupies the S1 specificity pocket of the substrate-binding channel formed by amino acid 45 (for details see Supplementary Note 2).	RESULTS
176	201	substrate-binding channel	site	For subunit β1, this process was previously inferred to require that the propeptide residue at position (-2) of the subunit precursor occupies the S1 specificity pocket of the substrate-binding channel formed by amino acid 45 (for details see Supplementary Note 2).	RESULTS
223	225	45	residue_number	For subunit β1, this process was previously inferred to require that the propeptide residue at position (-2) of the subunit precursor occupies the S1 specificity pocket of the substrate-binding channel formed by amino acid 45 (for details see Supplementary Note 2).	RESULTS
38	48	prosegment	structure_element	Furthermore, it was observed that the prosegment forms an antiparallel β-sheet in the active site, and that Gly(-1) adopts a γ-turn conformation, which by definition is characterized by a hydrogen bond between Leu(-2)O and Thr1NH (ref.).	RESULTS
58	78	antiparallel β-sheet	structure_element	Furthermore, it was observed that the prosegment forms an antiparallel β-sheet in the active site, and that Gly(-1) adopts a γ-turn conformation, which by definition is characterized by a hydrogen bond between Leu(-2)O and Thr1NH (ref.).	RESULTS
86	97	active site	site	Furthermore, it was observed that the prosegment forms an antiparallel β-sheet in the active site, and that Gly(-1) adopts a γ-turn conformation, which by definition is characterized by a hydrogen bond between Leu(-2)O and Thr1NH (ref.).	RESULTS
108	115	Gly(-1)	residue_name_number	Furthermore, it was observed that the prosegment forms an antiparallel β-sheet in the active site, and that Gly(-1) adopts a γ-turn conformation, which by definition is characterized by a hydrogen bond between Leu(-2)O and Thr1NH (ref.).	RESULTS
125	144	γ-turn conformation	structure_element	Furthermore, it was observed that the prosegment forms an antiparallel β-sheet in the active site, and that Gly(-1) adopts a γ-turn conformation, which by definition is characterized by a hydrogen bond between Leu(-2)O and Thr1NH (ref.).	RESULTS
210	217	Leu(-2)	residue_name_number	Furthermore, it was observed that the prosegment forms an antiparallel β-sheet in the active site, and that Gly(-1) adopts a γ-turn conformation, which by definition is characterized by a hydrogen bond between Leu(-2)O and Thr1NH (ref.).	RESULTS
223	227	Thr1	residue_name_number	Furthermore, it was observed that the prosegment forms an antiparallel β-sheet in the active site, and that Gly(-1) adopts a γ-turn conformation, which by definition is characterized by a hydrogen bond between Leu(-2)O and Thr1NH (ref.).	RESULTS
27	33	β1-T1A	mutant	Here we again analysed the β1-T1A mutant crystallographically but in addition determined the structures of the β2-T1A single and β1-T1A-β2-T1A double mutants (Protein Data Bank (PDB) entry codes are provided in Supplementary Table 1).	RESULTS
34	40	mutant	protein_state	Here we again analysed the β1-T1A mutant crystallographically but in addition determined the structures of the β2-T1A single and β1-T1A-β2-T1A double mutants (Protein Data Bank (PDB) entry codes are provided in Supplementary Table 1).	RESULTS
41	61	crystallographically	experimental_method	Here we again analysed the β1-T1A mutant crystallographically but in addition determined the structures of the β2-T1A single and β1-T1A-β2-T1A double mutants (Protein Data Bank (PDB) entry codes are provided in Supplementary Table 1).	RESULTS
93	103	structures	evidence	Here we again analysed the β1-T1A mutant crystallographically but in addition determined the structures of the β2-T1A single and β1-T1A-β2-T1A double mutants (Protein Data Bank (PDB) entry codes are provided in Supplementary Table 1).	RESULTS
111	117	β2-T1A	mutant	Here we again analysed the β1-T1A mutant crystallographically but in addition determined the structures of the β2-T1A single and β1-T1A-β2-T1A double mutants (Protein Data Bank (PDB) entry codes are provided in Supplementary Table 1).	RESULTS
129	142	β1-T1A-β2-T1A	mutant	Here we again analysed the β1-T1A mutant crystallographically but in addition determined the structures of the β2-T1A single and β1-T1A-β2-T1A double mutants (Protein Data Bank (PDB) entry codes are provided in Supplementary Table 1).	RESULTS
11	13	β1	protein	In subunit β1, we found that Gly(-1) indeed forms a sharp turn, which relaxes on prosegment cleavage (Fig. 1a and Supplementary Fig. 2a).	RESULTS
29	36	Gly(-1)	residue_name_number	In subunit β1, we found that Gly(-1) indeed forms a sharp turn, which relaxes on prosegment cleavage (Fig. 1a and Supplementary Fig. 2a).	RESULTS
52	62	sharp turn	structure_element	In subunit β1, we found that Gly(-1) indeed forms a sharp turn, which relaxes on prosegment cleavage (Fig. 1a and Supplementary Fig. 2a).	RESULTS
81	100	prosegment cleavage	ptm	In subunit β1, we found that Gly(-1) indeed forms a sharp turn, which relaxes on prosegment cleavage (Fig. 1a and Supplementary Fig. 2a).	RESULTS
13	32	γ-turn conformation	structure_element	However, the γ-turn conformation and the associated hydrogen bond initially proposed is for geometric and chemical reasons inappropriate and would not perfectly position the carbonyl carbon atom of Gly(-1) for nucleophilic attack by Thr1.	RESULTS
198	205	Gly(-1)	residue_name_number	However, the γ-turn conformation and the associated hydrogen bond initially proposed is for geometric and chemical reasons inappropriate and would not perfectly position the carbonyl carbon atom of Gly(-1) for nucleophilic attack by Thr1.	RESULTS
233	237	Thr1	residue_name_number	However, the γ-turn conformation and the associated hydrogen bond initially proposed is for geometric and chemical reasons inappropriate and would not perfectly position the carbonyl carbon atom of Gly(-1) for nucleophilic attack by Thr1.	RESULTS
14	16	β2	protein	Regarding the β2 propeptide, Thr(-2) occupies the S1 pocket but is less deeply anchored compared with Leu(-2) in β1, which might be due to the rather large β2-S1 pocket created by Gly45.	RESULTS
17	27	propeptide	structure_element	Regarding the β2 propeptide, Thr(-2) occupies the S1 pocket but is less deeply anchored compared with Leu(-2) in β1, which might be due to the rather large β2-S1 pocket created by Gly45.	RESULTS
29	36	Thr(-2)	residue_name_number	Regarding the β2 propeptide, Thr(-2) occupies the S1 pocket but is less deeply anchored compared with Leu(-2) in β1, which might be due to the rather large β2-S1 pocket created by Gly45.	RESULTS
50	59	S1 pocket	site	Regarding the β2 propeptide, Thr(-2) occupies the S1 pocket but is less deeply anchored compared with Leu(-2) in β1, which might be due to the rather large β2-S1 pocket created by Gly45.	RESULTS
102	109	Leu(-2)	residue_name_number	Regarding the β2 propeptide, Thr(-2) occupies the S1 pocket but is less deeply anchored compared with Leu(-2) in β1, which might be due to the rather large β2-S1 pocket created by Gly45.	RESULTS
113	115	β1	protein	Regarding the β2 propeptide, Thr(-2) occupies the S1 pocket but is less deeply anchored compared with Leu(-2) in β1, which might be due to the rather large β2-S1 pocket created by Gly45.	RESULTS
156	158	β2	protein	Regarding the β2 propeptide, Thr(-2) occupies the S1 pocket but is less deeply anchored compared with Leu(-2) in β1, which might be due to the rather large β2-S1 pocket created by Gly45.	RESULTS
159	168	S1 pocket	site	Regarding the β2 propeptide, Thr(-2) occupies the S1 pocket but is less deeply anchored compared with Leu(-2) in β1, which might be due to the rather large β2-S1 pocket created by Gly45.	RESULTS
180	185	Gly45	residue_name_number	Regarding the β2 propeptide, Thr(-2) occupies the S1 pocket but is less deeply anchored compared with Leu(-2) in β1, which might be due to the rather large β2-S1 pocket created by Gly45.	RESULTS
0	7	Thr(-2)	residue_name_number	Thr(-2) positions Gly(-1)O via hydrogen bonding (∼2.8 Å) in a perfect trajectory for the nucleophilic attack by Thr1Oγ (Fig. 1b and Supplementary Fig. 2b).	RESULTS
18	25	Gly(-1)	residue_name_number	Thr(-2) positions Gly(-1)O via hydrogen bonding (∼2.8 Å) in a perfect trajectory for the nucleophilic attack by Thr1Oγ (Fig. 1b and Supplementary Fig. 2b).	RESULTS
112	116	Thr1	residue_name_number	Thr(-2) positions Gly(-1)O via hydrogen bonding (∼2.8 Å) in a perfect trajectory for the nucleophilic attack by Thr1Oγ (Fig. 1b and Supplementary Fig. 2b).	RESULTS
38	40	β5	protein	Next, we examined the position of the β5 propeptide in the β5-T1A-K81R mutant.	RESULTS
41	51	propeptide	structure_element	Next, we examined the position of the β5 propeptide in the β5-T1A-K81R mutant.	RESULTS
59	70	β5-T1A-K81R	mutant	Next, we examined the position of the β5 propeptide in the β5-T1A-K81R mutant.	RESULTS
71	77	mutant	protein_state	Next, we examined the position of the β5 propeptide in the β5-T1A-K81R mutant.	RESULTS
14	21	Gly(-1)	residue_name_number	Surprisingly, Gly(-1) is completely extended and forces the histidine side chain at position (-2) to occupy the S2 instead of the S1 pocket, thereby disrupting the antiparallel β-sheet.	RESULTS
60	69	histidine	residue_name	Surprisingly, Gly(-1) is completely extended and forces the histidine side chain at position (-2) to occupy the S2 instead of the S1 pocket, thereby disrupting the antiparallel β-sheet.	RESULTS
93	97	(-2)	residue_number	Surprisingly, Gly(-1) is completely extended and forces the histidine side chain at position (-2) to occupy the S2 instead of the S1 pocket, thereby disrupting the antiparallel β-sheet.	RESULTS
112	114	S2	site	Surprisingly, Gly(-1) is completely extended and forces the histidine side chain at position (-2) to occupy the S2 instead of the S1 pocket, thereby disrupting the antiparallel β-sheet.	RESULTS
130	139	S1 pocket	site	Surprisingly, Gly(-1) is completely extended and forces the histidine side chain at position (-2) to occupy the S2 instead of the S1 pocket, thereby disrupting the antiparallel β-sheet.	RESULTS
164	184	antiparallel β-sheet	structure_element	Surprisingly, Gly(-1) is completely extended and forces the histidine side chain at position (-2) to occupy the S2 instead of the S1 pocket, thereby disrupting the antiparallel β-sheet.	RESULTS
36	43	Gly(-1)	residue_name_number	Nonetheless, the carbonyl carbon of Gly(-1) would be ideally placed for nucleophilic attack by Thr1Oγ (Fig. 1c and Supplementary Fig. 2c,d).	RESULTS
95	99	Thr1	residue_name_number	Nonetheless, the carbonyl carbon of Gly(-1) would be ideally placed for nucleophilic attack by Thr1Oγ (Fig. 1c and Supplementary Fig. 2c,d).	RESULTS
7	11	K81R	mutant	As the K81R mutation is located far from the active site (Thr1Cα–Arg81Cα: 24 Å), any influence on propeptide conformation can be excluded.	RESULTS
45	56	active site	site	As the K81R mutation is located far from the active site (Thr1Cα–Arg81Cα: 24 Å), any influence on propeptide conformation can be excluded.	RESULTS
58	62	Thr1	residue_name_number	As the K81R mutation is located far from the active site (Thr1Cα–Arg81Cα: 24 Å), any influence on propeptide conformation can be excluded.	RESULTS
65	70	Arg81	residue_name_number	As the K81R mutation is located far from the active site (Thr1Cα–Arg81Cα: 24 Å), any influence on propeptide conformation can be excluded.	RESULTS
98	108	propeptide	structure_element	As the K81R mutation is located far from the active site (Thr1Cα–Arg81Cα: 24 Å), any influence on propeptide conformation can be excluded.	RESULTS
31	33	β5	protein	Instead, the plasticity of the β5 S1 pocket caused by the rotational flexibility of Met45 might prevent stable accommodation of His(-2) in the S1 site and thus also promote its immediate release after autolysis.	RESULTS
34	43	S1 pocket	site	Instead, the plasticity of the β5 S1 pocket caused by the rotational flexibility of Met45 might prevent stable accommodation of His(-2) in the S1 site and thus also promote its immediate release after autolysis.	RESULTS
84	89	Met45	residue_name_number	Instead, the plasticity of the β5 S1 pocket caused by the rotational flexibility of Met45 might prevent stable accommodation of His(-2) in the S1 site and thus also promote its immediate release after autolysis.	RESULTS
128	135	His(-2)	residue_name_number	Instead, the plasticity of the β5 S1 pocket caused by the rotational flexibility of Met45 might prevent stable accommodation of His(-2) in the S1 site and thus also promote its immediate release after autolysis.	RESULTS
143	150	S1 site	site	Instead, the plasticity of the β5 S1 pocket caused by the rotational flexibility of Met45 might prevent stable accommodation of His(-2) in the S1 site and thus also promote its immediate release after autolysis.	RESULTS
201	210	autolysis	ptm	Instead, the plasticity of the β5 S1 pocket caused by the rotational flexibility of Met45 might prevent stable accommodation of His(-2) in the S1 site and thus also promote its immediate release after autolysis.	RESULTS
61	65	Thr1	residue_name_number	Processing of β-subunit precursors requires deprotonation of Thr1OH; however, the general base initiating autolysis is unknown.	RESULTS
106	115	autolysis	ptm	Processing of β-subunit precursors requires deprotonation of Thr1OH; however, the general base initiating autolysis is unknown.	RESULTS
12	22	eukaryotic	taxonomy_domain	Remarkably, eukaryotic proteasomal β5 subunits bear a His residue in position (-2) of the propeptide (Supplementary Fig. 3a).	RESULTS
35	37	β5	protein	Remarkably, eukaryotic proteasomal β5 subunits bear a His residue in position (-2) of the propeptide (Supplementary Fig. 3a).	RESULTS
54	57	His	residue_name	Remarkably, eukaryotic proteasomal β5 subunits bear a His residue in position (-2) of the propeptide (Supplementary Fig. 3a).	RESULTS
78	82	(-2)	residue_number	Remarkably, eukaryotic proteasomal β5 subunits bear a His residue in position (-2) of the propeptide (Supplementary Fig. 3a).	RESULTS
90	100	propeptide	structure_element	Remarkably, eukaryotic proteasomal β5 subunits bear a His residue in position (-2) of the propeptide (Supplementary Fig. 3a).	RESULTS
3	12	histidine	residue_name	As histidine commonly functions as a proton shuttle in the catalytic triads of serine proteases, we investigated the role of His(-2) in processing of the β5 propeptide by exchanging it for Asn, Lys, Phe and Ala. All yeast mutants were viable at 30 °C, but suffered from growth defects at 37 °C with the H(-2)N and H(-2)F mutants being most affected (Supplementary Fig. 3b and Table 1).	RESULTS
59	75	catalytic triads	site	As histidine commonly functions as a proton shuttle in the catalytic triads of serine proteases, we investigated the role of His(-2) in processing of the β5 propeptide by exchanging it for Asn, Lys, Phe and Ala. All yeast mutants were viable at 30 °C, but suffered from growth defects at 37 °C with the H(-2)N and H(-2)F mutants being most affected (Supplementary Fig. 3b and Table 1).	RESULTS
79	95	serine proteases	protein_type	As histidine commonly functions as a proton shuttle in the catalytic triads of serine proteases, we investigated the role of His(-2) in processing of the β5 propeptide by exchanging it for Asn, Lys, Phe and Ala. All yeast mutants were viable at 30 °C, but suffered from growth defects at 37 °C with the H(-2)N and H(-2)F mutants being most affected (Supplementary Fig. 3b and Table 1).	RESULTS
125	132	His(-2)	residue_name_number	As histidine commonly functions as a proton shuttle in the catalytic triads of serine proteases, we investigated the role of His(-2) in processing of the β5 propeptide by exchanging it for Asn, Lys, Phe and Ala. All yeast mutants were viable at 30 °C, but suffered from growth defects at 37 °C with the H(-2)N and H(-2)F mutants being most affected (Supplementary Fig. 3b and Table 1).	RESULTS
154	156	β5	protein	As histidine commonly functions as a proton shuttle in the catalytic triads of serine proteases, we investigated the role of His(-2) in processing of the β5 propeptide by exchanging it for Asn, Lys, Phe and Ala. All yeast mutants were viable at 30 °C, but suffered from growth defects at 37 °C with the H(-2)N and H(-2)F mutants being most affected (Supplementary Fig. 3b and Table 1).	RESULTS
157	167	propeptide	structure_element	As histidine commonly functions as a proton shuttle in the catalytic triads of serine proteases, we investigated the role of His(-2) in processing of the β5 propeptide by exchanging it for Asn, Lys, Phe and Ala. All yeast mutants were viable at 30 °C, but suffered from growth defects at 37 °C with the H(-2)N and H(-2)F mutants being most affected (Supplementary Fig. 3b and Table 1).	RESULTS
171	188	exchanging it for	experimental_method	As histidine commonly functions as a proton shuttle in the catalytic triads of serine proteases, we investigated the role of His(-2) in processing of the β5 propeptide by exchanging it for Asn, Lys, Phe and Ala. All yeast mutants were viable at 30 °C, but suffered from growth defects at 37 °C with the H(-2)N and H(-2)F mutants being most affected (Supplementary Fig. 3b and Table 1).	RESULTS
189	192	Asn	residue_name	As histidine commonly functions as a proton shuttle in the catalytic triads of serine proteases, we investigated the role of His(-2) in processing of the β5 propeptide by exchanging it for Asn, Lys, Phe and Ala. All yeast mutants were viable at 30 °C, but suffered from growth defects at 37 °C with the H(-2)N and H(-2)F mutants being most affected (Supplementary Fig. 3b and Table 1).	RESULTS
194	197	Lys	residue_name	As histidine commonly functions as a proton shuttle in the catalytic triads of serine proteases, we investigated the role of His(-2) in processing of the β5 propeptide by exchanging it for Asn, Lys, Phe and Ala. All yeast mutants were viable at 30 °C, but suffered from growth defects at 37 °C with the H(-2)N and H(-2)F mutants being most affected (Supplementary Fig. 3b and Table 1).	RESULTS
199	202	Phe	residue_name	As histidine commonly functions as a proton shuttle in the catalytic triads of serine proteases, we investigated the role of His(-2) in processing of the β5 propeptide by exchanging it for Asn, Lys, Phe and Ala. All yeast mutants were viable at 30 °C, but suffered from growth defects at 37 °C with the H(-2)N and H(-2)F mutants being most affected (Supplementary Fig. 3b and Table 1).	RESULTS
207	210	Ala	residue_name	As histidine commonly functions as a proton shuttle in the catalytic triads of serine proteases, we investigated the role of His(-2) in processing of the β5 propeptide by exchanging it for Asn, Lys, Phe and Ala. All yeast mutants were viable at 30 °C, but suffered from growth defects at 37 °C with the H(-2)N and H(-2)F mutants being most affected (Supplementary Fig. 3b and Table 1).	RESULTS
216	221	yeast	taxonomy_domain	As histidine commonly functions as a proton shuttle in the catalytic triads of serine proteases, we investigated the role of His(-2) in processing of the β5 propeptide by exchanging it for Asn, Lys, Phe and Ala. All yeast mutants were viable at 30 °C, but suffered from growth defects at 37 °C with the H(-2)N and H(-2)F mutants being most affected (Supplementary Fig. 3b and Table 1).	RESULTS
303	309	H(-2)N	mutant	As histidine commonly functions as a proton shuttle in the catalytic triads of serine proteases, we investigated the role of His(-2) in processing of the β5 propeptide by exchanging it for Asn, Lys, Phe and Ala. All yeast mutants were viable at 30 °C, but suffered from growth defects at 37 °C with the H(-2)N and H(-2)F mutants being most affected (Supplementary Fig. 3b and Table 1).	RESULTS
314	320	H(-2)F	mutant	As histidine commonly functions as a proton shuttle in the catalytic triads of serine proteases, we investigated the role of His(-2) in processing of the β5 propeptide by exchanging it for Asn, Lys, Phe and Ala. All yeast mutants were viable at 30 °C, but suffered from growth defects at 37 °C with the H(-2)N and H(-2)F mutants being most affected (Supplementary Fig. 3b and Table 1).	RESULTS
56	62	H(-2)N	mutant	In agreement, the chymotrypsin-like (ChT-L) activity of H(-2)N and H(-2)F mutant yCPs was impaired in situ and in vitro (Supplementary Fig. 3c).	RESULTS
67	73	H(-2)F	mutant	In agreement, the chymotrypsin-like (ChT-L) activity of H(-2)N and H(-2)F mutant yCPs was impaired in situ and in vitro (Supplementary Fig. 3c).	RESULTS
74	80	mutant	protein_state	In agreement, the chymotrypsin-like (ChT-L) activity of H(-2)N and H(-2)F mutant yCPs was impaired in situ and in vitro (Supplementary Fig. 3c).	RESULTS
81	85	yCPs	complex_assembly	In agreement, the chymotrypsin-like (ChT-L) activity of H(-2)N and H(-2)F mutant yCPs was impaired in situ and in vitro (Supplementary Fig. 3c).	RESULTS
0	19	Structural analyses	experimental_method	Structural analyses revealed that the propeptides of all mutant yCPs shared residual 2FO–FC electron densities.	RESULTS
38	49	propeptides	structure_element	Structural analyses revealed that the propeptides of all mutant yCPs shared residual 2FO–FC electron densities.	RESULTS
57	63	mutant	protein_state	Structural analyses revealed that the propeptides of all mutant yCPs shared residual 2FO–FC electron densities.	RESULTS
64	68	yCPs	complex_assembly	Structural analyses revealed that the propeptides of all mutant yCPs shared residual 2FO–FC electron densities.	RESULTS
85	110	2FO–FC electron densities	evidence	Structural analyses revealed that the propeptides of all mutant yCPs shared residual 2FO–FC electron densities.	RESULTS
0	7	Gly(-1)	residue_name_number	Gly(-1) and Phe/Lys(-2) were visualized at low occupancy, while Ala/Asn(-2) could not be assigned.	RESULTS
12	15	Phe	residue_name	Gly(-1) and Phe/Lys(-2) were visualized at low occupancy, while Ala/Asn(-2) could not be assigned.	RESULTS
16	23	Lys(-2)	residue_name_number	Gly(-1) and Phe/Lys(-2) were visualized at low occupancy, while Ala/Asn(-2) could not be assigned.	RESULTS
64	67	Ala	residue_name	Gly(-1) and Phe/Lys(-2) were visualized at low occupancy, while Ala/Asn(-2) could not be assigned.	RESULTS
68	75	Asn(-2)	residue_name_number	Gly(-1) and Phe/Lys(-2) were visualized at low occupancy, while Ala/Asn(-2) could not be assigned.	RESULTS
40	49	processed	protein_state	This observation indicates a mixture of processed and unprocessed β5 subunits and partially impaired autolysis, thereby excluding any essential role of residue (-2) as the general base.	RESULTS
54	65	unprocessed	protein_state	This observation indicates a mixture of processed and unprocessed β5 subunits and partially impaired autolysis, thereby excluding any essential role of residue (-2) as the general base.	RESULTS
66	68	β5	protein	This observation indicates a mixture of processed and unprocessed β5 subunits and partially impaired autolysis, thereby excluding any essential role of residue (-2) as the general base.	RESULTS
101	110	autolysis	ptm	This observation indicates a mixture of processed and unprocessed β5 subunits and partially impaired autolysis, thereby excluding any essential role of residue (-2) as the general base.	RESULTS
160	164	(-2)	residue_number	This observation indicates a mixture of processed and unprocessed β5 subunits and partially impaired autolysis, thereby excluding any essential role of residue (-2) as the general base.	RESULTS
40	44	(-2)	residue_number	Next, we examined the effect of residue (-2) on the orientation of the propeptide by creating mutants that combine the T1A (K81R) mutation(s) with H(-2)L, H(-2)T or H(-2)A substitutions.	RESULTS
71	81	propeptide	structure_element	Next, we examined the effect of residue (-2) on the orientation of the propeptide by creating mutants that combine the T1A (K81R) mutation(s) with H(-2)L, H(-2)T or H(-2)A substitutions.	RESULTS
85	114	creating mutants that combine	experimental_method	Next, we examined the effect of residue (-2) on the orientation of the propeptide by creating mutants that combine the T1A (K81R) mutation(s) with H(-2)L, H(-2)T or H(-2)A substitutions.	RESULTS
119	122	T1A	mutant	Next, we examined the effect of residue (-2) on the orientation of the propeptide by creating mutants that combine the T1A (K81R) mutation(s) with H(-2)L, H(-2)T or H(-2)A substitutions.	RESULTS
124	128	K81R	mutant	Next, we examined the effect of residue (-2) on the orientation of the propeptide by creating mutants that combine the T1A (K81R) mutation(s) with H(-2)L, H(-2)T or H(-2)A substitutions.	RESULTS
130	141	mutation(s)	experimental_method	Next, we examined the effect of residue (-2) on the orientation of the propeptide by creating mutants that combine the T1A (K81R) mutation(s) with H(-2)L, H(-2)T or H(-2)A substitutions.	RESULTS
147	153	H(-2)L	mutant	Next, we examined the effect of residue (-2) on the orientation of the propeptide by creating mutants that combine the T1A (K81R) mutation(s) with H(-2)L, H(-2)T or H(-2)A substitutions.	RESULTS
155	161	H(-2)T	mutant	Next, we examined the effect of residue (-2) on the orientation of the propeptide by creating mutants that combine the T1A (K81R) mutation(s) with H(-2)L, H(-2)T or H(-2)A substitutions.	RESULTS
165	171	H(-2)A	mutant	Next, we examined the effect of residue (-2) on the orientation of the propeptide by creating mutants that combine the T1A (K81R) mutation(s) with H(-2)L, H(-2)T or H(-2)A substitutions.	RESULTS
172	185	substitutions	experimental_method	Next, we examined the effect of residue (-2) on the orientation of the propeptide by creating mutants that combine the T1A (K81R) mutation(s) with H(-2)L, H(-2)T or H(-2)A substitutions.	RESULTS
0	7	Leu(-2)	residue_name_number	Leu(-2) is encoded in the yeast β1 subunit precursor (Supplementary Fig. 3a); Thr(-2) is generally part of β2-propeptides (Supplementary Fig. 3a); and Ala(-2) was expected to fit the β5-S1 pocket without inducing conformational changes of Met45, allowing it to accommodate ‘β1-like' propeptide positioning.	RESULTS
26	31	yeast	taxonomy_domain	Leu(-2) is encoded in the yeast β1 subunit precursor (Supplementary Fig. 3a); Thr(-2) is generally part of β2-propeptides (Supplementary Fig. 3a); and Ala(-2) was expected to fit the β5-S1 pocket without inducing conformational changes of Met45, allowing it to accommodate ‘β1-like' propeptide positioning.	RESULTS
32	34	β1	protein	Leu(-2) is encoded in the yeast β1 subunit precursor (Supplementary Fig. 3a); Thr(-2) is generally part of β2-propeptides (Supplementary Fig. 3a); and Ala(-2) was expected to fit the β5-S1 pocket without inducing conformational changes of Met45, allowing it to accommodate ‘β1-like' propeptide positioning.	RESULTS
78	85	Thr(-2)	residue_name_number	Leu(-2) is encoded in the yeast β1 subunit precursor (Supplementary Fig. 3a); Thr(-2) is generally part of β2-propeptides (Supplementary Fig. 3a); and Ala(-2) was expected to fit the β5-S1 pocket without inducing conformational changes of Met45, allowing it to accommodate ‘β1-like' propeptide positioning.	RESULTS
107	109	β2	protein	Leu(-2) is encoded in the yeast β1 subunit precursor (Supplementary Fig. 3a); Thr(-2) is generally part of β2-propeptides (Supplementary Fig. 3a); and Ala(-2) was expected to fit the β5-S1 pocket without inducing conformational changes of Met45, allowing it to accommodate ‘β1-like' propeptide positioning.	RESULTS
110	121	propeptides	structure_element	Leu(-2) is encoded in the yeast β1 subunit precursor (Supplementary Fig. 3a); Thr(-2) is generally part of β2-propeptides (Supplementary Fig. 3a); and Ala(-2) was expected to fit the β5-S1 pocket without inducing conformational changes of Met45, allowing it to accommodate ‘β1-like' propeptide positioning.	RESULTS
151	158	Ala(-2)	residue_name_number	Leu(-2) is encoded in the yeast β1 subunit precursor (Supplementary Fig. 3a); Thr(-2) is generally part of β2-propeptides (Supplementary Fig. 3a); and Ala(-2) was expected to fit the β5-S1 pocket without inducing conformational changes of Met45, allowing it to accommodate ‘β1-like' propeptide positioning.	RESULTS
183	185	β5	protein	Leu(-2) is encoded in the yeast β1 subunit precursor (Supplementary Fig. 3a); Thr(-2) is generally part of β2-propeptides (Supplementary Fig. 3a); and Ala(-2) was expected to fit the β5-S1 pocket without inducing conformational changes of Met45, allowing it to accommodate ‘β1-like' propeptide positioning.	RESULTS
186	195	S1 pocket	site	Leu(-2) is encoded in the yeast β1 subunit precursor (Supplementary Fig. 3a); Thr(-2) is generally part of β2-propeptides (Supplementary Fig. 3a); and Ala(-2) was expected to fit the β5-S1 pocket without inducing conformational changes of Met45, allowing it to accommodate ‘β1-like' propeptide positioning.	RESULTS
239	244	Met45	residue_name_number	Leu(-2) is encoded in the yeast β1 subunit precursor (Supplementary Fig. 3a); Thr(-2) is generally part of β2-propeptides (Supplementary Fig. 3a); and Ala(-2) was expected to fit the β5-S1 pocket without inducing conformational changes of Met45, allowing it to accommodate ‘β1-like' propeptide positioning.	RESULTS
17	23	β5-T1A	mutant	As expected from β5-T1A mutants, the yeasts show severe growth phenotypes, with minor variations (Supplementary Fig. 4a and Table 1).	RESULTS
37	43	yeasts	taxonomy_domain	As expected from β5-T1A mutants, the yeasts show severe growth phenotypes, with minor variations (Supplementary Fig. 4a and Table 1).	RESULTS
14	32	crystal structures	evidence	We determined crystal structures of the β5-H(-2)L-T1A, β5-H(-2)T-T1A and the β5-H(-2)A-T1A-K81R mutants (Supplementary Table 1).	RESULTS
40	53	β5-H(-2)L-T1A	mutant	We determined crystal structures of the β5-H(-2)L-T1A, β5-H(-2)T-T1A and the β5-H(-2)A-T1A-K81R mutants (Supplementary Table 1).	RESULTS
55	68	β5-H(-2)T-T1A	mutant	We determined crystal structures of the β5-H(-2)L-T1A, β5-H(-2)T-T1A and the β5-H(-2)A-T1A-K81R mutants (Supplementary Table 1).	RESULTS
77	95	β5-H(-2)A-T1A-K81R	mutant	We determined crystal structures of the β5-H(-2)L-T1A, β5-H(-2)T-T1A and the β5-H(-2)A-T1A-K81R mutants (Supplementary Table 1).	RESULTS
8	26	β5-H(-2)A-T1A-K81R	mutant	For the β5-H(-2)A-T1A-K81R variant, only the residues Gly(-1) and Ala(-2) could be visualized, indicating that Ala(-2) leads to insufficient stabilization of the propeptide in the substrate-binding channel (Supplementary Fig. 4d).	RESULTS
54	61	Gly(-1)	residue_name_number	For the β5-H(-2)A-T1A-K81R variant, only the residues Gly(-1) and Ala(-2) could be visualized, indicating that Ala(-2) leads to insufficient stabilization of the propeptide in the substrate-binding channel (Supplementary Fig. 4d).	RESULTS
66	73	Ala(-2)	residue_name_number	For the β5-H(-2)A-T1A-K81R variant, only the residues Gly(-1) and Ala(-2) could be visualized, indicating that Ala(-2) leads to insufficient stabilization of the propeptide in the substrate-binding channel (Supplementary Fig. 4d).	RESULTS
111	118	Ala(-2)	residue_name_number	For the β5-H(-2)A-T1A-K81R variant, only the residues Gly(-1) and Ala(-2) could be visualized, indicating that Ala(-2) leads to insufficient stabilization of the propeptide in the substrate-binding channel (Supplementary Fig. 4d).	RESULTS
162	172	propeptide	structure_element	For the β5-H(-2)A-T1A-K81R variant, only the residues Gly(-1) and Ala(-2) could be visualized, indicating that Ala(-2) leads to insufficient stabilization of the propeptide in the substrate-binding channel (Supplementary Fig. 4d).	RESULTS
180	205	substrate-binding channel	site	For the β5-H(-2)A-T1A-K81R variant, only the residues Gly(-1) and Ala(-2) could be visualized, indicating that Ala(-2) leads to insufficient stabilization of the propeptide in the substrate-binding channel (Supplementary Fig. 4d).	RESULTS
17	28	prosegments	structure_element	By contrast, the prosegments of the β5-H(-2)L-T1A and the β5-H(-2)T-T1A mutants were significantly better resolved in the 2FO–FC electron-density maps yet not at full occupancy (Supplementary Fig. 4b,c and Supplementary Table 1), suggesting that the natural propeptide bearing His(-2) is most favourable.	RESULTS
36	49	β5-H(-2)L-T1A	mutant	By contrast, the prosegments of the β5-H(-2)L-T1A and the β5-H(-2)T-T1A mutants were significantly better resolved in the 2FO–FC electron-density maps yet not at full occupancy (Supplementary Fig. 4b,c and Supplementary Table 1), suggesting that the natural propeptide bearing His(-2) is most favourable.	RESULTS
58	71	β5-H(-2)T-T1A	mutant	By contrast, the prosegments of the β5-H(-2)L-T1A and the β5-H(-2)T-T1A mutants were significantly better resolved in the 2FO–FC electron-density maps yet not at full occupancy (Supplementary Fig. 4b,c and Supplementary Table 1), suggesting that the natural propeptide bearing His(-2) is most favourable.	RESULTS
122	150	2FO–FC electron-density maps	evidence	By contrast, the prosegments of the β5-H(-2)L-T1A and the β5-H(-2)T-T1A mutants were significantly better resolved in the 2FO–FC electron-density maps yet not at full occupancy (Supplementary Fig. 4b,c and Supplementary Table 1), suggesting that the natural propeptide bearing His(-2) is most favourable.	RESULTS
258	268	propeptide	structure_element	By contrast, the prosegments of the β5-H(-2)L-T1A and the β5-H(-2)T-T1A mutants were significantly better resolved in the 2FO–FC electron-density maps yet not at full occupancy (Supplementary Fig. 4b,c and Supplementary Table 1), suggesting that the natural propeptide bearing His(-2) is most favourable.	RESULTS
277	284	His(-2)	residue_name_number	By contrast, the prosegments of the β5-H(-2)L-T1A and the β5-H(-2)T-T1A mutants were significantly better resolved in the 2FO–FC electron-density maps yet not at full occupancy (Supplementary Fig. 4b,c and Supplementary Table 1), suggesting that the natural propeptide bearing His(-2) is most favourable.	RESULTS
19	26	Leu(-2)	residue_name_number	Nevertheless, both Leu(-2) and Thr(-2) were found to occupy the S1 specificity pocket formed by Met45 (Fig. 2a,b and Supplementary Fig. 4f–h).	RESULTS
31	38	Thr(-2)	residue_name_number	Nevertheless, both Leu(-2) and Thr(-2) were found to occupy the S1 specificity pocket formed by Met45 (Fig. 2a,b and Supplementary Fig. 4f–h).	RESULTS
64	85	S1 specificity pocket	site	Nevertheless, both Leu(-2) and Thr(-2) were found to occupy the S1 specificity pocket formed by Met45 (Fig. 2a,b and Supplementary Fig. 4f–h).	RESULTS
96	101	Met45	residue_name_number	Nevertheless, both Leu(-2) and Thr(-2) were found to occupy the S1 specificity pocket formed by Met45 (Fig. 2a,b and Supplementary Fig. 4f–h).	RESULTS
48	55	His(-2)	residue_name_number	This result proves that the naturally occurring His(-2) of the β5 propeptide does not stably fit into the S1 site.	RESULTS
63	65	β5	protein	This result proves that the naturally occurring His(-2) of the β5 propeptide does not stably fit into the S1 site.	RESULTS
66	76	propeptide	structure_element	This result proves that the naturally occurring His(-2) of the β5 propeptide does not stably fit into the S1 site.	RESULTS
106	113	S1 site	site	This result proves that the naturally occurring His(-2) of the β5 propeptide does not stably fit into the S1 site.	RESULTS
6	13	Gly(-1)	residue_name_number	Since Gly(-1) adopts the same position in both wild-type (WT) and mutant β5 propeptides, and since in all cases its carbonyl carbon is perfectly placed for nucleophilic attack by Thr1Oγ (Fig. 2b), we propose that neither binding of residue (-2) to the S1 pocket nor formation of the antiparallel β-sheet is essential for autolysis of the propeptide.	RESULTS
47	56	wild-type	protein_state	Since Gly(-1) adopts the same position in both wild-type (WT) and mutant β5 propeptides, and since in all cases its carbonyl carbon is perfectly placed for nucleophilic attack by Thr1Oγ (Fig. 2b), we propose that neither binding of residue (-2) to the S1 pocket nor formation of the antiparallel β-sheet is essential for autolysis of the propeptide.	RESULTS
58	60	WT	protein_state	Since Gly(-1) adopts the same position in both wild-type (WT) and mutant β5 propeptides, and since in all cases its carbonyl carbon is perfectly placed for nucleophilic attack by Thr1Oγ (Fig. 2b), we propose that neither binding of residue (-2) to the S1 pocket nor formation of the antiparallel β-sheet is essential for autolysis of the propeptide.	RESULTS
66	72	mutant	protein_state	Since Gly(-1) adopts the same position in both wild-type (WT) and mutant β5 propeptides, and since in all cases its carbonyl carbon is perfectly placed for nucleophilic attack by Thr1Oγ (Fig. 2b), we propose that neither binding of residue (-2) to the S1 pocket nor formation of the antiparallel β-sheet is essential for autolysis of the propeptide.	RESULTS
73	75	β5	protein	Since Gly(-1) adopts the same position in both wild-type (WT) and mutant β5 propeptides, and since in all cases its carbonyl carbon is perfectly placed for nucleophilic attack by Thr1Oγ (Fig. 2b), we propose that neither binding of residue (-2) to the S1 pocket nor formation of the antiparallel β-sheet is essential for autolysis of the propeptide.	RESULTS
76	87	propeptides	structure_element	Since Gly(-1) adopts the same position in both wild-type (WT) and mutant β5 propeptides, and since in all cases its carbonyl carbon is perfectly placed for nucleophilic attack by Thr1Oγ (Fig. 2b), we propose that neither binding of residue (-2) to the S1 pocket nor formation of the antiparallel β-sheet is essential for autolysis of the propeptide.	RESULTS
179	183	Thr1	residue_name_number	Since Gly(-1) adopts the same position in both wild-type (WT) and mutant β5 propeptides, and since in all cases its carbonyl carbon is perfectly placed for nucleophilic attack by Thr1Oγ (Fig. 2b), we propose that neither binding of residue (-2) to the S1 pocket nor formation of the antiparallel β-sheet is essential for autolysis of the propeptide.	RESULTS
240	244	(-2)	residue_number	Since Gly(-1) adopts the same position in both wild-type (WT) and mutant β5 propeptides, and since in all cases its carbonyl carbon is perfectly placed for nucleophilic attack by Thr1Oγ (Fig. 2b), we propose that neither binding of residue (-2) to the S1 pocket nor formation of the antiparallel β-sheet is essential for autolysis of the propeptide.	RESULTS
252	261	S1 pocket	site	Since Gly(-1) adopts the same position in both wild-type (WT) and mutant β5 propeptides, and since in all cases its carbonyl carbon is perfectly placed for nucleophilic attack by Thr1Oγ (Fig. 2b), we propose that neither binding of residue (-2) to the S1 pocket nor formation of the antiparallel β-sheet is essential for autolysis of the propeptide.	RESULTS
283	303	antiparallel β-sheet	structure_element	Since Gly(-1) adopts the same position in both wild-type (WT) and mutant β5 propeptides, and since in all cases its carbonyl carbon is perfectly placed for nucleophilic attack by Thr1Oγ (Fig. 2b), we propose that neither binding of residue (-2) to the S1 pocket nor formation of the antiparallel β-sheet is essential for autolysis of the propeptide.	RESULTS
321	330	autolysis	ptm	Since Gly(-1) adopts the same position in both wild-type (WT) and mutant β5 propeptides, and since in all cases its carbonyl carbon is perfectly placed for nucleophilic attack by Thr1Oγ (Fig. 2b), we propose that neither binding of residue (-2) to the S1 pocket nor formation of the antiparallel β-sheet is essential for autolysis of the propeptide.	RESULTS
338	348	propeptide	structure_element	Since Gly(-1) adopts the same position in both wild-type (WT) and mutant β5 propeptides, and since in all cases its carbonyl carbon is perfectly placed for nucleophilic attack by Thr1Oγ (Fig. 2b), we propose that neither binding of residue (-2) to the S1 pocket nor formation of the antiparallel β-sheet is essential for autolysis of the propeptide.	RESULTS
24	41	crystal structure	evidence	Next, we determined the crystal structure of a chimeric yCP having the yeast β1-propeptide replaced by its β5 counterpart.	RESULTS
47	55	chimeric	protein_state	Next, we determined the crystal structure of a chimeric yCP having the yeast β1-propeptide replaced by its β5 counterpart.	RESULTS
56	59	yCP	complex_assembly	Next, we determined the crystal structure of a chimeric yCP having the yeast β1-propeptide replaced by its β5 counterpart.	RESULTS
71	76	yeast	taxonomy_domain	Next, we determined the crystal structure of a chimeric yCP having the yeast β1-propeptide replaced by its β5 counterpart.	RESULTS
77	79	β1	protein	Next, we determined the crystal structure of a chimeric yCP having the yeast β1-propeptide replaced by its β5 counterpart.	RESULTS
80	90	propeptide	structure_element	Next, we determined the crystal structure of a chimeric yCP having the yeast β1-propeptide replaced by its β5 counterpart.	RESULTS
91	102	replaced by	experimental_method	Next, we determined the crystal structure of a chimeric yCP having the yeast β1-propeptide replaced by its β5 counterpart.	RESULTS
107	109	β5	protein	Next, we determined the crystal structure of a chimeric yCP having the yeast β1-propeptide replaced by its β5 counterpart.	RESULTS
110	121	counterpart	structure_element	Next, we determined the crystal structure of a chimeric yCP having the yeast β1-propeptide replaced by its β5 counterpart.	RESULTS
34	57	2FO–FC electron density	evidence	Although we observed fragments of 2FO–FC electron density in the β1 active site, the data were not interpretable.	RESULTS
65	67	β1	protein	Although we observed fragments of 2FO–FC electron density in the β1 active site, the data were not interpretable.	RESULTS
68	79	active site	site	Although we observed fragments of 2FO–FC electron density in the β1 active site, the data were not interpretable.	RESULTS
36	43	Thr(-2)	residue_name_number	Bearing in mind that in contrast to Thr(-2) in β2, Leu(-2) in subunit β1 is not conserved among species (Supplementary Fig. 3a), we created a β2-T(-2)V proteasome mutant.	RESULTS
47	49	β2	protein	Bearing in mind that in contrast to Thr(-2) in β2, Leu(-2) in subunit β1 is not conserved among species (Supplementary Fig. 3a), we created a β2-T(-2)V proteasome mutant.	RESULTS
51	58	Leu(-2)	residue_name_number	Bearing in mind that in contrast to Thr(-2) in β2, Leu(-2) in subunit β1 is not conserved among species (Supplementary Fig. 3a), we created a β2-T(-2)V proteasome mutant.	RESULTS
70	72	β1	protein	Bearing in mind that in contrast to Thr(-2) in β2, Leu(-2) in subunit β1 is not conserved among species (Supplementary Fig. 3a), we created a β2-T(-2)V proteasome mutant.	RESULTS
76	89	not conserved	protein_state	Bearing in mind that in contrast to Thr(-2) in β2, Leu(-2) in subunit β1 is not conserved among species (Supplementary Fig. 3a), we created a β2-T(-2)V proteasome mutant.	RESULTS
132	139	created	experimental_method	Bearing in mind that in contrast to Thr(-2) in β2, Leu(-2) in subunit β1 is not conserved among species (Supplementary Fig. 3a), we created a β2-T(-2)V proteasome mutant.	RESULTS
142	151	β2-T(-2)V	mutant	Bearing in mind that in contrast to Thr(-2) in β2, Leu(-2) in subunit β1 is not conserved among species (Supplementary Fig. 3a), we created a β2-T(-2)V proteasome mutant.	RESULTS
152	162	proteasome	complex_assembly	Bearing in mind that in contrast to Thr(-2) in β2, Leu(-2) in subunit β1 is not conserved among species (Supplementary Fig. 3a), we created a β2-T(-2)V proteasome mutant.	RESULTS
163	169	mutant	protein_state	Bearing in mind that in contrast to Thr(-2) in β2, Leu(-2) in subunit β1 is not conserved among species (Supplementary Fig. 3a), we created a β2-T(-2)V proteasome mutant.	RESULTS
17	23	β2-T1A	mutant	As proven by the β2-T1A crystal structures, Thr(-2) hydrogen bonds to Gly(-1)O. Although this interaction was not observed for the β5-H(-2)T-T1A mutant (Fig. 2c and Supplementary Fig. 4c,i), exchange of Thr(-2) by Val in β2, a conservative mutation regarding size but drastic with respect to polarity, was found to inhibit maturation of this subunit (Fig. 2d and Supplementary Fig. 4e,j).	RESULTS
24	42	crystal structures	evidence	As proven by the β2-T1A crystal structures, Thr(-2) hydrogen bonds to Gly(-1)O. Although this interaction was not observed for the β5-H(-2)T-T1A mutant (Fig. 2c and Supplementary Fig. 4c,i), exchange of Thr(-2) by Val in β2, a conservative mutation regarding size but drastic with respect to polarity, was found to inhibit maturation of this subunit (Fig. 2d and Supplementary Fig. 4e,j).	RESULTS
44	51	Thr(-2)	residue_name_number	As proven by the β2-T1A crystal structures, Thr(-2) hydrogen bonds to Gly(-1)O. Although this interaction was not observed for the β5-H(-2)T-T1A mutant (Fig. 2c and Supplementary Fig. 4c,i), exchange of Thr(-2) by Val in β2, a conservative mutation regarding size but drastic with respect to polarity, was found to inhibit maturation of this subunit (Fig. 2d and Supplementary Fig. 4e,j).	RESULTS
70	77	Gly(-1)	residue_name_number	As proven by the β2-T1A crystal structures, Thr(-2) hydrogen bonds to Gly(-1)O. Although this interaction was not observed for the β5-H(-2)T-T1A mutant (Fig. 2c and Supplementary Fig. 4c,i), exchange of Thr(-2) by Val in β2, a conservative mutation regarding size but drastic with respect to polarity, was found to inhibit maturation of this subunit (Fig. 2d and Supplementary Fig. 4e,j).	RESULTS
131	144	β5-H(-2)T-T1A	mutant	As proven by the β2-T1A crystal structures, Thr(-2) hydrogen bonds to Gly(-1)O. Although this interaction was not observed for the β5-H(-2)T-T1A mutant (Fig. 2c and Supplementary Fig. 4c,i), exchange of Thr(-2) by Val in β2, a conservative mutation regarding size but drastic with respect to polarity, was found to inhibit maturation of this subunit (Fig. 2d and Supplementary Fig. 4e,j).	RESULTS
145	151	mutant	protein_state	As proven by the β2-T1A crystal structures, Thr(-2) hydrogen bonds to Gly(-1)O. Although this interaction was not observed for the β5-H(-2)T-T1A mutant (Fig. 2c and Supplementary Fig. 4c,i), exchange of Thr(-2) by Val in β2, a conservative mutation regarding size but drastic with respect to polarity, was found to inhibit maturation of this subunit (Fig. 2d and Supplementary Fig. 4e,j).	RESULTS
191	199	exchange	experimental_method	As proven by the β2-T1A crystal structures, Thr(-2) hydrogen bonds to Gly(-1)O. Although this interaction was not observed for the β5-H(-2)T-T1A mutant (Fig. 2c and Supplementary Fig. 4c,i), exchange of Thr(-2) by Val in β2, a conservative mutation regarding size but drastic with respect to polarity, was found to inhibit maturation of this subunit (Fig. 2d and Supplementary Fig. 4e,j).	RESULTS
203	210	Thr(-2)	residue_name_number	As proven by the β2-T1A crystal structures, Thr(-2) hydrogen bonds to Gly(-1)O. Although this interaction was not observed for the β5-H(-2)T-T1A mutant (Fig. 2c and Supplementary Fig. 4c,i), exchange of Thr(-2) by Val in β2, a conservative mutation regarding size but drastic with respect to polarity, was found to inhibit maturation of this subunit (Fig. 2d and Supplementary Fig. 4e,j).	RESULTS
214	217	Val	residue_name	As proven by the β2-T1A crystal structures, Thr(-2) hydrogen bonds to Gly(-1)O. Although this interaction was not observed for the β5-H(-2)T-T1A mutant (Fig. 2c and Supplementary Fig. 4c,i), exchange of Thr(-2) by Val in β2, a conservative mutation regarding size but drastic with respect to polarity, was found to inhibit maturation of this subunit (Fig. 2d and Supplementary Fig. 4e,j).	RESULTS
221	223	β2	protein	As proven by the β2-T1A crystal structures, Thr(-2) hydrogen bonds to Gly(-1)O. Although this interaction was not observed for the β5-H(-2)T-T1A mutant (Fig. 2c and Supplementary Fig. 4c,i), exchange of Thr(-2) by Val in β2, a conservative mutation regarding size but drastic with respect to polarity, was found to inhibit maturation of this subunit (Fig. 2d and Supplementary Fig. 4e,j).	RESULTS
13	40	2FO–FC electron-density map	evidence	Notably, the 2FO–FC electron-density map displays a different orientation for the β2 propeptide than has been observed for the β2-T1A proteasome.	RESULTS
82	84	β2	protein	Notably, the 2FO–FC electron-density map displays a different orientation for the β2 propeptide than has been observed for the β2-T1A proteasome.	RESULTS
85	95	propeptide	structure_element	Notably, the 2FO–FC electron-density map displays a different orientation for the β2 propeptide than has been observed for the β2-T1A proteasome.	RESULTS
127	133	β2-T1A	mutant	Notably, the 2FO–FC electron-density map displays a different orientation for the β2 propeptide than has been observed for the β2-T1A proteasome.	RESULTS
134	144	proteasome	complex_assembly	Notably, the 2FO–FC electron-density map displays a different orientation for the β2 propeptide than has been observed for the β2-T1A proteasome.	RESULTS
15	22	Val(-2)	residue_name_number	In particular, Val(-2) is displaced from the S1 site and Gly(-1) is severely shifted (movement of the carbonyl oxygen atom of 3.8 Å), thereby preventing nucleophilic attack of Thr1 (Fig. 2d and Supplementary Fig. 4j,k).	RESULTS
45	52	S1 site	site	In particular, Val(-2) is displaced from the S1 site and Gly(-1) is severely shifted (movement of the carbonyl oxygen atom of 3.8 Å), thereby preventing nucleophilic attack of Thr1 (Fig. 2d and Supplementary Fig. 4j,k).	RESULTS
57	64	Gly(-1)	residue_name_number	In particular, Val(-2) is displaced from the S1 site and Gly(-1) is severely shifted (movement of the carbonyl oxygen atom of 3.8 Å), thereby preventing nucleophilic attack of Thr1 (Fig. 2d and Supplementary Fig. 4j,k).	RESULTS
176	180	Thr1	residue_name_number	In particular, Val(-2) is displaced from the S1 site and Gly(-1) is severely shifted (movement of the carbonyl oxygen atom of 3.8 Å), thereby preventing nucleophilic attack of Thr1 (Fig. 2d and Supplementary Fig. 4j,k).	RESULTS
62	82	active-site residues	site	These results further confirm that correct positioning of the active-site residues and Gly(-1) is decisive for the maturation of the proteasome.	RESULTS
87	94	Gly(-1)	residue_name_number	These results further confirm that correct positioning of the active-site residues and Gly(-1) is decisive for the maturation of the proteasome.	RESULTS
133	143	proteasome	complex_assembly	These results further confirm that correct positioning of the active-site residues and Gly(-1) is decisive for the maturation of the proteasome.	RESULTS
4	15	active site	site	The active site of the proteasome	RESULTS
23	33	proteasome	complex_assembly	The active site of the proteasome	RESULTS
38	49	active site	site	Proton shuttling from the proteasomal active site Thr1OH to Thr1NH2 via a nucleophilic water molecule was suggested to initiate peptide-bond hydrolysis.	RESULTS
50	54	Thr1	residue_name_number	Proton shuttling from the proteasomal active site Thr1OH to Thr1NH2 via a nucleophilic water molecule was suggested to initiate peptide-bond hydrolysis.	RESULTS
60	64	Thr1	residue_name_number	Proton shuttling from the proteasomal active site Thr1OH to Thr1NH2 via a nucleophilic water molecule was suggested to initiate peptide-bond hydrolysis.	RESULTS
87	92	water	chemical	Proton shuttling from the proteasomal active site Thr1OH to Thr1NH2 via a nucleophilic water molecule was suggested to initiate peptide-bond hydrolysis.	RESULTS
16	24	immature	protein_state	However, in the immature particle Thr1NH2 is blocked by the propeptide and cannot activate Thr1Oγ.	RESULTS
25	33	particle	complex_assembly	However, in the immature particle Thr1NH2 is blocked by the propeptide and cannot activate Thr1Oγ.	RESULTS
34	38	Thr1	residue_name_number	However, in the immature particle Thr1NH2 is blocked by the propeptide and cannot activate Thr1Oγ.	RESULTS
60	70	propeptide	structure_element	However, in the immature particle Thr1NH2 is blocked by the propeptide and cannot activate Thr1Oγ.	RESULTS
91	95	Thr1	residue_name_number	However, in the immature particle Thr1NH2 is blocked by the propeptide and cannot activate Thr1Oγ.	RESULTS
9	14	Lys33	residue_name_number	Instead, Lys33NH2, which is in hydrogen-bonding distance to Thr1Oγ (2.7 Å) in all catalytically active β subunits (Fig. 3a,b), was proposed to serve as the proton acceptor.	RESULTS
60	64	Thr1	residue_name_number	Instead, Lys33NH2, which is in hydrogen-bonding distance to Thr1Oγ (2.7 Å) in all catalytically active β subunits (Fig. 3a,b), was proposed to serve as the proton acceptor.	RESULTS
82	102	catalytically active	protein_state	Instead, Lys33NH2, which is in hydrogen-bonding distance to Thr1Oγ (2.7 Å) in all catalytically active β subunits (Fig. 3a,b), was proposed to serve as the proton acceptor.	RESULTS
103	113	β subunits	protein	Instead, Lys33NH2, which is in hydrogen-bonding distance to Thr1Oγ (2.7 Å) in all catalytically active β subunits (Fig. 3a,b), was proposed to serve as the proton acceptor.	RESULTS
11	27	catalytic tetrad	site	A proposed catalytic tetrad model involving Thr1OH, Thr1NH2, Lys33NH2 and Asp17Oδ, as well as a nucleophilic water molecule as the proton shuttle appeared to accommodate all possible views of the proteasomal active site.	RESULTS
44	48	Thr1	residue_name_number	A proposed catalytic tetrad model involving Thr1OH, Thr1NH2, Lys33NH2 and Asp17Oδ, as well as a nucleophilic water molecule as the proton shuttle appeared to accommodate all possible views of the proteasomal active site.	RESULTS
52	56	Thr1	residue_name_number	A proposed catalytic tetrad model involving Thr1OH, Thr1NH2, Lys33NH2 and Asp17Oδ, as well as a nucleophilic water molecule as the proton shuttle appeared to accommodate all possible views of the proteasomal active site.	RESULTS
61	66	Lys33	residue_name_number	A proposed catalytic tetrad model involving Thr1OH, Thr1NH2, Lys33NH2 and Asp17Oδ, as well as a nucleophilic water molecule as the proton shuttle appeared to accommodate all possible views of the proteasomal active site.	RESULTS
74	79	Asp17	residue_name_number	A proposed catalytic tetrad model involving Thr1OH, Thr1NH2, Lys33NH2 and Asp17Oδ, as well as a nucleophilic water molecule as the proton shuttle appeared to accommodate all possible views of the proteasomal active site.	RESULTS
109	114	water	chemical	A proposed catalytic tetrad model involving Thr1OH, Thr1NH2, Lys33NH2 and Asp17Oδ, as well as a nucleophilic water molecule as the proton shuttle appeared to accommodate all possible views of the proteasomal active site.	RESULTS
208	219	active site	site	A proposed catalytic tetrad model involving Thr1OH, Thr1NH2, Lys33NH2 and Asp17Oδ, as well as a nucleophilic water molecule as the proton shuttle appeared to accommodate all possible views of the proteasomal active site.	RESULTS
39	42	yCP	complex_assembly	Twenty years later, with a plethora of yCP X-ray structures in hand, we decided to re-analyse the active site of the proteasome and to resolve the uncertainty regarding the nature of the general base.	RESULTS
43	59	X-ray structures	evidence	Twenty years later, with a plethora of yCP X-ray structures in hand, we decided to re-analyse the active site of the proteasome and to resolve the uncertainty regarding the nature of the general base.	RESULTS
98	109	active site	site	Twenty years later, with a plethora of yCP X-ray structures in hand, we decided to re-analyse the active site of the proteasome and to resolve the uncertainty regarding the nature of the general base.	RESULTS
117	127	proteasome	complex_assembly	Twenty years later, with a plethora of yCP X-ray structures in hand, we decided to re-analyse the active site of the proteasome and to resolve the uncertainty regarding the nature of the general base.	RESULTS
0	8	Mutation	experimental_method	Mutation of β5-Lys33 to Ala causes a strongly deleterious phenotype, and previous structural and biochemical analyses confirmed that this is caused by failure of propeptide cleavage, and consequently, lack of ChT-L activity (Fig. 4a, Supplementary Fig. 3b and Table 1; for details see Supplementary Note 1).	RESULTS
12	14	β5	protein	Mutation of β5-Lys33 to Ala causes a strongly deleterious phenotype, and previous structural and biochemical analyses confirmed that this is caused by failure of propeptide cleavage, and consequently, lack of ChT-L activity (Fig. 4a, Supplementary Fig. 3b and Table 1; for details see Supplementary Note 1).	RESULTS
15	20	Lys33	residue_name_number	Mutation of β5-Lys33 to Ala causes a strongly deleterious phenotype, and previous structural and biochemical analyses confirmed that this is caused by failure of propeptide cleavage, and consequently, lack of ChT-L activity (Fig. 4a, Supplementary Fig. 3b and Table 1; for details see Supplementary Note 1).	RESULTS
24	27	Ala	residue_name	Mutation of β5-Lys33 to Ala causes a strongly deleterious phenotype, and previous structural and biochemical analyses confirmed that this is caused by failure of propeptide cleavage, and consequently, lack of ChT-L activity (Fig. 4a, Supplementary Fig. 3b and Table 1; for details see Supplementary Note 1).	RESULTS
82	117	structural and biochemical analyses	experimental_method	Mutation of β5-Lys33 to Ala causes a strongly deleterious phenotype, and previous structural and biochemical analyses confirmed that this is caused by failure of propeptide cleavage, and consequently, lack of ChT-L activity (Fig. 4a, Supplementary Fig. 3b and Table 1; for details see Supplementary Note 1).	RESULTS
162	181	propeptide cleavage	ptm	Mutation of β5-Lys33 to Ala causes a strongly deleterious phenotype, and previous structural and biochemical analyses confirmed that this is caused by failure of propeptide cleavage, and consequently, lack of ChT-L activity (Fig. 4a, Supplementary Fig. 3b and Table 1; for details see Supplementary Note 1).	RESULTS
21	28	β5-K33A	mutant	The phenotype of the β5-K33A mutant was however less pronounced than for the β5-T1A-K81R yeast (Fig. 4a).	RESULTS
29	35	mutant	protein_state	The phenotype of the β5-K33A mutant was however less pronounced than for the β5-T1A-K81R yeast (Fig. 4a).	RESULTS
77	88	β5-T1A-K81R	mutant	The phenotype of the β5-K33A mutant was however less pronounced than for the β5-T1A-K81R yeast (Fig. 4a).	RESULTS
89	94	yeast	taxonomy_domain	The phenotype of the β5-K33A mutant was however less pronounced than for the β5-T1A-K81R yeast (Fig. 4a).	RESULTS
70	77	L(-49)S	mutant	This discrepancy in growth was traced to an additional point mutation L(-49)S in the β5-propeptide of the β5-K33A mutant (see also Supplementary Note 1).	RESULTS
85	87	β5	protein	This discrepancy in growth was traced to an additional point mutation L(-49)S in the β5-propeptide of the β5-K33A mutant (see also Supplementary Note 1).	RESULTS
88	98	propeptide	structure_element	This discrepancy in growth was traced to an additional point mutation L(-49)S in the β5-propeptide of the β5-K33A mutant (see also Supplementary Note 1).	RESULTS
106	113	β5-K33A	mutant	This discrepancy in growth was traced to an additional point mutation L(-49)S in the β5-propeptide of the β5-K33A mutant (see also Supplementary Note 1).	RESULTS
114	120	mutant	protein_state	This discrepancy in growth was traced to an additional point mutation L(-49)S in the β5-propeptide of the β5-K33A mutant (see also Supplementary Note 1).	RESULTS
0	21	Structural comparison	experimental_method	Structural comparison of the β5-L(-49)S-K33A and β5-T1A-K81R active sites revealed that mutation of Lys33 to Ala creates a cavity that is filled with Thr1 and the remnant propeptide.	RESULTS
29	44	β5-L(-49)S-K33A	mutant	Structural comparison of the β5-L(-49)S-K33A and β5-T1A-K81R active sites revealed that mutation of Lys33 to Ala creates a cavity that is filled with Thr1 and the remnant propeptide.	RESULTS
49	60	β5-T1A-K81R	mutant	Structural comparison of the β5-L(-49)S-K33A and β5-T1A-K81R active sites revealed that mutation of Lys33 to Ala creates a cavity that is filled with Thr1 and the remnant propeptide.	RESULTS
61	73	active sites	site	Structural comparison of the β5-L(-49)S-K33A and β5-T1A-K81R active sites revealed that mutation of Lys33 to Ala creates a cavity that is filled with Thr1 and the remnant propeptide.	RESULTS
88	96	mutation	experimental_method	Structural comparison of the β5-L(-49)S-K33A and β5-T1A-K81R active sites revealed that mutation of Lys33 to Ala creates a cavity that is filled with Thr1 and the remnant propeptide.	RESULTS
100	105	Lys33	residue_name_number	Structural comparison of the β5-L(-49)S-K33A and β5-T1A-K81R active sites revealed that mutation of Lys33 to Ala creates a cavity that is filled with Thr1 and the remnant propeptide.	RESULTS
109	112	Ala	residue_name	Structural comparison of the β5-L(-49)S-K33A and β5-T1A-K81R active sites revealed that mutation of Lys33 to Ala creates a cavity that is filled with Thr1 and the remnant propeptide.	RESULTS
150	154	Thr1	residue_name_number	Structural comparison of the β5-L(-49)S-K33A and β5-T1A-K81R active sites revealed that mutation of Lys33 to Ala creates a cavity that is filled with Thr1 and the remnant propeptide.	RESULTS
171	181	propeptide	structure_element	Structural comparison of the β5-L(-49)S-K33A and β5-T1A-K81R active sites revealed that mutation of Lys33 to Ala creates a cavity that is filled with Thr1 and the remnant propeptide.	RESULTS
36	47	active-site	site	This structural alteration destroys active-site integrity and abolishes catalytic activity of the β5 active site (Supplementary Fig. 5a).	RESULTS
98	100	β5	protein	This structural alteration destroys active-site integrity and abolishes catalytic activity of the β5 active site (Supplementary Fig. 5a).	RESULTS
101	112	active site	site	This structural alteration destroys active-site integrity and abolishes catalytic activity of the β5 active site (Supplementary Fig. 5a).	RESULTS
41	46	Lys33	residue_name_number	Additional proof for the key function of Lys33 was obtained from the β5-K33A mutant, with the propeptide expressed separately from the main subunit (pp trans).	RESULTS
69	76	β5-K33A	mutant	Additional proof for the key function of Lys33 was obtained from the β5-K33A mutant, with the propeptide expressed separately from the main subunit (pp trans).	RESULTS
77	83	mutant	protein_state	Additional proof for the key function of Lys33 was obtained from the β5-K33A mutant, with the propeptide expressed separately from the main subunit (pp trans).	RESULTS
94	104	propeptide	structure_element	Additional proof for the key function of Lys33 was obtained from the β5-K33A mutant, with the propeptide expressed separately from the main subunit (pp trans).	RESULTS
105	125	expressed separately	experimental_method	Additional proof for the key function of Lys33 was obtained from the β5-K33A mutant, with the propeptide expressed separately from the main subunit (pp trans).	RESULTS
149	151	pp	chemical	Additional proof for the key function of Lys33 was obtained from the β5-K33A mutant, with the propeptide expressed separately from the main subunit (pp trans).	RESULTS
152	157	trans	protein_state	Additional proof for the key function of Lys33 was obtained from the β5-K33A mutant, with the propeptide expressed separately from the main subunit (pp trans).	RESULTS
4	8	Thr1	residue_name_number	The Thr1 N terminus of this mutant is not blocked by the propeptide, yet its catalytic activity is reduced by ∼83% (Supplementary Fig. 6b).	RESULTS
28	34	mutant	protein_state	The Thr1 N terminus of this mutant is not blocked by the propeptide, yet its catalytic activity is reduced by ∼83% (Supplementary Fig. 6b).	RESULTS
57	67	propeptide	structure_element	The Thr1 N terminus of this mutant is not blocked by the propeptide, yet its catalytic activity is reduced by ∼83% (Supplementary Fig. 6b).	RESULTS
26	43	crystal structure	evidence	Consistent with this, the crystal structure of the β5-K33A pp trans mutant in complex with carfilzomib only showed partial occupancy of the ligand at the β5 active sites (Supplementary Fig. 5b and Supplementary Table 1).	RESULTS
51	58	β5-K33A	mutant	Consistent with this, the crystal structure of the β5-K33A pp trans mutant in complex with carfilzomib only showed partial occupancy of the ligand at the β5 active sites (Supplementary Fig. 5b and Supplementary Table 1).	RESULTS
59	61	pp	chemical	Consistent with this, the crystal structure of the β5-K33A pp trans mutant in complex with carfilzomib only showed partial occupancy of the ligand at the β5 active sites (Supplementary Fig. 5b and Supplementary Table 1).	RESULTS
62	67	trans	protein_state	Consistent with this, the crystal structure of the β5-K33A pp trans mutant in complex with carfilzomib only showed partial occupancy of the ligand at the β5 active sites (Supplementary Fig. 5b and Supplementary Table 1).	RESULTS
68	74	mutant	protein_state	Consistent with this, the crystal structure of the β5-K33A pp trans mutant in complex with carfilzomib only showed partial occupancy of the ligand at the β5 active sites (Supplementary Fig. 5b and Supplementary Table 1).	RESULTS
75	90	in complex with	protein_state	Consistent with this, the crystal structure of the β5-K33A pp trans mutant in complex with carfilzomib only showed partial occupancy of the ligand at the β5 active sites (Supplementary Fig. 5b and Supplementary Table 1).	RESULTS
91	102	carfilzomib	chemical	Consistent with this, the crystal structure of the β5-K33A pp trans mutant in complex with carfilzomib only showed partial occupancy of the ligand at the β5 active sites (Supplementary Fig. 5b and Supplementary Table 1).	RESULTS
154	156	β5	protein	Consistent with this, the crystal structure of the β5-K33A pp trans mutant in complex with carfilzomib only showed partial occupancy of the ligand at the β5 active sites (Supplementary Fig. 5b and Supplementary Table 1).	RESULTS
157	169	active sites	site	Consistent with this, the crystal structure of the β5-K33A pp trans mutant in complex with carfilzomib only showed partial occupancy of the ligand at the β5 active sites (Supplementary Fig. 5b and Supplementary Table 1).	RESULTS
9	20	acetylation	ptm	Since no acetylation of the Thr1 N terminus was observed for the β5-K33A pp trans apo crystal structure, the reduced reactivity towards substrates and inhibitors indicates that Lys33NH2, rather than Thr1NH2, deprotonates and activates Thr1OH.	RESULTS
28	32	Thr1	residue_name_number	Since no acetylation of the Thr1 N terminus was observed for the β5-K33A pp trans apo crystal structure, the reduced reactivity towards substrates and inhibitors indicates that Lys33NH2, rather than Thr1NH2, deprotonates and activates Thr1OH.	RESULTS
65	72	β5-K33A	mutant	Since no acetylation of the Thr1 N terminus was observed for the β5-K33A pp trans apo crystal structure, the reduced reactivity towards substrates and inhibitors indicates that Lys33NH2, rather than Thr1NH2, deprotonates and activates Thr1OH.	RESULTS
73	75	pp	chemical	Since no acetylation of the Thr1 N terminus was observed for the β5-K33A pp trans apo crystal structure, the reduced reactivity towards substrates and inhibitors indicates that Lys33NH2, rather than Thr1NH2, deprotonates and activates Thr1OH.	RESULTS
76	81	trans	protein_state	Since no acetylation of the Thr1 N terminus was observed for the β5-K33A pp trans apo crystal structure, the reduced reactivity towards substrates and inhibitors indicates that Lys33NH2, rather than Thr1NH2, deprotonates and activates Thr1OH.	RESULTS
82	85	apo	protein_state	Since no acetylation of the Thr1 N terminus was observed for the β5-K33A pp trans apo crystal structure, the reduced reactivity towards substrates and inhibitors indicates that Lys33NH2, rather than Thr1NH2, deprotonates and activates Thr1OH.	RESULTS
86	103	crystal structure	evidence	Since no acetylation of the Thr1 N terminus was observed for the β5-K33A pp trans apo crystal structure, the reduced reactivity towards substrates and inhibitors indicates that Lys33NH2, rather than Thr1NH2, deprotonates and activates Thr1OH.	RESULTS
177	182	Lys33	residue_name_number	Since no acetylation of the Thr1 N terminus was observed for the β5-K33A pp trans apo crystal structure, the reduced reactivity towards substrates and inhibitors indicates that Lys33NH2, rather than Thr1NH2, deprotonates and activates Thr1OH.	RESULTS
199	203	Thr1	residue_name_number	Since no acetylation of the Thr1 N terminus was observed for the β5-K33A pp trans apo crystal structure, the reduced reactivity towards substrates and inhibitors indicates that Lys33NH2, rather than Thr1NH2, deprotonates and activates Thr1OH.	RESULTS
235	239	Thr1	residue_name_number	Since no acetylation of the Thr1 N terminus was observed for the β5-K33A pp trans apo crystal structure, the reduced reactivity towards substrates and inhibitors indicates that Lys33NH2, rather than Thr1NH2, deprotonates and activates Thr1OH.	RESULTS
17	34	crystal structure	evidence	Furthermore, the crystal structure of the β5-K33A pp trans mutant without inhibitor revealed that Thr1Oγ strongly coordinates a well-defined water molecule (∼2 Å; Fig. 3c and Supplementary Fig. 5c,d).	RESULTS
42	49	β5-K33A	mutant	Furthermore, the crystal structure of the β5-K33A pp trans mutant without inhibitor revealed that Thr1Oγ strongly coordinates a well-defined water molecule (∼2 Å; Fig. 3c and Supplementary Fig. 5c,d).	RESULTS
50	52	pp	chemical	Furthermore, the crystal structure of the β5-K33A pp trans mutant without inhibitor revealed that Thr1Oγ strongly coordinates a well-defined water molecule (∼2 Å; Fig. 3c and Supplementary Fig. 5c,d).	RESULTS
53	58	trans	protein_state	Furthermore, the crystal structure of the β5-K33A pp trans mutant without inhibitor revealed that Thr1Oγ strongly coordinates a well-defined water molecule (∼2 Å; Fig. 3c and Supplementary Fig. 5c,d).	RESULTS
59	65	mutant	protein_state	Furthermore, the crystal structure of the β5-K33A pp trans mutant without inhibitor revealed that Thr1Oγ strongly coordinates a well-defined water molecule (∼2 Å; Fig. 3c and Supplementary Fig. 5c,d).	RESULTS
66	83	without inhibitor	protein_state	Furthermore, the crystal structure of the β5-K33A pp trans mutant without inhibitor revealed that Thr1Oγ strongly coordinates a well-defined water molecule (∼2 Å; Fig. 3c and Supplementary Fig. 5c,d).	RESULTS
98	102	Thr1	residue_name_number	Furthermore, the crystal structure of the β5-K33A pp trans mutant without inhibitor revealed that Thr1Oγ strongly coordinates a well-defined water molecule (∼2 Å; Fig. 3c and Supplementary Fig. 5c,d).	RESULTS
141	146	water	chemical	Furthermore, the crystal structure of the β5-K33A pp trans mutant without inhibitor revealed that Thr1Oγ strongly coordinates a well-defined water molecule (∼2 Å; Fig. 3c and Supplementary Fig. 5c,d).	RESULTS
5	10	water	chemical	This water hydrogen bonds also to Arg19O (∼3.0 Å) and Asp17Oδ (∼3.0 Å), and thereby presumably enables residual activity of the mutant.	RESULTS
34	39	Arg19	residue_name_number	This water hydrogen bonds also to Arg19O (∼3.0 Å) and Asp17Oδ (∼3.0 Å), and thereby presumably enables residual activity of the mutant.	RESULTS
54	59	Asp17	residue_name_number	This water hydrogen bonds also to Arg19O (∼3.0 Å) and Asp17Oδ (∼3.0 Å), and thereby presumably enables residual activity of the mutant.	RESULTS
128	134	mutant	protein_state	This water hydrogen bonds also to Arg19O (∼3.0 Å) and Asp17Oδ (∼3.0 Å), and thereby presumably enables residual activity of the mutant.	RESULTS
73	78	Lys33	residue_name_number	Remarkably, the solvent molecule occupies the position normally taken by Lys33NH2 in the WT proteasome structure (Fig. 3c), further corroborating the essential role of Lys33 as the general base for autolysis and proteolysis.	RESULTS
89	91	WT	protein_state	Remarkably, the solvent molecule occupies the position normally taken by Lys33NH2 in the WT proteasome structure (Fig. 3c), further corroborating the essential role of Lys33 as the general base for autolysis and proteolysis.	RESULTS
92	102	proteasome	complex_assembly	Remarkably, the solvent molecule occupies the position normally taken by Lys33NH2 in the WT proteasome structure (Fig. 3c), further corroborating the essential role of Lys33 as the general base for autolysis and proteolysis.	RESULTS
103	112	structure	evidence	Remarkably, the solvent molecule occupies the position normally taken by Lys33NH2 in the WT proteasome structure (Fig. 3c), further corroborating the essential role of Lys33 as the general base for autolysis and proteolysis.	RESULTS
168	173	Lys33	residue_name_number	Remarkably, the solvent molecule occupies the position normally taken by Lys33NH2 in the WT proteasome structure (Fig. 3c), further corroborating the essential role of Lys33 as the general base for autolysis and proteolysis.	RESULTS
198	207	autolysis	ptm	Remarkably, the solvent molecule occupies the position normally taken by Lys33NH2 in the WT proteasome structure (Fig. 3c), further corroborating the essential role of Lys33 as the general base for autolysis and proteolysis.	RESULTS
0	25	Conservative substitution	experimental_method	Conservative substitution of Lys33 by Arg delays autolysis of the β5 precursor and impairs yeast growth (for details see Supplementary Note 1).	RESULTS
29	34	Lys33	residue_name_number	Conservative substitution of Lys33 by Arg delays autolysis of the β5 precursor and impairs yeast growth (for details see Supplementary Note 1).	RESULTS
38	41	Arg	residue_name	Conservative substitution of Lys33 by Arg delays autolysis of the β5 precursor and impairs yeast growth (for details see Supplementary Note 1).	RESULTS
49	58	autolysis	ptm	Conservative substitution of Lys33 by Arg delays autolysis of the β5 precursor and impairs yeast growth (for details see Supplementary Note 1).	RESULTS
66	68	β5	protein	Conservative substitution of Lys33 by Arg delays autolysis of the β5 precursor and impairs yeast growth (for details see Supplementary Note 1).	RESULTS
91	96	yeast	taxonomy_domain	Conservative substitution of Lys33 by Arg delays autolysis of the β5 precursor and impairs yeast growth (for details see Supplementary Note 1).	RESULTS
6	10	Thr1	residue_name_number	While Thr1 occupies the same position as in WT yCPs, Arg33 is unable to hydrogen bond to Asp17, thereby inactivating the β5 active site (Supplementary Fig. 5e).	RESULTS
44	46	WT	protein_state	While Thr1 occupies the same position as in WT yCPs, Arg33 is unable to hydrogen bond to Asp17, thereby inactivating the β5 active site (Supplementary Fig. 5e).	RESULTS
47	51	yCPs	complex_assembly	While Thr1 occupies the same position as in WT yCPs, Arg33 is unable to hydrogen bond to Asp17, thereby inactivating the β5 active site (Supplementary Fig. 5e).	RESULTS
53	58	Arg33	residue_name_number	While Thr1 occupies the same position as in WT yCPs, Arg33 is unable to hydrogen bond to Asp17, thereby inactivating the β5 active site (Supplementary Fig. 5e).	RESULTS
89	94	Asp17	residue_name_number	While Thr1 occupies the same position as in WT yCPs, Arg33 is unable to hydrogen bond to Asp17, thereby inactivating the β5 active site (Supplementary Fig. 5e).	RESULTS
121	123	β5	protein	While Thr1 occupies the same position as in WT yCPs, Arg33 is unable to hydrogen bond to Asp17, thereby inactivating the β5 active site (Supplementary Fig. 5e).	RESULTS
124	135	active site	site	While Thr1 occupies the same position as in WT yCPs, Arg33 is unable to hydrogen bond to Asp17, thereby inactivating the β5 active site (Supplementary Fig. 5e).	RESULTS
4	25	conservative mutation	experimental_method	The conservative mutation of Asp17 to Asn in subunit β5 of the yCP also provokes a severe growth defect (Supplementary Note 1, Supplementary Fig. 6a and Table 1).	RESULTS
29	34	Asp17	residue_name_number	The conservative mutation of Asp17 to Asn in subunit β5 of the yCP also provokes a severe growth defect (Supplementary Note 1, Supplementary Fig. 6a and Table 1).	RESULTS
38	41	Asn	residue_name	The conservative mutation of Asp17 to Asn in subunit β5 of the yCP also provokes a severe growth defect (Supplementary Note 1, Supplementary Fig. 6a and Table 1).	RESULTS
53	55	β5	protein	The conservative mutation of Asp17 to Asn in subunit β5 of the yCP also provokes a severe growth defect (Supplementary Note 1, Supplementary Fig. 6a and Table 1).	RESULTS
63	66	yCP	complex_assembly	The conservative mutation of Asp17 to Asn in subunit β5 of the yCP also provokes a severe growth defect (Supplementary Note 1, Supplementary Fig. 6a and Table 1).	RESULTS
49	56	L(-49)S	mutant	Notably, only with the additional point mutation L(-49)S present in the β5 propeptide could we purify a small amount of the β5-D17N mutant yCP.	RESULTS
72	74	β5	protein	Notably, only with the additional point mutation L(-49)S present in the β5 propeptide could we purify a small amount of the β5-D17N mutant yCP.	RESULTS
75	85	propeptide	structure_element	Notably, only with the additional point mutation L(-49)S present in the β5 propeptide could we purify a small amount of the β5-D17N mutant yCP.	RESULTS
124	131	β5-D17N	mutant	Notably, only with the additional point mutation L(-49)S present in the β5 propeptide could we purify a small amount of the β5-D17N mutant yCP.	RESULTS
132	138	mutant	protein_state	Notably, only with the additional point mutation L(-49)S present in the β5 propeptide could we purify a small amount of the β5-D17N mutant yCP.	RESULTS
139	142	yCP	complex_assembly	Notably, only with the additional point mutation L(-49)S present in the β5 propeptide could we purify a small amount of the β5-D17N mutant yCP.	RESULTS
17	42	crystallographic analysis	experimental_method	As determined by crystallographic analysis, this mutant β5 subunit was partially processed (Table 1) but displayed impaired reactivity towards the proteasome inhibitor carfilzomib compared with the subunits β1 and β2, and with WT β5 (Supplementary Fig. 7a).	RESULTS
49	55	mutant	protein_state	As determined by crystallographic analysis, this mutant β5 subunit was partially processed (Table 1) but displayed impaired reactivity towards the proteasome inhibitor carfilzomib compared with the subunits β1 and β2, and with WT β5 (Supplementary Fig. 7a).	RESULTS
56	58	β5	protein	As determined by crystallographic analysis, this mutant β5 subunit was partially processed (Table 1) but displayed impaired reactivity towards the proteasome inhibitor carfilzomib compared with the subunits β1 and β2, and with WT β5 (Supplementary Fig. 7a).	RESULTS
71	90	partially processed	protein_state	As determined by crystallographic analysis, this mutant β5 subunit was partially processed (Table 1) but displayed impaired reactivity towards the proteasome inhibitor carfilzomib compared with the subunits β1 and β2, and with WT β5 (Supplementary Fig. 7a).	RESULTS
147	157	proteasome	complex_assembly	As determined by crystallographic analysis, this mutant β5 subunit was partially processed (Table 1) but displayed impaired reactivity towards the proteasome inhibitor carfilzomib compared with the subunits β1 and β2, and with WT β5 (Supplementary Fig. 7a).	RESULTS
168	179	carfilzomib	chemical	As determined by crystallographic analysis, this mutant β5 subunit was partially processed (Table 1) but displayed impaired reactivity towards the proteasome inhibitor carfilzomib compared with the subunits β1 and β2, and with WT β5 (Supplementary Fig. 7a).	RESULTS
207	209	β1	protein	As determined by crystallographic analysis, this mutant β5 subunit was partially processed (Table 1) but displayed impaired reactivity towards the proteasome inhibitor carfilzomib compared with the subunits β1 and β2, and with WT β5 (Supplementary Fig. 7a).	RESULTS
214	216	β2	protein	As determined by crystallographic analysis, this mutant β5 subunit was partially processed (Table 1) but displayed impaired reactivity towards the proteasome inhibitor carfilzomib compared with the subunits β1 and β2, and with WT β5 (Supplementary Fig. 7a).	RESULTS
227	229	WT	protein_state	As determined by crystallographic analysis, this mutant β5 subunit was partially processed (Table 1) but displayed impaired reactivity towards the proteasome inhibitor carfilzomib compared with the subunits β1 and β2, and with WT β5 (Supplementary Fig. 7a).	RESULTS
230	232	β5	protein	As determined by crystallographic analysis, this mutant β5 subunit was partially processed (Table 1) but displayed impaired reactivity towards the proteasome inhibitor carfilzomib compared with the subunits β1 and β2, and with WT β5 (Supplementary Fig. 7a).	RESULTS
19	22	cis	protein_state	In contrast to the cis-construct, expression of the β5 propeptide in trans allowed straightforward isolation and crystallization of the D17N mutant proteasome.	RESULTS
34	44	expression	experimental_method	In contrast to the cis-construct, expression of the β5 propeptide in trans allowed straightforward isolation and crystallization of the D17N mutant proteasome.	RESULTS
52	54	β5	protein	In contrast to the cis-construct, expression of the β5 propeptide in trans allowed straightforward isolation and crystallization of the D17N mutant proteasome.	RESULTS
55	65	propeptide	structure_element	In contrast to the cis-construct, expression of the β5 propeptide in trans allowed straightforward isolation and crystallization of the D17N mutant proteasome.	RESULTS
69	74	trans	protein_state	In contrast to the cis-construct, expression of the β5 propeptide in trans allowed straightforward isolation and crystallization of the D17N mutant proteasome.	RESULTS
99	108	isolation	experimental_method	In contrast to the cis-construct, expression of the β5 propeptide in trans allowed straightforward isolation and crystallization of the D17N mutant proteasome.	RESULTS
113	128	crystallization	experimental_method	In contrast to the cis-construct, expression of the β5 propeptide in trans allowed straightforward isolation and crystallization of the D17N mutant proteasome.	RESULTS
136	140	D17N	mutant	In contrast to the cis-construct, expression of the β5 propeptide in trans allowed straightforward isolation and crystallization of the D17N mutant proteasome.	RESULTS
141	147	mutant	protein_state	In contrast to the cis-construct, expression of the β5 propeptide in trans allowed straightforward isolation and crystallization of the D17N mutant proteasome.	RESULTS
148	158	proteasome	complex_assembly	In contrast to the cis-construct, expression of the β5 propeptide in trans allowed straightforward isolation and crystallization of the D17N mutant proteasome.	RESULTS
26	33	β5-D17N	mutant	The ChT-L activity of the β5-D17N pp in trans CP towards the canonical β5 model substrates N-succinyl-Leu-Leu-Val-Tyr-7-amino-4-methylcoumarin (Suc-LLVY-AMC) and carboxybenzyl-Gly-Gly-Leu-para-nitroanilide (Z-GGL-pNA) was severely reduced (Supplementary Fig. 6b), confirming that Asp17 is of fundamental importance for the catalytic activity of the mature proteasome.	RESULTS
34	36	pp	chemical	The ChT-L activity of the β5-D17N pp in trans CP towards the canonical β5 model substrates N-succinyl-Leu-Leu-Val-Tyr-7-amino-4-methylcoumarin (Suc-LLVY-AMC) and carboxybenzyl-Gly-Gly-Leu-para-nitroanilide (Z-GGL-pNA) was severely reduced (Supplementary Fig. 6b), confirming that Asp17 is of fundamental importance for the catalytic activity of the mature proteasome.	RESULTS
40	45	trans	protein_state	The ChT-L activity of the β5-D17N pp in trans CP towards the canonical β5 model substrates N-succinyl-Leu-Leu-Val-Tyr-7-amino-4-methylcoumarin (Suc-LLVY-AMC) and carboxybenzyl-Gly-Gly-Leu-para-nitroanilide (Z-GGL-pNA) was severely reduced (Supplementary Fig. 6b), confirming that Asp17 is of fundamental importance for the catalytic activity of the mature proteasome.	RESULTS
46	48	CP	complex_assembly	The ChT-L activity of the β5-D17N pp in trans CP towards the canonical β5 model substrates N-succinyl-Leu-Leu-Val-Tyr-7-amino-4-methylcoumarin (Suc-LLVY-AMC) and carboxybenzyl-Gly-Gly-Leu-para-nitroanilide (Z-GGL-pNA) was severely reduced (Supplementary Fig. 6b), confirming that Asp17 is of fundamental importance for the catalytic activity of the mature proteasome.	RESULTS
71	73	β5	protein	The ChT-L activity of the β5-D17N pp in trans CP towards the canonical β5 model substrates N-succinyl-Leu-Leu-Val-Tyr-7-amino-4-methylcoumarin (Suc-LLVY-AMC) and carboxybenzyl-Gly-Gly-Leu-para-nitroanilide (Z-GGL-pNA) was severely reduced (Supplementary Fig. 6b), confirming that Asp17 is of fundamental importance for the catalytic activity of the mature proteasome.	RESULTS
91	142	N-succinyl-Leu-Leu-Val-Tyr-7-amino-4-methylcoumarin	chemical	The ChT-L activity of the β5-D17N pp in trans CP towards the canonical β5 model substrates N-succinyl-Leu-Leu-Val-Tyr-7-amino-4-methylcoumarin (Suc-LLVY-AMC) and carboxybenzyl-Gly-Gly-Leu-para-nitroanilide (Z-GGL-pNA) was severely reduced (Supplementary Fig. 6b), confirming that Asp17 is of fundamental importance for the catalytic activity of the mature proteasome.	RESULTS
144	156	Suc-LLVY-AMC	chemical	The ChT-L activity of the β5-D17N pp in trans CP towards the canonical β5 model substrates N-succinyl-Leu-Leu-Val-Tyr-7-amino-4-methylcoumarin (Suc-LLVY-AMC) and carboxybenzyl-Gly-Gly-Leu-para-nitroanilide (Z-GGL-pNA) was severely reduced (Supplementary Fig. 6b), confirming that Asp17 is of fundamental importance for the catalytic activity of the mature proteasome.	RESULTS
162	205	carboxybenzyl-Gly-Gly-Leu-para-nitroanilide	chemical	The ChT-L activity of the β5-D17N pp in trans CP towards the canonical β5 model substrates N-succinyl-Leu-Leu-Val-Tyr-7-amino-4-methylcoumarin (Suc-LLVY-AMC) and carboxybenzyl-Gly-Gly-Leu-para-nitroanilide (Z-GGL-pNA) was severely reduced (Supplementary Fig. 6b), confirming that Asp17 is of fundamental importance for the catalytic activity of the mature proteasome.	RESULTS
207	216	Z-GGL-pNA	chemical	The ChT-L activity of the β5-D17N pp in trans CP towards the canonical β5 model substrates N-succinyl-Leu-Leu-Val-Tyr-7-amino-4-methylcoumarin (Suc-LLVY-AMC) and carboxybenzyl-Gly-Gly-Leu-para-nitroanilide (Z-GGL-pNA) was severely reduced (Supplementary Fig. 6b), confirming that Asp17 is of fundamental importance for the catalytic activity of the mature proteasome.	RESULTS
280	285	Asp17	residue_name_number	The ChT-L activity of the β5-D17N pp in trans CP towards the canonical β5 model substrates N-succinyl-Leu-Leu-Val-Tyr-7-amino-4-methylcoumarin (Suc-LLVY-AMC) and carboxybenzyl-Gly-Gly-Leu-para-nitroanilide (Z-GGL-pNA) was severely reduced (Supplementary Fig. 6b), confirming that Asp17 is of fundamental importance for the catalytic activity of the mature proteasome.	RESULTS
349	355	mature	protein_state	The ChT-L activity of the β5-D17N pp in trans CP towards the canonical β5 model substrates N-succinyl-Leu-Leu-Val-Tyr-7-amino-4-methylcoumarin (Suc-LLVY-AMC) and carboxybenzyl-Gly-Gly-Leu-para-nitroanilide (Z-GGL-pNA) was severely reduced (Supplementary Fig. 6b), confirming that Asp17 is of fundamental importance for the catalytic activity of the mature proteasome.	RESULTS
356	366	proteasome	complex_assembly	The ChT-L activity of the β5-D17N pp in trans CP towards the canonical β5 model substrates N-succinyl-Leu-Leu-Val-Tyr-7-amino-4-methylcoumarin (Suc-LLVY-AMC) and carboxybenzyl-Gly-Gly-Leu-para-nitroanilide (Z-GGL-pNA) was severely reduced (Supplementary Fig. 6b), confirming that Asp17 is of fundamental importance for the catalytic activity of the mature proteasome.	RESULTS
16	23	β5-D17N	mutant	Even though the β5-D17N pp trans yCP crystal structure appeared identical to the WT yCP (Supplementary Fig. 7b), the co-crystal structure with the α′, β′ epoxyketone inhibitor carfilzomib visualized only partial occupancy of the ligand in the β5 active site (Supplementary Fig. 7a).	RESULTS
24	26	pp	chemical	Even though the β5-D17N pp trans yCP crystal structure appeared identical to the WT yCP (Supplementary Fig. 7b), the co-crystal structure with the α′, β′ epoxyketone inhibitor carfilzomib visualized only partial occupancy of the ligand in the β5 active site (Supplementary Fig. 7a).	RESULTS
27	32	trans	protein_state	Even though the β5-D17N pp trans yCP crystal structure appeared identical to the WT yCP (Supplementary Fig. 7b), the co-crystal structure with the α′, β′ epoxyketone inhibitor carfilzomib visualized only partial occupancy of the ligand in the β5 active site (Supplementary Fig. 7a).	RESULTS
33	36	yCP	complex_assembly	Even though the β5-D17N pp trans yCP crystal structure appeared identical to the WT yCP (Supplementary Fig. 7b), the co-crystal structure with the α′, β′ epoxyketone inhibitor carfilzomib visualized only partial occupancy of the ligand in the β5 active site (Supplementary Fig. 7a).	RESULTS
37	54	crystal structure	evidence	Even though the β5-D17N pp trans yCP crystal structure appeared identical to the WT yCP (Supplementary Fig. 7b), the co-crystal structure with the α′, β′ epoxyketone inhibitor carfilzomib visualized only partial occupancy of the ligand in the β5 active site (Supplementary Fig. 7a).	RESULTS
81	83	WT	protein_state	Even though the β5-D17N pp trans yCP crystal structure appeared identical to the WT yCP (Supplementary Fig. 7b), the co-crystal structure with the α′, β′ epoxyketone inhibitor carfilzomib visualized only partial occupancy of the ligand in the β5 active site (Supplementary Fig. 7a).	RESULTS
84	87	yCP	complex_assembly	Even though the β5-D17N pp trans yCP crystal structure appeared identical to the WT yCP (Supplementary Fig. 7b), the co-crystal structure with the α′, β′ epoxyketone inhibitor carfilzomib visualized only partial occupancy of the ligand in the β5 active site (Supplementary Fig. 7a).	RESULTS
117	137	co-crystal structure	evidence	Even though the β5-D17N pp trans yCP crystal structure appeared identical to the WT yCP (Supplementary Fig. 7b), the co-crystal structure with the α′, β′ epoxyketone inhibitor carfilzomib visualized only partial occupancy of the ligand in the β5 active site (Supplementary Fig. 7a).	RESULTS
147	165	α′, β′ epoxyketone	chemical	Even though the β5-D17N pp trans yCP crystal structure appeared identical to the WT yCP (Supplementary Fig. 7b), the co-crystal structure with the α′, β′ epoxyketone inhibitor carfilzomib visualized only partial occupancy of the ligand in the β5 active site (Supplementary Fig. 7a).	RESULTS
176	187	carfilzomib	chemical	Even though the β5-D17N pp trans yCP crystal structure appeared identical to the WT yCP (Supplementary Fig. 7b), the co-crystal structure with the α′, β′ epoxyketone inhibitor carfilzomib visualized only partial occupancy of the ligand in the β5 active site (Supplementary Fig. 7a).	RESULTS
243	245	β5	protein	Even though the β5-D17N pp trans yCP crystal structure appeared identical to the WT yCP (Supplementary Fig. 7b), the co-crystal structure with the α′, β′ epoxyketone inhibitor carfilzomib visualized only partial occupancy of the ligand in the β5 active site (Supplementary Fig. 7a).	RESULTS
246	257	active site	site	Even though the β5-D17N pp trans yCP crystal structure appeared identical to the WT yCP (Supplementary Fig. 7b), the co-crystal structure with the α′, β′ epoxyketone inhibitor carfilzomib visualized only partial occupancy of the ligand in the β5 active site (Supplementary Fig. 7a).	RESULTS
69	71	β5	protein	This observation is consistent with a strongly reduced reactivity of β5-Thr1 and the crystal structure of the β5-D17N pp cis mutant in complex with carfilzomib.	RESULTS
72	76	Thr1	residue_name_number	This observation is consistent with a strongly reduced reactivity of β5-Thr1 and the crystal structure of the β5-D17N pp cis mutant in complex with carfilzomib.	RESULTS
85	102	crystal structure	evidence	This observation is consistent with a strongly reduced reactivity of β5-Thr1 and the crystal structure of the β5-D17N pp cis mutant in complex with carfilzomib.	RESULTS
110	117	β5-D17N	mutant	This observation is consistent with a strongly reduced reactivity of β5-Thr1 and the crystal structure of the β5-D17N pp cis mutant in complex with carfilzomib.	RESULTS
118	120	pp	chemical	This observation is consistent with a strongly reduced reactivity of β5-Thr1 and the crystal structure of the β5-D17N pp cis mutant in complex with carfilzomib.	RESULTS
121	124	cis	protein_state	This observation is consistent with a strongly reduced reactivity of β5-Thr1 and the crystal structure of the β5-D17N pp cis mutant in complex with carfilzomib.	RESULTS
125	131	mutant	protein_state	This observation is consistent with a strongly reduced reactivity of β5-Thr1 and the crystal structure of the β5-D17N pp cis mutant in complex with carfilzomib.	RESULTS
132	147	in complex with	protein_state	This observation is consistent with a strongly reduced reactivity of β5-Thr1 and the crystal structure of the β5-D17N pp cis mutant in complex with carfilzomib.	RESULTS
148	159	carfilzomib	chemical	This observation is consistent with a strongly reduced reactivity of β5-Thr1 and the crystal structure of the β5-D17N pp cis mutant in complex with carfilzomib.	RESULTS
0	9	Autolysis	ptm	Autolysis and residual catalytic activity of the β5-D17N mutants may originate from the carbonyl group of Asn17, which albeit to a lower degree still can polarize Lys33 for the activation of Thr1.	RESULTS
49	56	β5-D17N	mutant	Autolysis and residual catalytic activity of the β5-D17N mutants may originate from the carbonyl group of Asn17, which albeit to a lower degree still can polarize Lys33 for the activation of Thr1.	RESULTS
106	111	Asn17	residue_name_number	Autolysis and residual catalytic activity of the β5-D17N mutants may originate from the carbonyl group of Asn17, which albeit to a lower degree still can polarize Lys33 for the activation of Thr1.	RESULTS
163	168	Lys33	residue_name_number	Autolysis and residual catalytic activity of the β5-D17N mutants may originate from the carbonyl group of Asn17, which albeit to a lower degree still can polarize Lys33 for the activation of Thr1.	RESULTS
191	195	Thr1	residue_name_number	Autolysis and residual catalytic activity of the β5-D17N mutants may originate from the carbonyl group of Asn17, which albeit to a lower degree still can polarize Lys33 for the activation of Thr1.	RESULTS
17	21	E17A	mutant	In agreement, an E17A mutant in the proteasomal β-subunit of the archaeon Thermoplasma acidophilum prevents autolysis and catalysis.	RESULTS
22	28	mutant	protein_state	In agreement, an E17A mutant in the proteasomal β-subunit of the archaeon Thermoplasma acidophilum prevents autolysis and catalysis.	RESULTS
48	57	β-subunit	protein	In agreement, an E17A mutant in the proteasomal β-subunit of the archaeon Thermoplasma acidophilum prevents autolysis and catalysis.	RESULTS
65	73	archaeon	taxonomy_domain	In agreement, an E17A mutant in the proteasomal β-subunit of the archaeon Thermoplasma acidophilum prevents autolysis and catalysis.	RESULTS
74	98	Thermoplasma acidophilum	species	In agreement, an E17A mutant in the proteasomal β-subunit of the archaeon Thermoplasma acidophilum prevents autolysis and catalysis.	RESULTS
108	117	autolysis	ptm	In agreement, an E17A mutant in the proteasomal β-subunit of the archaeon Thermoplasma acidophilum prevents autolysis and catalysis.	RESULTS
25	35	X-ray data	evidence	Strikingly, although the X-ray data on the β5-D17N mutant with the propeptide expressed in cis and in trans looked similar, there was a pronounced difference in their growth phenotypes observed (Supplementary Fig. 6a and Supplementary Fig. 7b).	RESULTS
43	50	β5-D17N	mutant	Strikingly, although the X-ray data on the β5-D17N mutant with the propeptide expressed in cis and in trans looked similar, there was a pronounced difference in their growth phenotypes observed (Supplementary Fig. 6a and Supplementary Fig. 7b).	RESULTS
51	57	mutant	protein_state	Strikingly, although the X-ray data on the β5-D17N mutant with the propeptide expressed in cis and in trans looked similar, there was a pronounced difference in their growth phenotypes observed (Supplementary Fig. 6a and Supplementary Fig. 7b).	RESULTS
67	77	propeptide	structure_element	Strikingly, although the X-ray data on the β5-D17N mutant with the propeptide expressed in cis and in trans looked similar, there was a pronounced difference in their growth phenotypes observed (Supplementary Fig. 6a and Supplementary Fig. 7b).	RESULTS
78	87	expressed	experimental_method	Strikingly, although the X-ray data on the β5-D17N mutant with the propeptide expressed in cis and in trans looked similar, there was a pronounced difference in their growth phenotypes observed (Supplementary Fig. 6a and Supplementary Fig. 7b).	RESULTS
91	94	cis	protein_state	Strikingly, although the X-ray data on the β5-D17N mutant with the propeptide expressed in cis and in trans looked similar, there was a pronounced difference in their growth phenotypes observed (Supplementary Fig. 6a and Supplementary Fig. 7b).	RESULTS
102	107	trans	protein_state	Strikingly, although the X-ray data on the β5-D17N mutant with the propeptide expressed in cis and in trans looked similar, there was a pronounced difference in their growth phenotypes observed (Supplementary Fig. 6a and Supplementary Fig. 7b).	RESULTS
47	50	CPs	complex_assembly	On the basis of these results, we propose that CPs from all domains of life use a catalytic triad consisting of Thr1, Lys33 and Asp/Glu17 for both autocatalytic precursor processing and proteolysis (Fig. 3d).	RESULTS
82	97	catalytic triad	site	On the basis of these results, we propose that CPs from all domains of life use a catalytic triad consisting of Thr1, Lys33 and Asp/Glu17 for both autocatalytic precursor processing and proteolysis (Fig. 3d).	RESULTS
112	116	Thr1	residue_name_number	On the basis of these results, we propose that CPs from all domains of life use a catalytic triad consisting of Thr1, Lys33 and Asp/Glu17 for both autocatalytic precursor processing and proteolysis (Fig. 3d).	RESULTS
118	123	Lys33	residue_name_number	On the basis of these results, we propose that CPs from all domains of life use a catalytic triad consisting of Thr1, Lys33 and Asp/Glu17 for both autocatalytic precursor processing and proteolysis (Fig. 3d).	RESULTS
128	131	Asp	residue_name	On the basis of these results, we propose that CPs from all domains of life use a catalytic triad consisting of Thr1, Lys33 and Asp/Glu17 for both autocatalytic precursor processing and proteolysis (Fig. 3d).	RESULTS
132	137	Glu17	residue_name_number	On the basis of these results, we propose that CPs from all domains of life use a catalytic triad consisting of Thr1, Lys33 and Asp/Glu17 for both autocatalytic precursor processing and proteolysis (Fig. 3d).	RESULTS
147	181	autocatalytic precursor processing	ptm	On the basis of these results, we propose that CPs from all domains of life use a catalytic triad consisting of Thr1, Lys33 and Asp/Glu17 for both autocatalytic precursor processing and proteolysis (Fig. 3d).	RESULTS
60	65	water	chemical	This model is also consistent with the fact that no defined water molecule is observed in the mature WT proteasomal active site that could shuttle the proton from Thr1Oγ to Thr1NH2.	RESULTS
94	100	mature	protein_state	This model is also consistent with the fact that no defined water molecule is observed in the mature WT proteasomal active site that could shuttle the proton from Thr1Oγ to Thr1NH2.	RESULTS
101	103	WT	protein_state	This model is also consistent with the fact that no defined water molecule is observed in the mature WT proteasomal active site that could shuttle the proton from Thr1Oγ to Thr1NH2.	RESULTS
116	127	active site	site	This model is also consistent with the fact that no defined water molecule is observed in the mature WT proteasomal active site that could shuttle the proton from Thr1Oγ to Thr1NH2.	RESULTS
163	167	Thr1	residue_name_number	This model is also consistent with the fact that no defined water molecule is observed in the mature WT proteasomal active site that could shuttle the proton from Thr1Oγ to Thr1NH2.	RESULTS
173	177	Thr1	residue_name_number	This model is also consistent with the fact that no defined water molecule is observed in the mature WT proteasomal active site that could shuttle the proton from Thr1Oγ to Thr1NH2.	RESULTS
16	27	active-site	site	To explore this active-site model further, we exchanged the conserved Asp166 residue for Asn in the yeast β5 subunit.	RESULTS
46	69	exchanged the conserved	experimental_method	To explore this active-site model further, we exchanged the conserved Asp166 residue for Asn in the yeast β5 subunit.	RESULTS
70	76	Asp166	residue_name_number	To explore this active-site model further, we exchanged the conserved Asp166 residue for Asn in the yeast β5 subunit.	RESULTS
89	92	Asn	residue_name	To explore this active-site model further, we exchanged the conserved Asp166 residue for Asn in the yeast β5 subunit.	RESULTS
100	105	yeast	taxonomy_domain	To explore this active-site model further, we exchanged the conserved Asp166 residue for Asn in the yeast β5 subunit.	RESULTS
106	108	β5	protein	To explore this active-site model further, we exchanged the conserved Asp166 residue for Asn in the yeast β5 subunit.	RESULTS
0	6	Asp166	residue_name_number	Asp166Oδ is hydrogen-bonded to Thr1NH2 via Ser129OH and Ser169OH, and therefore was proposed to be involved in catalysis.	RESULTS
31	35	Thr1	residue_name_number	Asp166Oδ is hydrogen-bonded to Thr1NH2 via Ser129OH and Ser169OH, and therefore was proposed to be involved in catalysis.	RESULTS
43	49	Ser129	residue_name_number	Asp166Oδ is hydrogen-bonded to Thr1NH2 via Ser129OH and Ser169OH, and therefore was proposed to be involved in catalysis.	RESULTS
56	62	Ser169	residue_name_number	Asp166Oδ is hydrogen-bonded to Thr1NH2 via Ser129OH and Ser169OH, and therefore was proposed to be involved in catalysis.	RESULTS
4	12	β5-D166N	mutant	The β5-D166N pp cis yeast mutant is significantly impaired in growth and its ChT-L activity is drastically reduced (Supplementary Fig. 6a,b and Table 1).	RESULTS
13	15	pp	chemical	The β5-D166N pp cis yeast mutant is significantly impaired in growth and its ChT-L activity is drastically reduced (Supplementary Fig. 6a,b and Table 1).	RESULTS
16	19	cis	protein_state	The β5-D166N pp cis yeast mutant is significantly impaired in growth and its ChT-L activity is drastically reduced (Supplementary Fig. 6a,b and Table 1).	RESULTS
20	25	yeast	taxonomy_domain	The β5-D166N pp cis yeast mutant is significantly impaired in growth and its ChT-L activity is drastically reduced (Supplementary Fig. 6a,b and Table 1).	RESULTS
26	32	mutant	protein_state	The β5-D166N pp cis yeast mutant is significantly impaired in growth and its ChT-L activity is drastically reduced (Supplementary Fig. 6a,b and Table 1).	RESULTS
0	10	X-ray data	evidence	X-ray data on the β5-D166N mutant indicate that the β5 propeptide is hydrolysed, but due to reorientation of Ser129OH, the interaction with Asn166Oδ is disrupted (Supplementary Fig. 8a).	RESULTS
18	26	β5-D166N	mutant	X-ray data on the β5-D166N mutant indicate that the β5 propeptide is hydrolysed, but due to reorientation of Ser129OH, the interaction with Asn166Oδ is disrupted (Supplementary Fig. 8a).	RESULTS
27	33	mutant	protein_state	X-ray data on the β5-D166N mutant indicate that the β5 propeptide is hydrolysed, but due to reorientation of Ser129OH, the interaction with Asn166Oδ is disrupted (Supplementary Fig. 8a).	RESULTS
52	54	β5	protein	X-ray data on the β5-D166N mutant indicate that the β5 propeptide is hydrolysed, but due to reorientation of Ser129OH, the interaction with Asn166Oδ is disrupted (Supplementary Fig. 8a).	RESULTS
55	65	propeptide	structure_element	X-ray data on the β5-D166N mutant indicate that the β5 propeptide is hydrolysed, but due to reorientation of Ser129OH, the interaction with Asn166Oδ is disrupted (Supplementary Fig. 8a).	RESULTS
109	115	Ser129	residue_name_number	X-ray data on the β5-D166N mutant indicate that the β5 propeptide is hydrolysed, but due to reorientation of Ser129OH, the interaction with Asn166Oδ is disrupted (Supplementary Fig. 8a).	RESULTS
140	146	Asn166	residue_name_number	X-ray data on the β5-D166N mutant indicate that the β5 propeptide is hydrolysed, but due to reorientation of Ser129OH, the interaction with Asn166Oδ is disrupted (Supplementary Fig. 8a).	RESULTS
11	16	water	chemical	Instead, a water molecule is bound to Ser129OH and Thr1NH2 (Supplementary Fig. 8b), which may enable precursor processing.	RESULTS
29	37	bound to	protein_state	Instead, a water molecule is bound to Ser129OH and Thr1NH2 (Supplementary Fig. 8b), which may enable precursor processing.	RESULTS
38	44	Ser129	residue_name_number	Instead, a water molecule is bound to Ser129OH and Thr1NH2 (Supplementary Fig. 8b), which may enable precursor processing.	RESULTS
51	55	Thr1	residue_name_number	Instead, a water molecule is bound to Ser129OH and Thr1NH2 (Supplementary Fig. 8b), which may enable precursor processing.	RESULTS
101	121	precursor processing	ptm	Instead, a water molecule is bound to Ser129OH and Thr1NH2 (Supplementary Fig. 8b), which may enable precursor processing.	RESULTS
29	35	Ser169	residue_name_number	The hydrogen bonds involving Ser169OH are intact and may account for residual substrate turnover.	RESULTS
0	7	Soaking	experimental_method	Soaking the β5-D166N crystals with carfilzomib and MG132 resulted in covalent modification of Thr1 at high occupancy (Supplementary Fig. 8c).	RESULTS
12	20	β5-D166N	mutant	Soaking the β5-D166N crystals with carfilzomib and MG132 resulted in covalent modification of Thr1 at high occupancy (Supplementary Fig. 8c).	RESULTS
21	29	crystals	experimental_method	Soaking the β5-D166N crystals with carfilzomib and MG132 resulted in covalent modification of Thr1 at high occupancy (Supplementary Fig. 8c).	RESULTS
35	46	carfilzomib	chemical	Soaking the β5-D166N crystals with carfilzomib and MG132 resulted in covalent modification of Thr1 at high occupancy (Supplementary Fig. 8c).	RESULTS
51	56	MG132	chemical	Soaking the β5-D166N crystals with carfilzomib and MG132 resulted in covalent modification of Thr1 at high occupancy (Supplementary Fig. 8c).	RESULTS
94	98	Thr1	residue_name_number	Soaking the β5-D166N crystals with carfilzomib and MG132 resulted in covalent modification of Thr1 at high occupancy (Supplementary Fig. 8c).	RESULTS
7	26	carfilzomib complex	complex_assembly	In the carfilzomib complex structure, Thr1Oγ and Thr1N incorporate into a morpholine ring structure and Ser129 adopts its WT-like orientation.	RESULTS
27	36	structure	evidence	In the carfilzomib complex structure, Thr1Oγ and Thr1N incorporate into a morpholine ring structure and Ser129 adopts its WT-like orientation.	RESULTS
38	42	Thr1	residue_name_number	In the carfilzomib complex structure, Thr1Oγ and Thr1N incorporate into a morpholine ring structure and Ser129 adopts its WT-like orientation.	RESULTS
49	53	Thr1	residue_name_number	In the carfilzomib complex structure, Thr1Oγ and Thr1N incorporate into a morpholine ring structure and Ser129 adopts its WT-like orientation.	RESULTS
104	110	Ser129	residue_name_number	In the carfilzomib complex structure, Thr1Oγ and Thr1N incorporate into a morpholine ring structure and Ser129 adopts its WT-like orientation.	RESULTS
122	124	WT	protein_state	In the carfilzomib complex structure, Thr1Oγ and Thr1N incorporate into a morpholine ring structure and Ser129 adopts its WT-like orientation.	RESULTS
7	24	MG132-bound state	protein_state	In the MG132-bound state, Thr1N is unmodified, and we again observe that Ser129 is hydrogen-bonded to a water molecule instead of Asn166.	RESULTS
26	30	Thr1	residue_name_number	In the MG132-bound state, Thr1N is unmodified, and we again observe that Ser129 is hydrogen-bonded to a water molecule instead of Asn166.	RESULTS
35	45	unmodified	protein_state	In the MG132-bound state, Thr1N is unmodified, and we again observe that Ser129 is hydrogen-bonded to a water molecule instead of Asn166.	RESULTS
73	79	Ser129	residue_name_number	In the MG132-bound state, Thr1N is unmodified, and we again observe that Ser129 is hydrogen-bonded to a water molecule instead of Asn166.	RESULTS
104	109	water	chemical	In the MG132-bound state, Thr1N is unmodified, and we again observe that Ser129 is hydrogen-bonded to a water molecule instead of Asn166.	RESULTS
130	136	Asn166	residue_name_number	In the MG132-bound state, Thr1N is unmodified, and we again observe that Ser129 is hydrogen-bonded to a water molecule instead of Asn166.	RESULTS
8	11	Asn	residue_name	Whereas Asn can to some degree replace Asp166 due to its carbonyl group in the side chain, Ala at this position was found to prevent both autolysis and catalysis.	RESULTS
39	45	Asp166	residue_name_number	Whereas Asn can to some degree replace Asp166 due to its carbonyl group in the side chain, Ala at this position was found to prevent both autolysis and catalysis.	RESULTS
91	94	Ala	residue_name	Whereas Asn can to some degree replace Asp166 due to its carbonyl group in the side chain, Ala at this position was found to prevent both autolysis and catalysis.	RESULTS
138	147	autolysis	ptm	Whereas Asn can to some degree replace Asp166 due to its carbonyl group in the side chain, Ala at this position was found to prevent both autolysis and catalysis.	RESULTS
27	33	Asp166	residue_name_number	These results suggest that Asp166 and Ser129 function as a proton shuttle and affect the protonation state of Thr1N during autolysis and catalysis.	RESULTS
38	44	Ser129	residue_name_number	These results suggest that Asp166 and Ser129 function as a proton shuttle and affect the protonation state of Thr1N during autolysis and catalysis.	RESULTS
110	114	Thr1	residue_name_number	These results suggest that Asp166 and Ser129 function as a proton shuttle and affect the protonation state of Thr1N during autolysis and catalysis.	RESULTS
123	132	autolysis	ptm	These results suggest that Asp166 and Ser129 function as a proton shuttle and affect the protonation state of Thr1N during autolysis and catalysis.	RESULTS
0	12	Substitution	experimental_method	Substitution of the active-site Thr1 by Cys	RESULTS
20	31	active-site	site	Substitution of the active-site Thr1 by Cys	RESULTS
32	36	Thr1	residue_name_number	Substitution of the active-site Thr1 by Cys	RESULTS
40	43	Cys	residue_name	Substitution of the active-site Thr1 by Cys	RESULTS
0	8	Mutation	experimental_method	Mutation of Thr1 to Cys inactivates the 20S proteasome from the archaeon T. acidophilum.	RESULTS
12	16	Thr1	residue_name_number	Mutation of Thr1 to Cys inactivates the 20S proteasome from the archaeon T. acidophilum.	RESULTS
20	23	Cys	residue_name	Mutation of Thr1 to Cys inactivates the 20S proteasome from the archaeon T. acidophilum.	RESULTS
40	54	20S proteasome	complex_assembly	Mutation of Thr1 to Cys inactivates the 20S proteasome from the archaeon T. acidophilum.	RESULTS
64	72	archaeon	taxonomy_domain	Mutation of Thr1 to Cys inactivates the 20S proteasome from the archaeon T. acidophilum.	RESULTS
73	87	T. acidophilum	species	Mutation of Thr1 to Cys inactivates the 20S proteasome from the archaeon T. acidophilum.	RESULTS
3	8	yeast	taxonomy_domain	In yeast, this mutation causes a strong growth defect (Fig. 4a and Table 1), although the propeptide is hydrolysed, as shown here by its X-ray structure.	RESULTS
15	23	mutation	experimental_method	In yeast, this mutation causes a strong growth defect (Fig. 4a and Table 1), although the propeptide is hydrolysed, as shown here by its X-ray structure.	RESULTS
90	100	propeptide	structure_element	In yeast, this mutation causes a strong growth defect (Fig. 4a and Table 1), although the propeptide is hydrolysed, as shown here by its X-ray structure.	RESULTS
137	152	X-ray structure	evidence	In yeast, this mutation causes a strong growth defect (Fig. 4a and Table 1), although the propeptide is hydrolysed, as shown here by its X-ray structure.	RESULTS
18	20	β5	protein	In one of the two β5 subunits, however, we found the cleaved propeptide still bound in the substrate-binding channel (Fig. 4c).	RESULTS
53	60	cleaved	protein_state	In one of the two β5 subunits, however, we found the cleaved propeptide still bound in the substrate-binding channel (Fig. 4c).	RESULTS
61	71	propeptide	structure_element	In one of the two β5 subunits, however, we found the cleaved propeptide still bound in the substrate-binding channel (Fig. 4c).	RESULTS
72	83	still bound	protein_state	In one of the two β5 subunits, however, we found the cleaved propeptide still bound in the substrate-binding channel (Fig. 4c).	RESULTS
91	116	substrate-binding channel	site	In one of the two β5 subunits, however, we found the cleaved propeptide still bound in the substrate-binding channel (Fig. 4c).	RESULTS
0	7	His(-2)	residue_name_number	His(-2) occupies the S2 pocket like observed for the β5-T1A-K81R mutant, but in contrast to the latter, the propeptide in the T1C mutant adopts an antiparallel β-sheet conformation as known from inhibitors like MG132 (Fig. 4c–e and Supplementary Fig. 9b).	RESULTS
21	30	S2 pocket	site	His(-2) occupies the S2 pocket like observed for the β5-T1A-K81R mutant, but in contrast to the latter, the propeptide in the T1C mutant adopts an antiparallel β-sheet conformation as known from inhibitors like MG132 (Fig. 4c–e and Supplementary Fig. 9b).	RESULTS
53	64	β5-T1A-K81R	mutant	His(-2) occupies the S2 pocket like observed for the β5-T1A-K81R mutant, but in contrast to the latter, the propeptide in the T1C mutant adopts an antiparallel β-sheet conformation as known from inhibitors like MG132 (Fig. 4c–e and Supplementary Fig. 9b).	RESULTS
65	71	mutant	protein_state	His(-2) occupies the S2 pocket like observed for the β5-T1A-K81R mutant, but in contrast to the latter, the propeptide in the T1C mutant adopts an antiparallel β-sheet conformation as known from inhibitors like MG132 (Fig. 4c–e and Supplementary Fig. 9b).	RESULTS
108	118	propeptide	structure_element	His(-2) occupies the S2 pocket like observed for the β5-T1A-K81R mutant, but in contrast to the latter, the propeptide in the T1C mutant adopts an antiparallel β-sheet conformation as known from inhibitors like MG132 (Fig. 4c–e and Supplementary Fig. 9b).	RESULTS
126	129	T1C	mutant	His(-2) occupies the S2 pocket like observed for the β5-T1A-K81R mutant, but in contrast to the latter, the propeptide in the T1C mutant adopts an antiparallel β-sheet conformation as known from inhibitors like MG132 (Fig. 4c–e and Supplementary Fig. 9b).	RESULTS
130	136	mutant	protein_state	His(-2) occupies the S2 pocket like observed for the β5-T1A-K81R mutant, but in contrast to the latter, the propeptide in the T1C mutant adopts an antiparallel β-sheet conformation as known from inhibitors like MG132 (Fig. 4c–e and Supplementary Fig. 9b).	RESULTS
147	167	antiparallel β-sheet	structure_element	His(-2) occupies the S2 pocket like observed for the β5-T1A-K81R mutant, but in contrast to the latter, the propeptide in the T1C mutant adopts an antiparallel β-sheet conformation as known from inhibitors like MG132 (Fig. 4c–e and Supplementary Fig. 9b).	RESULTS
211	216	MG132	chemical	His(-2) occupies the S2 pocket like observed for the β5-T1A-K81R mutant, but in contrast to the latter, the propeptide in the T1C mutant adopts an antiparallel β-sheet conformation as known from inhibitors like MG132 (Fig. 4c–e and Supplementary Fig. 9b).	RESULTS
37	40	T1C	mutant	On the basis of the phenotype of the T1C mutant and the propeptide remnant identified in its active site, we suppose that autolysis is retarded and may not have been completed before crystallization.	RESULTS
41	47	mutant	protein_state	On the basis of the phenotype of the T1C mutant and the propeptide remnant identified in its active site, we suppose that autolysis is retarded and may not have been completed before crystallization.	RESULTS
56	66	propeptide	structure_element	On the basis of the phenotype of the T1C mutant and the propeptide remnant identified in its active site, we suppose that autolysis is retarded and may not have been completed before crystallization.	RESULTS
93	104	active site	site	On the basis of the phenotype of the T1C mutant and the propeptide remnant identified in its active site, we suppose that autolysis is retarded and may not have been completed before crystallization.	RESULTS
122	131	autolysis	ptm	On the basis of the phenotype of the T1C mutant and the propeptide remnant identified in its active site, we suppose that autolysis is retarded and may not have been completed before crystallization.	RESULTS
183	198	crystallization	experimental_method	On the basis of the phenotype of the T1C mutant and the propeptide remnant identified in its active site, we suppose that autolysis is retarded and may not have been completed before crystallization.	RESULTS
42	44	β5	protein	Owing to the unequal positions of the two β5 subunits within the CP in the crystal lattice, maturation and propeptide displacement may occur at different timescales in the two subunits.	RESULTS
65	67	CP	complex_assembly	Owing to the unequal positions of the two β5 subunits within the CP in the crystal lattice, maturation and propeptide displacement may occur at different timescales in the two subunits.	RESULTS
107	117	propeptide	structure_element	Owing to the unequal positions of the two β5 subunits within the CP in the crystal lattice, maturation and propeptide displacement may occur at different timescales in the two subunits.	RESULTS
8	29	propeptide hydrolysis	ptm	Despite propeptide hydrolysis, the β5-T1C active site is catalytically inactive (Fig. 4b and Supplementary Fig. 9a).	RESULTS
35	41	β5-T1C	mutant	Despite propeptide hydrolysis, the β5-T1C active site is catalytically inactive (Fig. 4b and Supplementary Fig. 9a).	RESULTS
42	53	active site	site	Despite propeptide hydrolysis, the β5-T1C active site is catalytically inactive (Fig. 4b and Supplementary Fig. 9a).	RESULTS
57	79	catalytically inactive	protein_state	Despite propeptide hydrolysis, the β5-T1C active site is catalytically inactive (Fig. 4b and Supplementary Fig. 9a).	RESULTS
14	30	soaking crystals	experimental_method	In agreement, soaking crystals with the CP inhibitors bortezomib or carfilzomib modifies only the β1 and β2 active sites, while leaving the β5-T1C proteolytic centres unmodified even though they are only partially occupied by the cleaved propeptide remnant.	RESULTS
40	42	CP	complex_assembly	In agreement, soaking crystals with the CP inhibitors bortezomib or carfilzomib modifies only the β1 and β2 active sites, while leaving the β5-T1C proteolytic centres unmodified even though they are only partially occupied by the cleaved propeptide remnant.	RESULTS
54	64	bortezomib	chemical	In agreement, soaking crystals with the CP inhibitors bortezomib or carfilzomib modifies only the β1 and β2 active sites, while leaving the β5-T1C proteolytic centres unmodified even though they are only partially occupied by the cleaved propeptide remnant.	RESULTS
68	79	carfilzomib	chemical	In agreement, soaking crystals with the CP inhibitors bortezomib or carfilzomib modifies only the β1 and β2 active sites, while leaving the β5-T1C proteolytic centres unmodified even though they are only partially occupied by the cleaved propeptide remnant.	RESULTS
98	100	β1	protein	In agreement, soaking crystals with the CP inhibitors bortezomib or carfilzomib modifies only the β1 and β2 active sites, while leaving the β5-T1C proteolytic centres unmodified even though they are only partially occupied by the cleaved propeptide remnant.	RESULTS
105	107	β2	protein	In agreement, soaking crystals with the CP inhibitors bortezomib or carfilzomib modifies only the β1 and β2 active sites, while leaving the β5-T1C proteolytic centres unmodified even though they are only partially occupied by the cleaved propeptide remnant.	RESULTS
108	120	active sites	site	In agreement, soaking crystals with the CP inhibitors bortezomib or carfilzomib modifies only the β1 and β2 active sites, while leaving the β5-T1C proteolytic centres unmodified even though they are only partially occupied by the cleaved propeptide remnant.	RESULTS
140	146	β5-T1C	mutant	In agreement, soaking crystals with the CP inhibitors bortezomib or carfilzomib modifies only the β1 and β2 active sites, while leaving the β5-T1C proteolytic centres unmodified even though they are only partially occupied by the cleaved propeptide remnant.	RESULTS
147	166	proteolytic centres	site	In agreement, soaking crystals with the CP inhibitors bortezomib or carfilzomib modifies only the β1 and β2 active sites, while leaving the β5-T1C proteolytic centres unmodified even though they are only partially occupied by the cleaved propeptide remnant.	RESULTS
167	177	unmodified	protein_state	In agreement, soaking crystals with the CP inhibitors bortezomib or carfilzomib modifies only the β1 and β2 active sites, while leaving the β5-T1C proteolytic centres unmodified even though they are only partially occupied by the cleaved propeptide remnant.	RESULTS
230	237	cleaved	protein_state	In agreement, soaking crystals with the CP inhibitors bortezomib or carfilzomib modifies only the β1 and β2 active sites, while leaving the β5-T1C proteolytic centres unmodified even though they are only partially occupied by the cleaved propeptide remnant.	RESULTS
238	248	propeptide	structure_element	In agreement, soaking crystals with the CP inhibitors bortezomib or carfilzomib modifies only the β1 and β2 active sites, while leaving the β5-T1C proteolytic centres unmodified even though they are only partially occupied by the cleaved propeptide remnant.	RESULTS
14	29	structural data	evidence	Moreover, the structural data reveal that the thiol group of Cys1 is rotated by 74° with respect to the hydroxyl side chain of Thr1 (Fig. 4f and Supplementary Fig. 9b).	RESULTS
61	65	Cys1	residue_name_number	Moreover, the structural data reveal that the thiol group of Cys1 is rotated by 74° with respect to the hydroxyl side chain of Thr1 (Fig. 4f and Supplementary Fig. 9b).	RESULTS
127	131	Thr1	residue_name_number	Moreover, the structural data reveal that the thiol group of Cys1 is rotated by 74° with respect to the hydroxyl side chain of Thr1 (Fig. 4f and Supplementary Fig. 9b).	RESULTS
73	78	Lys33	residue_name_number	Consequently, the hydrogen bond bridging the active-site nucleophile and Lys33 in WT CPs is broken with Cys1.	RESULTS
82	84	WT	protein_state	Consequently, the hydrogen bond bridging the active-site nucleophile and Lys33 in WT CPs is broken with Cys1.	RESULTS
85	88	CPs	complex_assembly	Consequently, the hydrogen bond bridging the active-site nucleophile and Lys33 in WT CPs is broken with Cys1.	RESULTS
104	108	Cys1	residue_name_number	Consequently, the hydrogen bond bridging the active-site nucleophile and Lys33 in WT CPs is broken with Cys1.	RESULTS
13	40	2FO–FC electron-density map	evidence	Notably, the 2FO–FC electron-density map of the T1C mutant also indicates that Lys33NH2 is disordered.	RESULTS
48	51	T1C	mutant	Notably, the 2FO–FC electron-density map of the T1C mutant also indicates that Lys33NH2 is disordered.	RESULTS
52	58	mutant	protein_state	Notably, the 2FO–FC electron-density map of the T1C mutant also indicates that Lys33NH2 is disordered.	RESULTS
79	84	Lys33	residue_name_number	Notably, the 2FO–FC electron-density map of the T1C mutant also indicates that Lys33NH2 is disordered.	RESULTS
91	101	disordered	protein_state	Notably, the 2FO–FC electron-density map of the T1C mutant also indicates that Lys33NH2 is disordered.	RESULTS
90	95	Lys33	residue_name_number	Together, these observations suggest that efficient peptide-bond hydrolysis requires that Lys33NH2 hydrogen bonds to the active site nucleophile.	RESULTS
15	18	Thr	residue_name	The benefit of Thr over Ser as the active-site nucleophile	RESULTS
24	27	Ser	residue_name	The benefit of Thr over Ser as the active-site nucleophile	RESULTS
4	15	proteasomes	complex_assembly	All proteasomes strictly employ threonine as the active-site residue instead of serine.	RESULTS
16	31	strictly employ	protein_state	All proteasomes strictly employ threonine as the active-site residue instead of serine.	RESULTS
32	41	threonine	residue_name	All proteasomes strictly employ threonine as the active-site residue instead of serine.	RESULTS
49	68	active-site residue	site	All proteasomes strictly employ threonine as the active-site residue instead of serine.	RESULTS
80	86	serine	residue_name	All proteasomes strictly employ threonine as the active-site residue instead of serine.	RESULTS
62	68	β5-T1S	mutant	To investigate the reason for this singularity, we analysed a β5-T1S mutant, which is viable but suffers from growth defects (Fig. 4a and Table 1).	RESULTS
69	75	mutant	protein_state	To investigate the reason for this singularity, we analysed a β5-T1S mutant, which is viable but suffers from growth defects (Fig. 4a and Table 1).	RESULTS
0	15	Activity assays	experimental_method	Activity assays with the β5-specific substrate Suc-LLVY-AMC demonstrated that the ChT-L activity of the T1S mutant is reduced by 40–45% compared with WT proteasomes depending on the incubation temperature (Fig. 4b and Supplementary Fig. 9c).	RESULTS
25	27	β5	protein	Activity assays with the β5-specific substrate Suc-LLVY-AMC demonstrated that the ChT-L activity of the T1S mutant is reduced by 40–45% compared with WT proteasomes depending on the incubation temperature (Fig. 4b and Supplementary Fig. 9c).	RESULTS
47	59	Suc-LLVY-AMC	chemical	Activity assays with the β5-specific substrate Suc-LLVY-AMC demonstrated that the ChT-L activity of the T1S mutant is reduced by 40–45% compared with WT proteasomes depending on the incubation temperature (Fig. 4b and Supplementary Fig. 9c).	RESULTS
104	107	T1S	mutant	Activity assays with the β5-specific substrate Suc-LLVY-AMC demonstrated that the ChT-L activity of the T1S mutant is reduced by 40–45% compared with WT proteasomes depending on the incubation temperature (Fig. 4b and Supplementary Fig. 9c).	RESULTS
108	114	mutant	protein_state	Activity assays with the β5-specific substrate Suc-LLVY-AMC demonstrated that the ChT-L activity of the T1S mutant is reduced by 40–45% compared with WT proteasomes depending on the incubation temperature (Fig. 4b and Supplementary Fig. 9c).	RESULTS
150	152	WT	protein_state	Activity assays with the β5-specific substrate Suc-LLVY-AMC demonstrated that the ChT-L activity of the T1S mutant is reduced by 40–45% compared with WT proteasomes depending on the incubation temperature (Fig. 4b and Supplementary Fig. 9c).	RESULTS
153	164	proteasomes	complex_assembly	Activity assays with the β5-specific substrate Suc-LLVY-AMC demonstrated that the ChT-L activity of the T1S mutant is reduced by 40–45% compared with WT proteasomes depending on the incubation temperature (Fig. 4b and Supplementary Fig. 9c).	RESULTS
39	48	Z-GGL-pNA	chemical	By contrast, turnover of the substrate Z-GGL-pNA, used to monitor ChT-L activity in situ but in a less quantitative fashion, is not detectably impaired (Supplementary Fig. 9a).	RESULTS
0	17	Crystal structure	evidence	Crystal structure analysis of the β5-T1S mutant confirmed precursor processing (Fig. 4g), and ligand-complex structures with bortezomib and carfilzomib unambiguously corroborated the reactivity of Ser1 (Fig. 5).	RESULTS
34	40	β5-T1S	mutant	Crystal structure analysis of the β5-T1S mutant confirmed precursor processing (Fig. 4g), and ligand-complex structures with bortezomib and carfilzomib unambiguously corroborated the reactivity of Ser1 (Fig. 5).	RESULTS
41	47	mutant	protein_state	Crystal structure analysis of the β5-T1S mutant confirmed precursor processing (Fig. 4g), and ligand-complex structures with bortezomib and carfilzomib unambiguously corroborated the reactivity of Ser1 (Fig. 5).	RESULTS
58	78	precursor processing	ptm	Crystal structure analysis of the β5-T1S mutant confirmed precursor processing (Fig. 4g), and ligand-complex structures with bortezomib and carfilzomib unambiguously corroborated the reactivity of Ser1 (Fig. 5).	RESULTS
94	108	ligand-complex	complex_assembly	Crystal structure analysis of the β5-T1S mutant confirmed precursor processing (Fig. 4g), and ligand-complex structures with bortezomib and carfilzomib unambiguously corroborated the reactivity of Ser1 (Fig. 5).	RESULTS
109	119	structures	evidence	Crystal structure analysis of the β5-T1S mutant confirmed precursor processing (Fig. 4g), and ligand-complex structures with bortezomib and carfilzomib unambiguously corroborated the reactivity of Ser1 (Fig. 5).	RESULTS
125	135	bortezomib	chemical	Crystal structure analysis of the β5-T1S mutant confirmed precursor processing (Fig. 4g), and ligand-complex structures with bortezomib and carfilzomib unambiguously corroborated the reactivity of Ser1 (Fig. 5).	RESULTS
140	151	carfilzomib	chemical	Crystal structure analysis of the β5-T1S mutant confirmed precursor processing (Fig. 4g), and ligand-complex structures with bortezomib and carfilzomib unambiguously corroborated the reactivity of Ser1 (Fig. 5).	RESULTS
197	201	Ser1	residue_name_number	Crystal structure analysis of the β5-T1S mutant confirmed precursor processing (Fig. 4g), and ligand-complex structures with bortezomib and carfilzomib unambiguously corroborated the reactivity of Ser1 (Fig. 5).	RESULTS
13	16	apo	protein_state	However, the apo crystal structure revealed that Ser1Oγ is turned away from the substrate-binding channel (Fig. 4g).	RESULTS
17	34	crystal structure	evidence	However, the apo crystal structure revealed that Ser1Oγ is turned away from the substrate-binding channel (Fig. 4g).	RESULTS
49	53	Ser1	residue_name_number	However, the apo crystal structure revealed that Ser1Oγ is turned away from the substrate-binding channel (Fig. 4g).	RESULTS
80	105	substrate-binding channel	site	However, the apo crystal structure revealed that Ser1Oγ is turned away from the substrate-binding channel (Fig. 4g).	RESULTS
14	18	Thr1	residue_name_number	Compared with Thr1Oγ in WT CP structures, Ser1Oγ is rotated by 60°.	RESULTS
24	26	WT	protein_state	Compared with Thr1Oγ in WT CP structures, Ser1Oγ is rotated by 60°.	RESULTS
27	29	CP	complex_assembly	Compared with Thr1Oγ in WT CP structures, Ser1Oγ is rotated by 60°.	RESULTS
30	40	structures	evidence	Compared with Thr1Oγ in WT CP structures, Ser1Oγ is rotated by 60°.	RESULTS
42	46	Ser1	residue_name_number	Compared with Thr1Oγ in WT CP structures, Ser1Oγ is rotated by 60°.	RESULTS
30	34	Ser1	residue_name_number	Because both conformations of Ser1Oγ are hydrogen-bonded to Lys33NH2 (Fig. 4h), the relay system is capable of hydrolysing peptide substrates, albeit at lower rates compared with Thr1.	RESULTS
60	65	Lys33	residue_name_number	Because both conformations of Ser1Oγ are hydrogen-bonded to Lys33NH2 (Fig. 4h), the relay system is capable of hydrolysing peptide substrates, albeit at lower rates compared with Thr1.	RESULTS
179	183	Thr1	residue_name_number	Because both conformations of Ser1Oγ are hydrogen-bonded to Lys33NH2 (Fig. 4h), the relay system is capable of hydrolysing peptide substrates, albeit at lower rates compared with Thr1.	RESULTS
4	23	active-site residue	site	The active-site residue Thr1 is fixed in its position, as its methyl group is engaged in hydrophobic interactions with Thr3 and Ala46 (Fig. 4h).	RESULTS
24	28	Thr1	residue_name_number	The active-site residue Thr1 is fixed in its position, as its methyl group is engaged in hydrophobic interactions with Thr3 and Ala46 (Fig. 4h).	RESULTS
119	123	Thr3	residue_name_number	The active-site residue Thr1 is fixed in its position, as its methyl group is engaged in hydrophobic interactions with Thr3 and Ala46 (Fig. 4h).	RESULTS
128	133	Ala46	residue_name_number	The active-site residue Thr1 is fixed in its position, as its methyl group is engaged in hydrophobic interactions with Thr3 and Ala46 (Fig. 4h).	RESULTS
36	40	Thr1	residue_name_number	Consequently, the hydroxyl group of Thr1 requires no reorientation before substrate cleavage and is thus more catalytically efficient than Ser1.	RESULTS
139	143	Ser1	residue_name_number	Consequently, the hydroxyl group of Thr1 requires no reorientation before substrate cleavage and is thus more catalytically efficient than Ser1.	RESULTS
62	65	T1S	mutant	In agreement, at an elevated growing temperature of 37 °C the T1S mutant is unable to grow (Fig. 4a).	RESULTS
66	72	mutant	protein_state	In agreement, at an elevated growing temperature of 37 °C the T1S mutant is unable to grow (Fig. 4a).	RESULTS
14	20	mutant	protein_state	In vitro, the mutant proteasome is less susceptible to proteasome inhibition by bortezomib (3.7-fold) and carfilzomib (1.8-fold; Fig. 5).	RESULTS
21	31	proteasome	complex_assembly	In vitro, the mutant proteasome is less susceptible to proteasome inhibition by bortezomib (3.7-fold) and carfilzomib (1.8-fold; Fig. 5).	RESULTS
55	65	proteasome	complex_assembly	In vitro, the mutant proteasome is less susceptible to proteasome inhibition by bortezomib (3.7-fold) and carfilzomib (1.8-fold; Fig. 5).	RESULTS
80	90	bortezomib	chemical	In vitro, the mutant proteasome is less susceptible to proteasome inhibition by bortezomib (3.7-fold) and carfilzomib (1.8-fold; Fig. 5).	RESULTS
106	117	carfilzomib	chemical	In vitro, the mutant proteasome is less susceptible to proteasome inhibition by bortezomib (3.7-fold) and carfilzomib (1.8-fold; Fig. 5).	RESULTS
14	31	inhibitor complex	complex_assembly	Nevertheless, inhibitor complex structures indicate identical binding modes compared with the WT yCP structures, with the same inhibitors.	RESULTS
32	42	structures	evidence	Nevertheless, inhibitor complex structures indicate identical binding modes compared with the WT yCP structures, with the same inhibitors.	RESULTS
94	96	WT	protein_state	Nevertheless, inhibitor complex structures indicate identical binding modes compared with the WT yCP structures, with the same inhibitors.	RESULTS
97	100	yCP	complex_assembly	Nevertheless, inhibitor complex structures indicate identical binding modes compared with the WT yCP structures, with the same inhibitors.	RESULTS
101	111	structures	evidence	Nevertheless, inhibitor complex structures indicate identical binding modes compared with the WT yCP structures, with the same inhibitors.	RESULTS
113	137	with the same inhibitors	protein_state	Nevertheless, inhibitor complex structures indicate identical binding modes compared with the WT yCP structures, with the same inhibitors.	RESULTS
13	21	affinity	evidence	Notably, the affinity of the tetrapeptide carfilzomib is less impaired, as it is better stabilized in the substrate-binding channel than the dipeptide bortezomib, which lacks a defined P3 site and has only a few interactions with the surrounding protein.	RESULTS
42	53	carfilzomib	chemical	Notably, the affinity of the tetrapeptide carfilzomib is less impaired, as it is better stabilized in the substrate-binding channel than the dipeptide bortezomib, which lacks a defined P3 site and has only a few interactions with the surrounding protein.	RESULTS
106	131	substrate-binding channel	site	Notably, the affinity of the tetrapeptide carfilzomib is less impaired, as it is better stabilized in the substrate-binding channel than the dipeptide bortezomib, which lacks a defined P3 site and has only a few interactions with the surrounding protein.	RESULTS
151	161	bortezomib	chemical	Notably, the affinity of the tetrapeptide carfilzomib is less impaired, as it is better stabilized in the substrate-binding channel than the dipeptide bortezomib, which lacks a defined P3 site and has only a few interactions with the surrounding protein.	RESULTS
11	30	mean residence time	evidence	Hence, the mean residence time of carfilzomib at the active site is prolonged and the probability to covalently react with Ser1 is increased.	RESULTS
34	45	carfilzomib	chemical	Hence, the mean residence time of carfilzomib at the active site is prolonged and the probability to covalently react with Ser1 is increased.	RESULTS
53	64	active site	site	Hence, the mean residence time of carfilzomib at the active site is prolonged and the probability to covalently react with Ser1 is increased.	RESULTS
123	127	Ser1	residue_name_number	Hence, the mean residence time of carfilzomib at the active site is prolonged and the probability to covalently react with Ser1 is increased.	RESULTS
89	98	threonine	residue_name	Considered together, these results provide a plausible explanation for the invariance of threonine as the active-site nucleophile in proteasomes in all three domains of life, as well as in proteasome-like proteases such as HslV (ref.).	RESULTS
133	144	proteasomes	complex_assembly	Considered together, these results provide a plausible explanation for the invariance of threonine as the active-site nucleophile in proteasomes in all three domains of life, as well as in proteasome-like proteases such as HslV (ref.).	RESULTS
189	214	proteasome-like proteases	protein_type	Considered together, these results provide a plausible explanation for the invariance of threonine as the active-site nucleophile in proteasomes in all three domains of life, as well as in proteasome-like proteases such as HslV (ref.).	RESULTS
223	227	HslV	protein	Considered together, these results provide a plausible explanation for the invariance of threonine as the active-site nucleophile in proteasomes in all three domains of life, as well as in proteasome-like proteases such as HslV (ref.).	RESULTS
4	18	20S proteasome	complex_assembly	The 20S proteasome CP is the major non-lysosomal protease in eukaryotic cells, and its assembly is highly organized.	DISCUSS
19	21	CP	complex_assembly	The 20S proteasome CP is the major non-lysosomal protease in eukaryotic cells, and its assembly is highly organized.	DISCUSS
35	57	non-lysosomal protease	protein_type	The 20S proteasome CP is the major non-lysosomal protease in eukaryotic cells, and its assembly is highly organized.	DISCUSS
61	71	eukaryotic	taxonomy_domain	The 20S proteasome CP is the major non-lysosomal protease in eukaryotic cells, and its assembly is highly organized.	DISCUSS
4	13	β-subunit	protein	The β-subunit propeptides, particularly that of β5, are key factors that help drive proper assembly of the CP complex.	DISCUSS
14	25	propeptides	structure_element	The β-subunit propeptides, particularly that of β5, are key factors that help drive proper assembly of the CP complex.	DISCUSS
48	50	β5	protein	The β-subunit propeptides, particularly that of β5, are key factors that help drive proper assembly of the CP complex.	DISCUSS
107	109	CP	complex_assembly	The β-subunit propeptides, particularly that of β5, are key factors that help drive proper assembly of the CP complex.	DISCUSS
59	63	Thr1	residue_name_number	In addition, they prevent irreversible inactivation of the Thr1 N terminus by N-acetylation.	DISCUSS
78	91	N-acetylation	ptm	In addition, they prevent irreversible inactivation of the Thr1 N terminus by N-acetylation.	DISCUSS
17	28	prosegments	structure_element	By contrast, the prosegments of β subunits are dispensable for archaeal proteasome assembly, at least when heterologously expressed in Escherichia coli.	DISCUSS
32	42	β subunits	protein	By contrast, the prosegments of β subunits are dispensable for archaeal proteasome assembly, at least when heterologously expressed in Escherichia coli.	DISCUSS
63	71	archaeal	taxonomy_domain	By contrast, the prosegments of β subunits are dispensable for archaeal proteasome assembly, at least when heterologously expressed in Escherichia coli.	DISCUSS
72	82	proteasome	complex_assembly	By contrast, the prosegments of β subunits are dispensable for archaeal proteasome assembly, at least when heterologously expressed in Escherichia coli.	DISCUSS
107	131	heterologously expressed	experimental_method	By contrast, the prosegments of β subunits are dispensable for archaeal proteasome assembly, at least when heterologously expressed in Escherichia coli.	DISCUSS
135	151	Escherichia coli	species	By contrast, the prosegments of β subunits are dispensable for archaeal proteasome assembly, at least when heterologously expressed in Escherichia coli.	DISCUSS
3	13	eukaryotes	taxonomy_domain	In eukaryotes, deletion of or failure to cleave the β1 and β2 propeptides is well tolerated.	DISCUSS
52	54	β1	protein	In eukaryotes, deletion of or failure to cleave the β1 and β2 propeptides is well tolerated.	DISCUSS
59	61	β2	protein	In eukaryotes, deletion of or failure to cleave the β1 and β2 propeptides is well tolerated.	DISCUSS
62	73	propeptides	structure_element	In eukaryotes, deletion of or failure to cleave the β1 and β2 propeptides is well tolerated.	DISCUSS
9	19	removal of	experimental_method	However, removal of the β5 prosegment or any interference with its cleavage causes severe phenotypic defects.	DISCUSS
24	26	β5	protein	However, removal of the β5 prosegment or any interference with its cleavage causes severe phenotypic defects.	DISCUSS
27	37	prosegment	structure_element	However, removal of the β5 prosegment or any interference with its cleavage causes severe phenotypic defects.	DISCUSS
71	73	β5	protein	These observations highlight the unique function and importance of the β5 propeptide as well as the β5 active site for maturation and function of the eukaryotic CP.	DISCUSS
74	84	propeptide	structure_element	These observations highlight the unique function and importance of the β5 propeptide as well as the β5 active site for maturation and function of the eukaryotic CP.	DISCUSS
100	102	β5	protein	These observations highlight the unique function and importance of the β5 propeptide as well as the β5 active site for maturation and function of the eukaryotic CP.	DISCUSS
103	114	active site	site	These observations highlight the unique function and importance of the β5 propeptide as well as the β5 active site for maturation and function of the eukaryotic CP.	DISCUSS
150	160	eukaryotic	taxonomy_domain	These observations highlight the unique function and importance of the β5 propeptide as well as the β5 active site for maturation and function of the eukaryotic CP.	DISCUSS
161	163	CP	complex_assembly	These observations highlight the unique function and importance of the β5 propeptide as well as the β5 active site for maturation and function of the eukaryotic CP.	DISCUSS
27	44	atomic structures	evidence	Here we have described the atomic structures of various β5-T1A mutants, which allowed for the first time visualization of the residual β5 propeptide.	DISCUSS
56	62	β5-T1A	mutant	Here we have described the atomic structures of various β5-T1A mutants, which allowed for the first time visualization of the residual β5 propeptide.	DISCUSS
135	137	β5	protein	Here we have described the atomic structures of various β5-T1A mutants, which allowed for the first time visualization of the residual β5 propeptide.	DISCUSS
138	148	propeptide	structure_element	Here we have described the atomic structures of various β5-T1A mutants, which allowed for the first time visualization of the residual β5 propeptide.	DISCUSS
17	21	(-2)	residue_number	Depending on the (-2) residue we observed various propeptide conformations, but Gly(-1) is in all structures perfectly located for the nucleophilic attack by Thr1Oγ, although it does not adopt the tight turn observed for the prosegment of subunit β1.	DISCUSS
50	60	propeptide	structure_element	Depending on the (-2) residue we observed various propeptide conformations, but Gly(-1) is in all structures perfectly located for the nucleophilic attack by Thr1Oγ, although it does not adopt the tight turn observed for the prosegment of subunit β1.	DISCUSS
80	87	Gly(-1)	residue_name_number	Depending on the (-2) residue we observed various propeptide conformations, but Gly(-1) is in all structures perfectly located for the nucleophilic attack by Thr1Oγ, although it does not adopt the tight turn observed for the prosegment of subunit β1.	DISCUSS
98	108	structures	evidence	Depending on the (-2) residue we observed various propeptide conformations, but Gly(-1) is in all structures perfectly located for the nucleophilic attack by Thr1Oγ, although it does not adopt the tight turn observed for the prosegment of subunit β1.	DISCUSS
158	162	Thr1	residue_name_number	Depending on the (-2) residue we observed various propeptide conformations, but Gly(-1) is in all structures perfectly located for the nucleophilic attack by Thr1Oγ, although it does not adopt the tight turn observed for the prosegment of subunit β1.	DISCUSS
197	207	tight turn	structure_element	Depending on the (-2) residue we observed various propeptide conformations, but Gly(-1) is in all structures perfectly located for the nucleophilic attack by Thr1Oγ, although it does not adopt the tight turn observed for the prosegment of subunit β1.	DISCUSS
225	235	prosegment	structure_element	Depending on the (-2) residue we observed various propeptide conformations, but Gly(-1) is in all structures perfectly located for the nucleophilic attack by Thr1Oγ, although it does not adopt the tight turn observed for the prosegment of subunit β1.	DISCUSS
247	249	β1	protein	Depending on the (-2) residue we observed various propeptide conformations, but Gly(-1) is in all structures perfectly located for the nucleophilic attack by Thr1Oγ, although it does not adopt the tight turn observed for the prosegment of subunit β1.	DISCUSS
57	64	Gly(-1)	residue_name_number	From these data we conclude that only the positioning of Gly(-1) and Thr1 as well as the integrity of the proteasomal active site are required for autolysis.	DISCUSS
69	73	Thr1	residue_name_number	From these data we conclude that only the positioning of Gly(-1) and Thr1 as well as the integrity of the proteasomal active site are required for autolysis.	DISCUSS
118	129	active site	site	From these data we conclude that only the positioning of Gly(-1) and Thr1 as well as the integrity of the proteasomal active site are required for autolysis.	DISCUSS
147	156	autolysis	ptm	From these data we conclude that only the positioning of Gly(-1) and Thr1 as well as the integrity of the proteasomal active site are required for autolysis.	DISCUSS
30	43	N-acetylation	ptm	In this regard, inappropriate N-acetylation of the Thr1 N terminus cannot be removed by Thr1Oγ due to the rotational freedom and flexibility of the acetyl group.	DISCUSS
51	55	Thr1	residue_name_number	In this regard, inappropriate N-acetylation of the Thr1 N terminus cannot be removed by Thr1Oγ due to the rotational freedom and flexibility of the acetyl group.	DISCUSS
88	92	Thr1	residue_name_number	In this regard, inappropriate N-acetylation of the Thr1 N terminus cannot be removed by Thr1Oγ due to the rotational freedom and flexibility of the acetyl group.	DISCUSS
4	14	propeptide	structure_element	The propeptide needs some anchoring in the substrate-binding channel to properly position Gly(-1), but this seems to be independent of the orientation of residue (-2).	DISCUSS
43	68	substrate-binding channel	site	The propeptide needs some anchoring in the substrate-binding channel to properly position Gly(-1), but this seems to be independent of the orientation of residue (-2).	DISCUSS
90	97	Gly(-1)	residue_name_number	The propeptide needs some anchoring in the substrate-binding channel to properly position Gly(-1), but this seems to be independent of the orientation of residue (-2).	DISCUSS
162	166	(-2)	residue_number	The propeptide needs some anchoring in the substrate-binding channel to properly position Gly(-1), but this seems to be independent of the orientation of residue (-2).	DISCUSS
28	30	CP	complex_assembly	Autolytic activation of the CP constitutes one of the final steps of proteasome biogenesis, but the trigger for propeptide cleavage had remained enigmatic.	DISCUSS
112	131	propeptide cleavage	ptm	Autolytic activation of the CP constitutes one of the final steps of proteasome biogenesis, but the trigger for propeptide cleavage had remained enigmatic.	DISCUSS
29	38	CP:ligand	complex_assembly	On the basis of the numerous CP:ligand complexes solved during the past 18 years and in the current study, we provide a revised interpretation of proteasome active-site architecture.	DISCUSS
146	156	proteasome	complex_assembly	On the basis of the numerous CP:ligand complexes solved during the past 18 years and in the current study, we provide a revised interpretation of proteasome active-site architecture.	DISCUSS
157	181	active-site architecture	site	On the basis of the numerous CP:ligand complexes solved during the past 18 years and in the current study, we provide a revised interpretation of proteasome active-site architecture.	DISCUSS
13	28	catalytic triad	site	We propose a catalytic triad for the active site of the CP consisting of residues Thr1, Lys33 and Asp/Glu17, which are conserved among all proteolytically active eukaryotic, bacterial and archaeal proteasome subunits.	DISCUSS
37	48	active site	site	We propose a catalytic triad for the active site of the CP consisting of residues Thr1, Lys33 and Asp/Glu17, which are conserved among all proteolytically active eukaryotic, bacterial and archaeal proteasome subunits.	DISCUSS
56	58	CP	complex_assembly	We propose a catalytic triad for the active site of the CP consisting of residues Thr1, Lys33 and Asp/Glu17, which are conserved among all proteolytically active eukaryotic, bacterial and archaeal proteasome subunits.	DISCUSS
82	86	Thr1	residue_name_number	We propose a catalytic triad for the active site of the CP consisting of residues Thr1, Lys33 and Asp/Glu17, which are conserved among all proteolytically active eukaryotic, bacterial and archaeal proteasome subunits.	DISCUSS
88	93	Lys33	residue_name_number	We propose a catalytic triad for the active site of the CP consisting of residues Thr1, Lys33 and Asp/Glu17, which are conserved among all proteolytically active eukaryotic, bacterial and archaeal proteasome subunits.	DISCUSS
98	101	Asp	residue_name	We propose a catalytic triad for the active site of the CP consisting of residues Thr1, Lys33 and Asp/Glu17, which are conserved among all proteolytically active eukaryotic, bacterial and archaeal proteasome subunits.	DISCUSS
102	107	Glu17	residue_name_number	We propose a catalytic triad for the active site of the CP consisting of residues Thr1, Lys33 and Asp/Glu17, which are conserved among all proteolytically active eukaryotic, bacterial and archaeal proteasome subunits.	DISCUSS
162	172	eukaryotic	taxonomy_domain	We propose a catalytic triad for the active site of the CP consisting of residues Thr1, Lys33 and Asp/Glu17, which are conserved among all proteolytically active eukaryotic, bacterial and archaeal proteasome subunits.	DISCUSS
174	183	bacterial	taxonomy_domain	We propose a catalytic triad for the active site of the CP consisting of residues Thr1, Lys33 and Asp/Glu17, which are conserved among all proteolytically active eukaryotic, bacterial and archaeal proteasome subunits.	DISCUSS
188	196	archaeal	taxonomy_domain	We propose a catalytic triad for the active site of the CP consisting of residues Thr1, Lys33 and Asp/Glu17, which are conserved among all proteolytically active eukaryotic, bacterial and archaeal proteasome subunits.	DISCUSS
197	207	proteasome	complex_assembly	We propose a catalytic triad for the active site of the CP consisting of residues Thr1, Lys33 and Asp/Glu17, which are conserved among all proteolytically active eukaryotic, bacterial and archaeal proteasome subunits.	DISCUSS
0	5	Lys33	residue_name_number	Lys33NH2 is expected to act as the proton acceptor during autocatalytic removal of the propeptides, as well as during substrate proteolysis, while Asp17Oδ orients Lys33NH2 and makes it more prone to protonation by raising its pKa (hydrogen bond distance: Lys33NH3+–Asp17Oδ: 2.9 Å).	DISCUSS
58	79	autocatalytic removal	ptm	Lys33NH2 is expected to act as the proton acceptor during autocatalytic removal of the propeptides, as well as during substrate proteolysis, while Asp17Oδ orients Lys33NH2 and makes it more prone to protonation by raising its pKa (hydrogen bond distance: Lys33NH3+–Asp17Oδ: 2.9 Å).	DISCUSS
87	98	propeptides	structure_element	Lys33NH2 is expected to act as the proton acceptor during autocatalytic removal of the propeptides, as well as during substrate proteolysis, while Asp17Oδ orients Lys33NH2 and makes it more prone to protonation by raising its pKa (hydrogen bond distance: Lys33NH3+–Asp17Oδ: 2.9 Å).	DISCUSS
147	152	Asp17	residue_name_number	Lys33NH2 is expected to act as the proton acceptor during autocatalytic removal of the propeptides, as well as during substrate proteolysis, while Asp17Oδ orients Lys33NH2 and makes it more prone to protonation by raising its pKa (hydrogen bond distance: Lys33NH3+–Asp17Oδ: 2.9 Å).	DISCUSS
163	168	Lys33	residue_name_number	Lys33NH2 is expected to act as the proton acceptor during autocatalytic removal of the propeptides, as well as during substrate proteolysis, while Asp17Oδ orients Lys33NH2 and makes it more prone to protonation by raising its pKa (hydrogen bond distance: Lys33NH3+–Asp17Oδ: 2.9 Å).	DISCUSS
255	260	Lys33	residue_name_number	Lys33NH2 is expected to act as the proton acceptor during autocatalytic removal of the propeptides, as well as during substrate proteolysis, while Asp17Oδ orients Lys33NH2 and makes it more prone to protonation by raising its pKa (hydrogen bond distance: Lys33NH3+–Asp17Oδ: 2.9 Å).	DISCUSS
265	270	Asp17	residue_name_number	Lys33NH2 is expected to act as the proton acceptor during autocatalytic removal of the propeptides, as well as during substrate proteolysis, while Asp17Oδ orients Lys33NH2 and makes it more prone to protonation by raising its pKa (hydrogen bond distance: Lys33NH3+–Asp17Oδ: 2.9 Å).	DISCUSS
19	29	proteasome	complex_assembly	Analogously to the proteasome, a Thr–Lys–Asp triad is also found in L-asparaginase.	DISCUSS
33	50	Thr–Lys–Asp triad	site	Analogously to the proteasome, a Thr–Lys–Asp triad is also found in L-asparaginase.	DISCUSS
68	82	L-asparaginase	protein_type	Analogously to the proteasome, a Thr–Lys–Asp triad is also found in L-asparaginase.	DISCUSS
107	110	Lys	residue_name	Thus, specific protein surroundings can significantly alter the chemical properties of amino acids such as Lys to function as an acid–base catalyst.	DISCUSS
36	47	active site	site	In this new view of the proteasomal active site, the positively charged Thr1NH3+-terminus hydrogen bonds to the amide nitrogen of incoming peptide substrates and stabilizes as well as activates them for the endoproteolytic cleavage by Thr1Oγ (Fig. 3d).	DISCUSS
72	76	Thr1	residue_name_number	In this new view of the proteasomal active site, the positively charged Thr1NH3+-terminus hydrogen bonds to the amide nitrogen of incoming peptide substrates and stabilizes as well as activates them for the endoproteolytic cleavage by Thr1Oγ (Fig. 3d).	DISCUSS
207	231	endoproteolytic cleavage	ptm	In this new view of the proteasomal active site, the positively charged Thr1NH3+-terminus hydrogen bonds to the amide nitrogen of incoming peptide substrates and stabilizes as well as activates them for the endoproteolytic cleavage by Thr1Oγ (Fig. 3d).	DISCUSS
235	239	Thr1	residue_name_number	In this new view of the proteasomal active site, the positively charged Thr1NH3+-terminus hydrogen bonds to the amide nitrogen of incoming peptide substrates and stabilizes as well as activates them for the endoproteolytic cleavage by Thr1Oγ (Fig. 3d).	DISCUSS
51	55	Thr1	residue_name_number	Consistent with this model, the positively charged Thr1 N terminus is engaged in hydrogen bonds with inhibitory compounds like fellutamide B (ref.), α-ketoamides, homobelactosin C (ref.) and salinosporamide A (ref.).	DISCUSS
127	140	fellutamide B	chemical	Consistent with this model, the positively charged Thr1 N terminus is engaged in hydrogen bonds with inhibitory compounds like fellutamide B (ref.), α-ketoamides, homobelactosin C (ref.) and salinosporamide A (ref.).	DISCUSS
149	161	α-ketoamides	chemical	Consistent with this model, the positively charged Thr1 N terminus is engaged in hydrogen bonds with inhibitory compounds like fellutamide B (ref.), α-ketoamides, homobelactosin C (ref.) and salinosporamide A (ref.).	DISCUSS
163	179	homobelactosin C	chemical	Consistent with this model, the positively charged Thr1 N terminus is engaged in hydrogen bonds with inhibitory compounds like fellutamide B (ref.), α-ketoamides, homobelactosin C (ref.) and salinosporamide A (ref.).	DISCUSS
191	208	salinosporamide A	chemical	Consistent with this model, the positively charged Thr1 N terminus is engaged in hydrogen bonds with inhibitory compounds like fellutamide B (ref.), α-ketoamides, homobelactosin C (ref.) and salinosporamide A (ref.).	DISCUSS
47	56	omuralide	chemical	Furthermore, opening of the β-lactone compound omuralide by Thr1 creates a C3-hydroxyl group, whose proton originates from Thr1NH3+.	DISCUSS
60	64	Thr1	residue_name_number	Furthermore, opening of the β-lactone compound omuralide by Thr1 creates a C3-hydroxyl group, whose proton originates from Thr1NH3+.	DISCUSS
123	127	Thr1	residue_name_number	Furthermore, opening of the β-lactone compound omuralide by Thr1 creates a C3-hydroxyl group, whose proton originates from Thr1NH3+.	DISCUSS
24	28	Thr1	residue_name_number	The resulting uncharged Thr1NH2 is hydrogen-bridged to the C3-OH group.	DISCUSS
14	25	acetylation	ptm	In agreement, acetylation of the Thr1 N terminus irreversibly blocks hydrolytic activity, and binding of substrates is prevented for steric reasons.	DISCUSS
33	37	Thr1	residue_name_number	In agreement, acetylation of the Thr1 N terminus irreversibly blocks hydrolytic activity, and binding of substrates is prevented for steric reasons.	DISCUSS
50	54	Thr1	residue_name_number	By acting as a proton donor during catalysis, the Thr1 N terminus may also favour cleavage of substrate peptide bonds (Fig. 3d).	DISCUSS
98	108	proteasome	complex_assembly	Cleavage of the scissile peptide bond requires protonation of the emerging free amine, and in the proteasome, the Thr1 amine group is likely to assume this function.	DISCUSS
114	118	Thr1	residue_name_number	Cleavage of the scissile peptide bond requires protonation of the emerging free amine, and in the proteasome, the Thr1 amine group is likely to assume this function.	DISCUSS
13	17	Thr1	residue_name_number	Analogously, Thr1NH3+ might promote the bivalent reaction mode of epoxyketone inhibitors by protonating the epoxide moiety to create a positively charged trivalent oxygen atom that is subsequently nucleophilically attacked by Thr1NH2.	DISCUSS
226	230	Thr1	residue_name_number	Analogously, Thr1NH3+ might promote the bivalent reaction mode of epoxyketone inhibitors by protonating the epoxide moiety to create a positively charged trivalent oxygen atom that is subsequently nucleophilically attacked by Thr1NH2.	DISCUSS
7	16	autolysis	ptm	During autolysis the Thr1 N terminus is engaged in a hydroxyoxazolidine ring intermediate (Fig. 3d), which is unstable and short-lived.	DISCUSS
21	25	Thr1	residue_name_number	During autolysis the Thr1 N terminus is engaged in a hydroxyoxazolidine ring intermediate (Fig. 3d), which is unstable and short-lived.	DISCUSS
60	64	Thr1	residue_name_number	Breakdown of this tetrahedral transition state releases the Thr1 N terminus that is protonated by aspartic acid 166 via Ser129OH to yield Thr1NH3+.	DISCUSS
98	115	aspartic acid 166	residue_name_number	Breakdown of this tetrahedral transition state releases the Thr1 N terminus that is protonated by aspartic acid 166 via Ser129OH to yield Thr1NH3+.	DISCUSS
120	126	Ser129	residue_name_number	Breakdown of this tetrahedral transition state releases the Thr1 N terminus that is protonated by aspartic acid 166 via Ser129OH to yield Thr1NH3+.	DISCUSS
138	142	Thr1	residue_name_number	Breakdown of this tetrahedral transition state releases the Thr1 N terminus that is protonated by aspartic acid 166 via Ser129OH to yield Thr1NH3+.	DISCUSS
13	19	Ser129	residue_name_number	The residues Ser129 and Asp166 are expected to increase the pKa value of Thr1N, thereby favouring its charged state.	DISCUSS
24	30	Asp166	residue_name_number	The residues Ser129 and Asp166 are expected to increase the pKa value of Thr1N, thereby favouring its charged state.	DISCUSS
73	77	Thr1	residue_name_number	The residues Ser129 and Asp166 are expected to increase the pKa value of Thr1N, thereby favouring its charged state.	DISCUSS
67	75	mutation	experimental_method	Consistent with playing an essential role in proton shuttling, the mutation D166A prevents autolysis of the archaeal CP and the exchange D166N impairs catalytic activity of the yeast CP about 60%.	DISCUSS
76	81	D166A	mutant	Consistent with playing an essential role in proton shuttling, the mutation D166A prevents autolysis of the archaeal CP and the exchange D166N impairs catalytic activity of the yeast CP about 60%.	DISCUSS
91	100	autolysis	ptm	Consistent with playing an essential role in proton shuttling, the mutation D166A prevents autolysis of the archaeal CP and the exchange D166N impairs catalytic activity of the yeast CP about 60%.	DISCUSS
108	116	archaeal	taxonomy_domain	Consistent with playing an essential role in proton shuttling, the mutation D166A prevents autolysis of the archaeal CP and the exchange D166N impairs catalytic activity of the yeast CP about 60%.	DISCUSS
117	119	CP	complex_assembly	Consistent with playing an essential role in proton shuttling, the mutation D166A prevents autolysis of the archaeal CP and the exchange D166N impairs catalytic activity of the yeast CP about 60%.	DISCUSS
128	136	exchange	experimental_method	Consistent with playing an essential role in proton shuttling, the mutation D166A prevents autolysis of the archaeal CP and the exchange D166N impairs catalytic activity of the yeast CP about 60%.	DISCUSS
137	142	D166N	mutant	Consistent with playing an essential role in proton shuttling, the mutation D166A prevents autolysis of the archaeal CP and the exchange D166N impairs catalytic activity of the yeast CP about 60%.	DISCUSS
177	182	yeast	taxonomy_domain	Consistent with playing an essential role in proton shuttling, the mutation D166A prevents autolysis of the archaeal CP and the exchange D166N impairs catalytic activity of the yeast CP about 60%.	DISCUSS
183	185	CP	complex_assembly	Consistent with playing an essential role in proton shuttling, the mutation D166A prevents autolysis of the archaeal CP and the exchange D166N impairs catalytic activity of the yeast CP about 60%.	DISCUSS
4	12	mutation	experimental_method	The mutation D166N lowers the pKa of Thr1N, which is thus more likely to exist in the uncharged deprotonated state (Thr1NH2).	DISCUSS
13	18	D166N	mutant	The mutation D166N lowers the pKa of Thr1N, which is thus more likely to exist in the uncharged deprotonated state (Thr1NH2).	DISCUSS
37	41	Thr1	residue_name_number	The mutation D166N lowers the pKa of Thr1N, which is thus more likely to exist in the uncharged deprotonated state (Thr1NH2).	DISCUSS
116	120	Thr1	residue_name_number	The mutation D166N lowers the pKa of Thr1N, which is thus more likely to exist in the uncharged deprotonated state (Thr1NH2).	DISCUSS
79	87	β5-D166N	mutant	This interpretation agrees with the strongly reduced catalytic activity of the β5-D166N mutant on the one hand, and the ability to react readily with carfilzomib on the other.	DISCUSS
88	94	mutant	protein_state	This interpretation agrees with the strongly reduced catalytic activity of the β5-D166N mutant on the one hand, and the ability to react readily with carfilzomib on the other.	DISCUSS
150	161	carfilzomib	chemical	This interpretation agrees with the strongly reduced catalytic activity of the β5-D166N mutant on the one hand, and the ability to react readily with carfilzomib on the other.	DISCUSS
11	21	proteasome	complex_assembly	Hence, the proteasome can be viewed as having a second triad that is essential for efficient proteolysis.	DISCUSS
48	60	second triad	site	Hence, the proteasome can be viewed as having a second triad that is essential for efficient proteolysis.	DISCUSS
6	11	Lys33	residue_name_number	While Lys33NH2 and Asp17Oδ are required to deprotonate the Thr1 hydroxyl side chain, Ser129OH and Asp166OH serve to protonate the N-terminal amine group of Thr1.	DISCUSS
19	24	Asp17	residue_name_number	While Lys33NH2 and Asp17Oδ are required to deprotonate the Thr1 hydroxyl side chain, Ser129OH and Asp166OH serve to protonate the N-terminal amine group of Thr1.	DISCUSS
59	63	Thr1	residue_name_number	While Lys33NH2 and Asp17Oδ are required to deprotonate the Thr1 hydroxyl side chain, Ser129OH and Asp166OH serve to protonate the N-terminal amine group of Thr1.	DISCUSS
85	91	Ser129	residue_name_number	While Lys33NH2 and Asp17Oδ are required to deprotonate the Thr1 hydroxyl side chain, Ser129OH and Asp166OH serve to protonate the N-terminal amine group of Thr1.	DISCUSS
98	104	Asp166	residue_name_number	While Lys33NH2 and Asp17Oδ are required to deprotonate the Thr1 hydroxyl side chain, Ser129OH and Asp166OH serve to protonate the N-terminal amine group of Thr1.	DISCUSS
156	160	Thr1	residue_name_number	While Lys33NH2 and Asp17Oδ are required to deprotonate the Thr1 hydroxyl side chain, Ser129OH and Asp166OH serve to protonate the N-terminal amine group of Thr1.	DISCUSS
28	32	Thr1	residue_name_number	In accord with the proposed Thr1–Lys33–Asp17 catalytic triad, crystallographic data on the proteolytically inactive β5-T1C mutant demonstrate that the interaction of Lys33NH2 and Cys1 is broken.	DISCUSS
33	38	Lys33	residue_name_number	In accord with the proposed Thr1–Lys33–Asp17 catalytic triad, crystallographic data on the proteolytically inactive β5-T1C mutant demonstrate that the interaction of Lys33NH2 and Cys1 is broken.	DISCUSS
39	44	Asp17	residue_name_number	In accord with the proposed Thr1–Lys33–Asp17 catalytic triad, crystallographic data on the proteolytically inactive β5-T1C mutant demonstrate that the interaction of Lys33NH2 and Cys1 is broken.	DISCUSS
45	60	catalytic triad	site	In accord with the proposed Thr1–Lys33–Asp17 catalytic triad, crystallographic data on the proteolytically inactive β5-T1C mutant demonstrate that the interaction of Lys33NH2 and Cys1 is broken.	DISCUSS
62	83	crystallographic data	evidence	In accord with the proposed Thr1–Lys33–Asp17 catalytic triad, crystallographic data on the proteolytically inactive β5-T1C mutant demonstrate that the interaction of Lys33NH2 and Cys1 is broken.	DISCUSS
91	115	proteolytically inactive	protein_state	In accord with the proposed Thr1–Lys33–Asp17 catalytic triad, crystallographic data on the proteolytically inactive β5-T1C mutant demonstrate that the interaction of Lys33NH2 and Cys1 is broken.	DISCUSS
116	122	β5-T1C	mutant	In accord with the proposed Thr1–Lys33–Asp17 catalytic triad, crystallographic data on the proteolytically inactive β5-T1C mutant demonstrate that the interaction of Lys33NH2 and Cys1 is broken.	DISCUSS
123	129	mutant	protein_state	In accord with the proposed Thr1–Lys33–Asp17 catalytic triad, crystallographic data on the proteolytically inactive β5-T1C mutant demonstrate that the interaction of Lys33NH2 and Cys1 is broken.	DISCUSS
166	171	Lys33	residue_name_number	In accord with the proposed Thr1–Lys33–Asp17 catalytic triad, crystallographic data on the proteolytically inactive β5-T1C mutant demonstrate that the interaction of Lys33NH2 and Cys1 is broken.	DISCUSS
179	183	Cys1	residue_name_number	In accord with the proposed Thr1–Lys33–Asp17 catalytic triad, crystallographic data on the proteolytically inactive β5-T1C mutant demonstrate that the interaction of Lys33NH2 and Cys1 is broken.	DISCUSS
18	21	Cys	residue_name	However, owing to Cys being a strong nucleophile, the propeptide can still be cleaved off over time.	DISCUSS
54	64	propeptide	structure_element	However, owing to Cys being a strong nucleophile, the propeptide can still be cleaved off over time.	DISCUSS
78	85	cleaved	protein_state	However, owing to Cys being a strong nucleophile, the propeptide can still be cleaved off over time.	DISCUSS
48	57	autolysis	ptm	While only one single turnover is necessary for autolysis, continuous enzymatic activity is required for significant and detectable substrate hydrolysis.	DISCUSS
16	29	Ntn hydrolase	protein_type	Notably, in the Ntn hydrolase penicillin acylase, substitution of the catalytic N-terminal Ser residue by Cys also inactivates the enzyme but still enables precursor processing.	DISCUSS
30	48	penicillin acylase	protein_type	Notably, in the Ntn hydrolase penicillin acylase, substitution of the catalytic N-terminal Ser residue by Cys also inactivates the enzyme but still enables precursor processing.	DISCUSS
50	62	substitution	experimental_method	Notably, in the Ntn hydrolase penicillin acylase, substitution of the catalytic N-terminal Ser residue by Cys also inactivates the enzyme but still enables precursor processing.	DISCUSS
70	79	catalytic	protein_state	Notably, in the Ntn hydrolase penicillin acylase, substitution of the catalytic N-terminal Ser residue by Cys also inactivates the enzyme but still enables precursor processing.	DISCUSS
91	94	Ser	residue_name	Notably, in the Ntn hydrolase penicillin acylase, substitution of the catalytic N-terminal Ser residue by Cys also inactivates the enzyme but still enables precursor processing.	DISCUSS
106	109	Cys	residue_name	Notably, in the Ntn hydrolase penicillin acylase, substitution of the catalytic N-terminal Ser residue by Cys also inactivates the enzyme but still enables precursor processing.	DISCUSS
115	126	inactivates	protein_state	Notably, in the Ntn hydrolase penicillin acylase, substitution of the catalytic N-terminal Ser residue by Cys also inactivates the enzyme but still enables precursor processing.	DISCUSS
131	137	enzyme	protein_type	Notably, in the Ntn hydrolase penicillin acylase, substitution of the catalytic N-terminal Ser residue by Cys also inactivates the enzyme but still enables precursor processing.	DISCUSS
156	176	precursor processing	ptm	Notably, in the Ntn hydrolase penicillin acylase, substitution of the catalytic N-terminal Ser residue by Cys also inactivates the enzyme but still enables precursor processing.	DISCUSS
23	25	CP	complex_assembly	To investigate why the CP specifically employs threonine as its active-site residue, we used a β5-T1S mutant of the yCP and characterized it biochemically and structurally.	DISCUSS
47	56	threonine	residue_name	To investigate why the CP specifically employs threonine as its active-site residue, we used a β5-T1S mutant of the yCP and characterized it biochemically and structurally.	DISCUSS
64	83	active-site residue	site	To investigate why the CP specifically employs threonine as its active-site residue, we used a β5-T1S mutant of the yCP and characterized it biochemically and structurally.	DISCUSS
95	101	β5-T1S	mutant	To investigate why the CP specifically employs threonine as its active-site residue, we used a β5-T1S mutant of the yCP and characterized it biochemically and structurally.	DISCUSS
102	108	mutant	protein_state	To investigate why the CP specifically employs threonine as its active-site residue, we used a β5-T1S mutant of the yCP and characterized it biochemically and structurally.	DISCUSS
116	119	yCP	complex_assembly	To investigate why the CP specifically employs threonine as its active-site residue, we used a β5-T1S mutant of the yCP and characterized it biochemically and structurally.	DISCUSS
141	171	biochemically and structurally	experimental_method	To investigate why the CP specifically employs threonine as its active-site residue, we used a β5-T1S mutant of the yCP and characterized it biochemically and structurally.	DISCUSS
0	15	Activity assays	experimental_method	Activity assays with the β5-T1S mutant revealed reduced turnover of Suc-LLVY-AMC.	DISCUSS
25	31	β5-T1S	mutant	Activity assays with the β5-T1S mutant revealed reduced turnover of Suc-LLVY-AMC.	DISCUSS
32	38	mutant	protein_state	Activity assays with the β5-T1S mutant revealed reduced turnover of Suc-LLVY-AMC.	DISCUSS
68	80	Suc-LLVY-AMC	chemical	Activity assays with the β5-T1S mutant revealed reduced turnover of Suc-LLVY-AMC.	DISCUSS
48	54	β5-T1S	mutant	We also observed slightly lower affinity of the β5-T1S mutant yCP for the Food and Drug Administration-approved proteasome inhibitors bortezomib and carfilzomib.	DISCUSS
55	61	mutant	protein_state	We also observed slightly lower affinity of the β5-T1S mutant yCP for the Food and Drug Administration-approved proteasome inhibitors bortezomib and carfilzomib.	DISCUSS
62	65	yCP	complex_assembly	We also observed slightly lower affinity of the β5-T1S mutant yCP for the Food and Drug Administration-approved proteasome inhibitors bortezomib and carfilzomib.	DISCUSS
112	122	proteasome	complex_assembly	We also observed slightly lower affinity of the β5-T1S mutant yCP for the Food and Drug Administration-approved proteasome inhibitors bortezomib and carfilzomib.	DISCUSS
134	144	bortezomib	chemical	We also observed slightly lower affinity of the β5-T1S mutant yCP for the Food and Drug Administration-approved proteasome inhibitors bortezomib and carfilzomib.	DISCUSS
149	160	carfilzomib	chemical	We also observed slightly lower affinity of the β5-T1S mutant yCP for the Food and Drug Administration-approved proteasome inhibitors bortezomib and carfilzomib.	DISCUSS
0	19	Structural analyses	evidence	Structural analyses support these findings with the T1S mutant and provide an explanation for the strict use of Thr residues in proteasomes.	DISCUSS
52	55	T1S	mutant	Structural analyses support these findings with the T1S mutant and provide an explanation for the strict use of Thr residues in proteasomes.	DISCUSS
56	62	mutant	protein_state	Structural analyses support these findings with the T1S mutant and provide an explanation for the strict use of Thr residues in proteasomes.	DISCUSS
98	111	strict use of	protein_state	Structural analyses support these findings with the T1S mutant and provide an explanation for the strict use of Thr residues in proteasomes.	DISCUSS
112	115	Thr	residue_name	Structural analyses support these findings with the T1S mutant and provide an explanation for the strict use of Thr residues in proteasomes.	DISCUSS
128	139	proteasomes	complex_assembly	Structural analyses support these findings with the T1S mutant and provide an explanation for the strict use of Thr residues in proteasomes.	DISCUSS
0	4	Thr1	residue_name_number	Thr1 is well anchored in the active site by hydrophobic interactions of its Cγ methyl group with Ala46 (Cβ), Lys33 (carbon side chain) and Thr3 (Cγ).	DISCUSS
29	40	active site	site	Thr1 is well anchored in the active site by hydrophobic interactions of its Cγ methyl group with Ala46 (Cβ), Lys33 (carbon side chain) and Thr3 (Cγ).	DISCUSS
97	102	Ala46	residue_name_number	Thr1 is well anchored in the active site by hydrophobic interactions of its Cγ methyl group with Ala46 (Cβ), Lys33 (carbon side chain) and Thr3 (Cγ).	DISCUSS
109	114	Lys33	residue_name_number	Thr1 is well anchored in the active site by hydrophobic interactions of its Cγ methyl group with Ala46 (Cβ), Lys33 (carbon side chain) and Thr3 (Cγ).	DISCUSS
139	143	Thr3	residue_name_number	Thr1 is well anchored in the active site by hydrophobic interactions of its Cγ methyl group with Ala46 (Cβ), Lys33 (carbon side chain) and Thr3 (Cγ).	DISCUSS
9	31	proteolytically active	protein_state	Notably, proteolytically active proteasome subunits from archaea, yeast and mammals, including constitutive, immuno- and thymoproteasome subunits, either encode Thr or Ile at position 3, indicating the importance of the Cγ for fixing the position of the nucleophilic Thr1.	DISCUSS
32	42	proteasome	complex_assembly	Notably, proteolytically active proteasome subunits from archaea, yeast and mammals, including constitutive, immuno- and thymoproteasome subunits, either encode Thr or Ile at position 3, indicating the importance of the Cγ for fixing the position of the nucleophilic Thr1.	DISCUSS
57	64	archaea	taxonomy_domain	Notably, proteolytically active proteasome subunits from archaea, yeast and mammals, including constitutive, immuno- and thymoproteasome subunits, either encode Thr or Ile at position 3, indicating the importance of the Cγ for fixing the position of the nucleophilic Thr1.	DISCUSS
66	71	yeast	taxonomy_domain	Notably, proteolytically active proteasome subunits from archaea, yeast and mammals, including constitutive, immuno- and thymoproteasome subunits, either encode Thr or Ile at position 3, indicating the importance of the Cγ for fixing the position of the nucleophilic Thr1.	DISCUSS
76	83	mammals	taxonomy_domain	Notably, proteolytically active proteasome subunits from archaea, yeast and mammals, including constitutive, immuno- and thymoproteasome subunits, either encode Thr or Ile at position 3, indicating the importance of the Cγ for fixing the position of the nucleophilic Thr1.	DISCUSS
161	164	Thr	residue_name	Notably, proteolytically active proteasome subunits from archaea, yeast and mammals, including constitutive, immuno- and thymoproteasome subunits, either encode Thr or Ile at position 3, indicating the importance of the Cγ for fixing the position of the nucleophilic Thr1.	DISCUSS
168	171	Ile	residue_name	Notably, proteolytically active proteasome subunits from archaea, yeast and mammals, including constitutive, immuno- and thymoproteasome subunits, either encode Thr or Ile at position 3, indicating the importance of the Cγ for fixing the position of the nucleophilic Thr1.	DISCUSS
184	185	3	residue_number	Notably, proteolytically active proteasome subunits from archaea, yeast and mammals, including constitutive, immuno- and thymoproteasome subunits, either encode Thr or Ile at position 3, indicating the importance of the Cγ for fixing the position of the nucleophilic Thr1.	DISCUSS
267	271	Thr1	residue_name_number	Notably, proteolytically active proteasome subunits from archaea, yeast and mammals, including constitutive, immuno- and thymoproteasome subunits, either encode Thr or Ile at position 3, indicating the importance of the Cγ for fixing the position of the nucleophilic Thr1.	DISCUSS
15	19	Thr1	residue_name_number	In contrast to Thr1, the hydroxyl group of Ser1 occupies the position of the Thr1 methyl side chain in the WT enzyme, which requires its reorientation relative to the substrate to allow cleavage (Fig. 4g,h).	DISCUSS
43	47	Ser1	residue_name_number	In contrast to Thr1, the hydroxyl group of Ser1 occupies the position of the Thr1 methyl side chain in the WT enzyme, which requires its reorientation relative to the substrate to allow cleavage (Fig. 4g,h).	DISCUSS
77	81	Thr1	residue_name_number	In contrast to Thr1, the hydroxyl group of Ser1 occupies the position of the Thr1 methyl side chain in the WT enzyme, which requires its reorientation relative to the substrate to allow cleavage (Fig. 4g,h).	DISCUSS
107	109	WT	protein_state	In contrast to Thr1, the hydroxyl group of Ser1 occupies the position of the Thr1 methyl side chain in the WT enzyme, which requires its reorientation relative to the substrate to allow cleavage (Fig. 4g,h).	DISCUSS
110	116	enzyme	complex_assembly	In contrast to Thr1, the hydroxyl group of Ser1 occupies the position of the Thr1 methyl side chain in the WT enzyme, which requires its reorientation relative to the substrate to allow cleavage (Fig. 4g,h).	DISCUSS
16	35	threonine aspartase	protein_type	Notably, in the threonine aspartase Taspase1, mutation of the active-site Thr234 to Ser also places the side chain in the position of the methyl group of Thr234 in the WT, thereby reducing catalytic activity.	DISCUSS
36	44	Taspase1	protein	Notably, in the threonine aspartase Taspase1, mutation of the active-site Thr234 to Ser also places the side chain in the position of the methyl group of Thr234 in the WT, thereby reducing catalytic activity.	DISCUSS
46	54	mutation	experimental_method	Notably, in the threonine aspartase Taspase1, mutation of the active-site Thr234 to Ser also places the side chain in the position of the methyl group of Thr234 in the WT, thereby reducing catalytic activity.	DISCUSS
62	73	active-site	site	Notably, in the threonine aspartase Taspase1, mutation of the active-site Thr234 to Ser also places the side chain in the position of the methyl group of Thr234 in the WT, thereby reducing catalytic activity.	DISCUSS
74	80	Thr234	residue_name_number	Notably, in the threonine aspartase Taspase1, mutation of the active-site Thr234 to Ser also places the side chain in the position of the methyl group of Thr234 in the WT, thereby reducing catalytic activity.	DISCUSS
84	87	Ser	residue_name	Notably, in the threonine aspartase Taspase1, mutation of the active-site Thr234 to Ser also places the side chain in the position of the methyl group of Thr234 in the WT, thereby reducing catalytic activity.	DISCUSS
154	160	Thr234	residue_name_number	Notably, in the threonine aspartase Taspase1, mutation of the active-site Thr234 to Ser also places the side chain in the position of the methyl group of Thr234 in the WT, thereby reducing catalytic activity.	DISCUSS
168	170	WT	protein_state	Notably, in the threonine aspartase Taspase1, mutation of the active-site Thr234 to Ser also places the side chain in the position of the methyl group of Thr234 in the WT, thereby reducing catalytic activity.	DISCUSS
24	30	serine	residue_name	Similarly, although the serine mutant is active, threonine is more efficient in the context of the proteasome active site.	DISCUSS
31	37	mutant	protein_state	Similarly, although the serine mutant is active, threonine is more efficient in the context of the proteasome active site.	DISCUSS
41	47	active	protein_state	Similarly, although the serine mutant is active, threonine is more efficient in the context of the proteasome active site.	DISCUSS
49	58	threonine	residue_name	Similarly, although the serine mutant is active, threonine is more efficient in the context of the proteasome active site.	DISCUSS
99	109	proteasome	complex_assembly	Similarly, although the serine mutant is active, threonine is more efficient in the context of the proteasome active site.	DISCUSS
110	121	active site	site	Similarly, although the serine mutant is active, threonine is more efficient in the context of the proteasome active site.	DISCUSS
27	36	threonine	residue_name	The greater suitability of threonine for the proteasome active site, which has been noted in biochemical as well as in kinetic studies, constitutes a likely reason for the conservation of the Thr1 residue in all proteasomes from bacteria to eukaryotes.	DISCUSS
45	55	proteasome	complex_assembly	The greater suitability of threonine for the proteasome active site, which has been noted in biochemical as well as in kinetic studies, constitutes a likely reason for the conservation of the Thr1 residue in all proteasomes from bacteria to eukaryotes.	DISCUSS
56	67	active site	site	The greater suitability of threonine for the proteasome active site, which has been noted in biochemical as well as in kinetic studies, constitutes a likely reason for the conservation of the Thr1 residue in all proteasomes from bacteria to eukaryotes.	DISCUSS
172	184	conservation	protein_state	The greater suitability of threonine for the proteasome active site, which has been noted in biochemical as well as in kinetic studies, constitutes a likely reason for the conservation of the Thr1 residue in all proteasomes from bacteria to eukaryotes.	DISCUSS
192	196	Thr1	residue_name_number	The greater suitability of threonine for the proteasome active site, which has been noted in biochemical as well as in kinetic studies, constitutes a likely reason for the conservation of the Thr1 residue in all proteasomes from bacteria to eukaryotes.	DISCUSS
212	223	proteasomes	complex_assembly	The greater suitability of threonine for the proteasome active site, which has been noted in biochemical as well as in kinetic studies, constitutes a likely reason for the conservation of the Thr1 residue in all proteasomes from bacteria to eukaryotes.	DISCUSS
229	237	bacteria	taxonomy_domain	The greater suitability of threonine for the proteasome active site, which has been noted in biochemical as well as in kinetic studies, constitutes a likely reason for the conservation of the Thr1 residue in all proteasomes from bacteria to eukaryotes.	DISCUSS
241	251	eukaryotes	taxonomy_domain	The greater suitability of threonine for the proteasome active site, which has been noted in biochemical as well as in kinetic studies, constitutes a likely reason for the conservation of the Thr1 residue in all proteasomes from bacteria to eukaryotes.	DISCUSS
28	39	propeptides	structure_element	Conformation of proteasomal propeptides.	FIG
4	28	Structural superposition	experimental_method	(a) Structural superposition of the β1-T1A propeptide and the matured WT β1 active-site Thr1.	FIG
36	42	β1-T1A	mutant	(a) Structural superposition of the β1-T1A propeptide and the matured WT β1 active-site Thr1.	FIG
43	53	propeptide	structure_element	(a) Structural superposition of the β1-T1A propeptide and the matured WT β1 active-site Thr1.	FIG
62	69	matured	protein_state	(a) Structural superposition of the β1-T1A propeptide and the matured WT β1 active-site Thr1.	FIG
70	72	WT	protein_state	(a) Structural superposition of the β1-T1A propeptide and the matured WT β1 active-site Thr1.	FIG
73	75	β1	protein	(a) Structural superposition of the β1-T1A propeptide and the matured WT β1 active-site Thr1.	FIG
76	87	active-site	site	(a) Structural superposition of the β1-T1A propeptide and the matured WT β1 active-site Thr1.	FIG
88	92	Thr1	residue_name_number	(a) Structural superposition of the β1-T1A propeptide and the matured WT β1 active-site Thr1.	FIG
18	30	(-5) to (-1)	residue_range	Only the residues (-5) to (-1) of the β1-T1A propeptide are displayed.	FIG
38	44	β1-T1A	mutant	Only the residues (-5) to (-1) of the β1-T1A propeptide are displayed.	FIG
45	55	propeptide	structure_element	Only the residues (-5) to (-1) of the β1-T1A propeptide are displayed.	FIG
29	50	S1 specificity pocket	site	The major determinant of the S1 specificity pocket, residue 45, is depicted.	FIG
60	62	45	residue_number	The major determinant of the S1 specificity pocket, residue 45, is depicted.	FIG
29	50	S1 specificity pocket	site	The major determinant of the S1 specificity pocket, residue 45, is depicted.	FIG
60	62	45	residue_number	The major determinant of the S1 specificity pocket, residue 45, is depicted.	FIG
31	38	Gly(-1)	residue_name_number	Note the tight conformation of Gly(-1) and Ala1 before propeptide removal (G(-1) turn; cyan double arrow) compared with the relaxed, processed WT active-site Thr1 (red double arrow).	FIG
43	47	Ala1	residue_name_number	Note the tight conformation of Gly(-1) and Ala1 before propeptide removal (G(-1) turn; cyan double arrow) compared with the relaxed, processed WT active-site Thr1 (red double arrow).	FIG
55	65	propeptide	structure_element	Note the tight conformation of Gly(-1) and Ala1 before propeptide removal (G(-1) turn; cyan double arrow) compared with the relaxed, processed WT active-site Thr1 (red double arrow).	FIG
75	80	G(-1)	residue_name_number	Note the tight conformation of Gly(-1) and Ala1 before propeptide removal (G(-1) turn; cyan double arrow) compared with the relaxed, processed WT active-site Thr1 (red double arrow).	FIG
133	142	processed	protein_state	Note the tight conformation of Gly(-1) and Ala1 before propeptide removal (G(-1) turn; cyan double arrow) compared with the relaxed, processed WT active-site Thr1 (red double arrow).	FIG
143	145	WT	protein_state	Note the tight conformation of Gly(-1) and Ala1 before propeptide removal (G(-1) turn; cyan double arrow) compared with the relaxed, processed WT active-site Thr1 (red double arrow).	FIG
146	157	active-site	site	Note the tight conformation of Gly(-1) and Ala1 before propeptide removal (G(-1) turn; cyan double arrow) compared with the relaxed, processed WT active-site Thr1 (red double arrow).	FIG
158	162	Thr1	residue_name_number	Note the tight conformation of Gly(-1) and Ala1 before propeptide removal (G(-1) turn; cyan double arrow) compared with the relaxed, processed WT active-site Thr1 (red double arrow).	FIG
40	44	Thr1	residue_name_number	The black arrow indicates the attack of Thr1Oγ onto the carbonyl carbon atom of Gly(-1).	FIG
80	87	Gly(-1)	residue_name_number	The black arrow indicates the attack of Thr1Oγ onto the carbonyl carbon atom of Gly(-1).	FIG
4	28	Structural superposition	experimental_method	(b) Structural superposition of the β1-T1A propeptide and the β2-T1A propeptide highlights subtle differences in their conformations, but illustrates that Ala1 and Gly(-1) match well.	FIG
36	42	β1-T1A	mutant	(b) Structural superposition of the β1-T1A propeptide and the β2-T1A propeptide highlights subtle differences in their conformations, but illustrates that Ala1 and Gly(-1) match well.	FIG
43	53	propeptide	structure_element	(b) Structural superposition of the β1-T1A propeptide and the β2-T1A propeptide highlights subtle differences in their conformations, but illustrates that Ala1 and Gly(-1) match well.	FIG
62	68	β2-T1A	mutant	(b) Structural superposition of the β1-T1A propeptide and the β2-T1A propeptide highlights subtle differences in their conformations, but illustrates that Ala1 and Gly(-1) match well.	FIG
69	79	propeptide	structure_element	(b) Structural superposition of the β1-T1A propeptide and the β2-T1A propeptide highlights subtle differences in their conformations, but illustrates that Ala1 and Gly(-1) match well.	FIG
155	159	Ala1	residue_name_number	(b) Structural superposition of the β1-T1A propeptide and the β2-T1A propeptide highlights subtle differences in their conformations, but illustrates that Ala1 and Gly(-1) match well.	FIG
164	171	Gly(-1)	residue_name_number	(b) Structural superposition of the β1-T1A propeptide and the β2-T1A propeptide highlights subtle differences in their conformations, but illustrates that Ala1 and Gly(-1) match well.	FIG
0	7	Thr(-2)	residue_name_number	Thr(-2)OH is hydrogen-bonded to Gly(-1)O (∼2.8 Å; black dashed line).	FIG
32	39	Gly(-1)	residue_name_number	Thr(-2)OH is hydrogen-bonded to Gly(-1)O (∼2.8 Å; black dashed line).	FIG
4	28	Structural superposition	experimental_method	(c) Structural superposition of the β1-T1A, the β2-T1A and the β5-T1A-K81R propeptide remnants depict their differences in conformation.	FIG
36	42	β1-T1A	mutant	(c) Structural superposition of the β1-T1A, the β2-T1A and the β5-T1A-K81R propeptide remnants depict their differences in conformation.	FIG
48	54	β2-T1A	mutant	(c) Structural superposition of the β1-T1A, the β2-T1A and the β5-T1A-K81R propeptide remnants depict their differences in conformation.	FIG
63	74	β5-T1A-K81R	mutant	(c) Structural superposition of the β1-T1A, the β2-T1A and the β5-T1A-K81R propeptide remnants depict their differences in conformation.	FIG
75	85	propeptide	structure_element	(c) Structural superposition of the β1-T1A, the β2-T1A and the β5-T1A-K81R propeptide remnants depict their differences in conformation.	FIG
14	18	(-2)	residue_number	While residue (-2) of the β1 and β2 prosegments fit the S1 pocket, His(-2) of the β5 propeptide occupies the S2 pocket.	FIG
26	28	β1	protein	While residue (-2) of the β1 and β2 prosegments fit the S1 pocket, His(-2) of the β5 propeptide occupies the S2 pocket.	FIG
33	35	β2	protein	While residue (-2) of the β1 and β2 prosegments fit the S1 pocket, His(-2) of the β5 propeptide occupies the S2 pocket.	FIG
36	47	prosegments	structure_element	While residue (-2) of the β1 and β2 prosegments fit the S1 pocket, His(-2) of the β5 propeptide occupies the S2 pocket.	FIG
56	65	S1 pocket	site	While residue (-2) of the β1 and β2 prosegments fit the S1 pocket, His(-2) of the β5 propeptide occupies the S2 pocket.	FIG
67	74	His(-2)	residue_name_number	While residue (-2) of the β1 and β2 prosegments fit the S1 pocket, His(-2) of the β5 propeptide occupies the S2 pocket.	FIG
82	84	β5	protein	While residue (-2) of the β1 and β2 prosegments fit the S1 pocket, His(-2) of the β5 propeptide occupies the S2 pocket.	FIG
85	95	propeptide	structure_element	While residue (-2) of the β1 and β2 prosegments fit the S1 pocket, His(-2) of the β5 propeptide occupies the S2 pocket.	FIG
109	118	S2 pocket	site	While residue (-2) of the β1 and β2 prosegments fit the S1 pocket, His(-2) of the β5 propeptide occupies the S2 pocket.	FIG
56	63	Gly(-1)	residue_name_number	Nonetheless, in all mutants the carbonyl carbon atom of Gly(-1) is ideally placed for the nucleophilic attack by Thr1Oγ.	FIG
113	117	Thr1	residue_name_number	Nonetheless, in all mutants the carbonyl carbon atom of Gly(-1) is ideally placed for the nucleophilic attack by Thr1Oγ.	FIG
26	33	Thr(-2)	residue_name_number	The hydrogen bond between Thr(-2)OH and Gly(-1)O (∼2.8 Å) is indicated by a black dashed line.	FIG
40	47	Gly(-1)	residue_name_number	The hydrogen bond between Thr(-2)OH and Gly(-1)O (∼2.8 Å) is indicated by a black dashed line.	FIG
0	9	Mutations	experimental_method	Mutations of residue (-2) and their influence on propeptide conformation and autolysis.	FIG
21	25	(-2)	residue_number	Mutations of residue (-2) and their influence on propeptide conformation and autolysis.	FIG
49	59	propeptide	structure_element	Mutations of residue (-2) and their influence on propeptide conformation and autolysis.	FIG
77	86	autolysis	ptm	Mutations of residue (-2) and their influence on propeptide conformation and autolysis.	FIG
4	28	Structural superposition	experimental_method	(a) Structural superposition of the β1-T1A propeptide and the β5-H(-2)L-T1A mutant propeptide.	FIG
36	42	β1-T1A	mutant	(a) Structural superposition of the β1-T1A propeptide and the β5-H(-2)L-T1A mutant propeptide.	FIG
43	53	propeptide	structure_element	(a) Structural superposition of the β1-T1A propeptide and the β5-H(-2)L-T1A mutant propeptide.	FIG
62	75	β5-H(-2)L-T1A	mutant	(a) Structural superposition of the β1-T1A propeptide and the β5-H(-2)L-T1A mutant propeptide.	FIG
76	82	mutant	protein_state	(a) Structural superposition of the β1-T1A propeptide and the β5-H(-2)L-T1A mutant propeptide.	FIG
83	93	propeptide	structure_element	(a) Structural superposition of the β1-T1A propeptide and the β5-H(-2)L-T1A mutant propeptide.	FIG
4	8	(-2)	residue_number	The (-2) residues of both prosegments point into the S1 pocket.	FIG
26	37	prosegments	structure_element	The (-2) residues of both prosegments point into the S1 pocket.	FIG
53	62	S1 pocket	site	The (-2) residues of both prosegments point into the S1 pocket.	FIG
4	28	Structural superposition	experimental_method	(b) Structural superposition of the β5 propeptides in the β5-H(-2)L-T1A, β5-H(-2)T-T1A, β5-(H-2)A-T1A-K81R and β5-T1A-K81R mutant proteasomes.	FIG
36	38	β5	protein	(b) Structural superposition of the β5 propeptides in the β5-H(-2)L-T1A, β5-H(-2)T-T1A, β5-(H-2)A-T1A-K81R and β5-T1A-K81R mutant proteasomes.	FIG
39	50	propeptides	structure_element	(b) Structural superposition of the β5 propeptides in the β5-H(-2)L-T1A, β5-H(-2)T-T1A, β5-(H-2)A-T1A-K81R and β5-T1A-K81R mutant proteasomes.	FIG
58	71	β5-H(-2)L-T1A	mutant	(b) Structural superposition of the β5 propeptides in the β5-H(-2)L-T1A, β5-H(-2)T-T1A, β5-(H-2)A-T1A-K81R and β5-T1A-K81R mutant proteasomes.	FIG
73	86	β5-H(-2)T-T1A	mutant	(b) Structural superposition of the β5 propeptides in the β5-H(-2)L-T1A, β5-H(-2)T-T1A, β5-(H-2)A-T1A-K81R and β5-T1A-K81R mutant proteasomes.	FIG
88	106	β5-(H-2)A-T1A-K81R	mutant	(b) Structural superposition of the β5 propeptides in the β5-H(-2)L-T1A, β5-H(-2)T-T1A, β5-(H-2)A-T1A-K81R and β5-T1A-K81R mutant proteasomes.	FIG
111	122	β5-T1A-K81R	mutant	(b) Structural superposition of the β5 propeptides in the β5-H(-2)L-T1A, β5-H(-2)T-T1A, β5-(H-2)A-T1A-K81R and β5-T1A-K81R mutant proteasomes.	FIG
123	129	mutant	protein_state	(b) Structural superposition of the β5 propeptides in the β5-H(-2)L-T1A, β5-H(-2)T-T1A, β5-(H-2)A-T1A-K81R and β5-T1A-K81R mutant proteasomes.	FIG
130	141	proteasomes	complex_assembly	(b) Structural superposition of the β5 propeptides in the β5-H(-2)L-T1A, β5-H(-2)T-T1A, β5-(H-2)A-T1A-K81R and β5-T1A-K81R mutant proteasomes.	FIG
19	31	(-2) to (-4)	residue_range	While the residues (-2) to (-4) vary in their conformation, Gly(-1) and Ala1 are located in all structures at the same positions.	FIG
60	67	Gly(-1)	residue_name_number	While the residues (-2) to (-4) vary in their conformation, Gly(-1) and Ala1 are located in all structures at the same positions.	FIG
72	76	Ala1	residue_name_number	While the residues (-2) to (-4) vary in their conformation, Gly(-1) and Ala1 are located in all structures at the same positions.	FIG
96	106	structures	evidence	While the residues (-2) to (-4) vary in their conformation, Gly(-1) and Ala1 are located in all structures at the same positions.	FIG
4	28	Structural superposition	experimental_method	(c) Structural superposition of the β2-T1A propeptide and the β5-H(-2)T-T1A mutant propeptide.	FIG
36	42	β2-T1A	mutant	(c) Structural superposition of the β2-T1A propeptide and the β5-H(-2)T-T1A mutant propeptide.	FIG
43	53	propeptide	structure_element	(c) Structural superposition of the β2-T1A propeptide and the β5-H(-2)T-T1A mutant propeptide.	FIG
62	75	β5-H(-2)T-T1A	mutant	(c) Structural superposition of the β2-T1A propeptide and the β5-H(-2)T-T1A mutant propeptide.	FIG
76	82	mutant	protein_state	(c) Structural superposition of the β2-T1A propeptide and the β5-H(-2)T-T1A mutant propeptide.	FIG
83	93	propeptide	structure_element	(c) Structural superposition of the β2-T1A propeptide and the β5-H(-2)T-T1A mutant propeptide.	FIG
4	8	(-2)	residue_number	The (-2) residues of both prosegments point into the S1 pocket, but only Thr(-2)OH of β2 forms a hydrogen bridge to Gly(-1)O (black dashed line).	FIG
26	37	prosegments	structure_element	The (-2) residues of both prosegments point into the S1 pocket, but only Thr(-2)OH of β2 forms a hydrogen bridge to Gly(-1)O (black dashed line).	FIG
53	62	S1 pocket	site	The (-2) residues of both prosegments point into the S1 pocket, but only Thr(-2)OH of β2 forms a hydrogen bridge to Gly(-1)O (black dashed line).	FIG
73	80	Thr(-2)	residue_name_number	The (-2) residues of both prosegments point into the S1 pocket, but only Thr(-2)OH of β2 forms a hydrogen bridge to Gly(-1)O (black dashed line).	FIG
86	88	β2	protein	The (-2) residues of both prosegments point into the S1 pocket, but only Thr(-2)OH of β2 forms a hydrogen bridge to Gly(-1)O (black dashed line).	FIG
116	123	Gly(-1)	residue_name_number	The (-2) residues of both prosegments point into the S1 pocket, but only Thr(-2)OH of β2 forms a hydrogen bridge to Gly(-1)O (black dashed line).	FIG
4	28	Structural superposition	experimental_method	(d) Structural superposition of the matured β2 active site, the WT β2-T1A propeptide and the β2-T(-2)V mutant propeptide.	FIG
36	43	matured	protein_state	(d) Structural superposition of the matured β2 active site, the WT β2-T1A propeptide and the β2-T(-2)V mutant propeptide.	FIG
44	46	β2	protein	(d) Structural superposition of the matured β2 active site, the WT β2-T1A propeptide and the β2-T(-2)V mutant propeptide.	FIG
47	58	active site	site	(d) Structural superposition of the matured β2 active site, the WT β2-T1A propeptide and the β2-T(-2)V mutant propeptide.	FIG
64	66	WT	protein_state	(d) Structural superposition of the matured β2 active site, the WT β2-T1A propeptide and the β2-T(-2)V mutant propeptide.	FIG
67	73	β2-T1A	mutant	(d) Structural superposition of the matured β2 active site, the WT β2-T1A propeptide and the β2-T(-2)V mutant propeptide.	FIG
74	84	propeptide	structure_element	(d) Structural superposition of the matured β2 active site, the WT β2-T1A propeptide and the β2-T(-2)V mutant propeptide.	FIG
93	102	β2-T(-2)V	mutant	(d) Structural superposition of the matured β2 active site, the WT β2-T1A propeptide and the β2-T(-2)V mutant propeptide.	FIG
103	109	mutant	protein_state	(d) Structural superposition of the matured β2 active site, the WT β2-T1A propeptide and the β2-T(-2)V mutant propeptide.	FIG
110	120	propeptide	structure_element	(d) Structural superposition of the matured β2 active site, the WT β2-T1A propeptide and the β2-T(-2)V mutant propeptide.	FIG
9	16	Val(-2)	residue_name_number	Notably, Val(-2) of the latter does not occupy the S1 pocket, thereby changing the orientation of Gly(-1) and preventing nucleophilic attack of Thr1Oγ on the carbonyl carbon atom of Gly(-1).	FIG
51	60	S1 pocket	site	Notably, Val(-2) of the latter does not occupy the S1 pocket, thereby changing the orientation of Gly(-1) and preventing nucleophilic attack of Thr1Oγ on the carbonyl carbon atom of Gly(-1).	FIG
98	105	Gly(-1)	residue_name_number	Notably, Val(-2) of the latter does not occupy the S1 pocket, thereby changing the orientation of Gly(-1) and preventing nucleophilic attack of Thr1Oγ on the carbonyl carbon atom of Gly(-1).	FIG
144	148	Thr1	residue_name_number	Notably, Val(-2) of the latter does not occupy the S1 pocket, thereby changing the orientation of Gly(-1) and preventing nucleophilic attack of Thr1Oγ on the carbonyl carbon atom of Gly(-1).	FIG
182	189	Gly(-1)	residue_name_number	Notably, Val(-2) of the latter does not occupy the S1 pocket, thereby changing the orientation of Gly(-1) and preventing nucleophilic attack of Thr1Oγ on the carbonyl carbon atom of Gly(-1).	FIG
64	75	active site	site	Architecture and proposed reaction mechanism of the proteasomal active site.	FIG
4	28	Hydrogen-bonding network	site	(a) Hydrogen-bonding network at the mature WT β5 proteasomal active site (dotted lines).	FIG
36	42	mature	protein_state	(a) Hydrogen-bonding network at the mature WT β5 proteasomal active site (dotted lines).	FIG
43	45	WT	protein_state	(a) Hydrogen-bonding network at the mature WT β5 proteasomal active site (dotted lines).	FIG
46	48	β5	protein	(a) Hydrogen-bonding network at the mature WT β5 proteasomal active site (dotted lines).	FIG
61	72	active site	site	(a) Hydrogen-bonding network at the mature WT β5 proteasomal active site (dotted lines).	FIG
0	4	Thr1	residue_name_number	Thr1OH is hydrogen-bonded to Lys33NH2 (2.7 Å), which in turn interacts with Asp17Oδ.	FIG
29	34	Lys33	residue_name_number	Thr1OH is hydrogen-bonded to Lys33NH2 (2.7 Å), which in turn interacts with Asp17Oδ.	FIG
76	81	Asp17	residue_name_number	Thr1OH is hydrogen-bonded to Lys33NH2 (2.7 Å), which in turn interacts with Asp17Oδ.	FIG
4	8	Thr1	residue_name_number	The Thr1 N terminus is engaged in hydrogen bonds with Ser129Oγ, the carbonyl oxygen of residue 168, Ser169Oγ and Asp166Oδ.	FIG
54	60	Ser129	residue_name_number	The Thr1 N terminus is engaged in hydrogen bonds with Ser129Oγ, the carbonyl oxygen of residue 168, Ser169Oγ and Asp166Oδ.	FIG
95	98	168	residue_number	The Thr1 N terminus is engaged in hydrogen bonds with Ser129Oγ, the carbonyl oxygen of residue 168, Ser169Oγ and Asp166Oδ.	FIG
100	106	Ser169	residue_name_number	The Thr1 N terminus is engaged in hydrogen bonds with Ser129Oγ, the carbonyl oxygen of residue 168, Ser169Oγ and Asp166Oδ.	FIG
113	119	Asp166	residue_name_number	The Thr1 N terminus is engaged in hydrogen bonds with Ser129Oγ, the carbonyl oxygen of residue 168, Ser169Oγ and Asp166Oδ.	FIG
28	48	active-site residues	site	(b) The orientations of the active-site residues involved in hydrogen bonding are strictly conserved in each proteolytic centre, as shown by superposition of the β subunits.	FIG
82	100	strictly conserved	protein_state	(b) The orientations of the active-site residues involved in hydrogen bonding are strictly conserved in each proteolytic centre, as shown by superposition of the β subunits.	FIG
109	127	proteolytic centre	site	(b) The orientations of the active-site residues involved in hydrogen bonding are strictly conserved in each proteolytic centre, as shown by superposition of the β subunits.	FIG
141	154	superposition	experimental_method	(b) The orientations of the active-site residues involved in hydrogen bonding are strictly conserved in each proteolytic centre, as shown by superposition of the β subunits.	FIG
162	172	β subunits	protein	(b) The orientations of the active-site residues involved in hydrogen bonding are strictly conserved in each proteolytic centre, as shown by superposition of the β subunits.	FIG
4	28	Structural superposition	experimental_method	(c) Structural superposition of the WT β5 and the β5-K33A pp trans mutant active site.	FIG
36	38	WT	protein_state	(c) Structural superposition of the WT β5 and the β5-K33A pp trans mutant active site.	FIG
39	41	β5	protein	(c) Structural superposition of the WT β5 and the β5-K33A pp trans mutant active site.	FIG
50	57	β5-K33A	mutant	(c) Structural superposition of the WT β5 and the β5-K33A pp trans mutant active site.	FIG
58	60	pp	chemical	(c) Structural superposition of the WT β5 and the β5-K33A pp trans mutant active site.	FIG
61	66	trans	protein_state	(c) Structural superposition of the WT β5 and the β5-K33A pp trans mutant active site.	FIG
67	73	mutant	protein_state	(c) Structural superposition of the WT β5 and the β5-K33A pp trans mutant active site.	FIG
74	85	active site	site	(c) Structural superposition of the WT β5 and the β5-K33A pp trans mutant active site.	FIG
17	22	water	chemical	In the latter, a water molecule (red sphere) is found at the position where in the WT structure the side chain amine group of Lys33 is located.	FIG
83	85	WT	protein_state	In the latter, a water molecule (red sphere) is found at the position where in the WT structure the side chain amine group of Lys33 is located.	FIG
126	131	Lys33	residue_name_number	In the latter, a water molecule (red sphere) is found at the position where in the WT structure the side chain amine group of Lys33 is located.	FIG
13	18	Lys33	residue_name_number	Similarly to Lys33, the water molecule hydrogen bonds to Arg19O, Asp17Oδ and Thr1OH.	FIG
24	29	water	chemical	Similarly to Lys33, the water molecule hydrogen bonds to Arg19O, Asp17Oδ and Thr1OH.	FIG
57	62	Arg19	residue_name_number	Similarly to Lys33, the water molecule hydrogen bonds to Arg19O, Asp17Oδ and Thr1OH.	FIG
65	70	Asp17	residue_name_number	Similarly to Lys33, the water molecule hydrogen bonds to Arg19O, Asp17Oδ and Thr1OH.	FIG
77	81	Thr1	residue_name_number	Similarly to Lys33, the water molecule hydrogen bonds to Arg19O, Asp17Oδ and Thr1OH.	FIG
38	43	water	chemical	Note, the strong interaction with the water molecule causes a minor shift of Thr1, while all other active-site residues remain in place.	FIG
77	81	Thr1	residue_name_number	Note, the strong interaction with the water molecule causes a minor shift of Thr1, while all other active-site residues remain in place.	FIG
99	119	active-site residues	site	Note, the strong interaction with the water molecule causes a minor shift of Thr1, while all other active-site residues remain in place.	FIG
45	79	autocatalytic precursor processing	ptm	(d) Proposed chemical reaction mechanism for autocatalytic precursor processing and proteolysis in the proteasome.	FIG
103	113	proteasome	complex_assembly	(d) Proposed chemical reaction mechanism for autocatalytic precursor processing and proteolysis in the proteasome.	FIG
4	15	active-site	site	The active-site Thr1 is depicted in blue, the propeptide segment and the peptide substrate are coloured in green, whereas the scissile peptide bond is highlighted in red.	FIG
16	20	Thr1	residue_name_number	The active-site Thr1 is depicted in blue, the propeptide segment and the peptide substrate are coloured in green, whereas the scissile peptide bond is highlighted in red.	FIG
46	56	propeptide	structure_element	The active-site Thr1 is depicted in blue, the propeptide segment and the peptide substrate are coloured in green, whereas the scissile peptide bond is highlighted in red.	FIG
0	9	Autolysis	ptm	Autolysis (left set of structures) is initiated by deprotonation of Thr1OH via Lys33NH2 and the formation of a tetrahedral transition state.	FIG
68	72	Thr1	residue_name_number	Autolysis (left set of structures) is initiated by deprotonation of Thr1OH via Lys33NH2 and the formation of a tetrahedral transition state.	FIG
79	84	Lys33	residue_name_number	Autolysis (left set of structures) is initiated by deprotonation of Thr1OH via Lys33NH2 and the formation of a tetrahedral transition state.	FIG
4	22	strictly conserved	protein_state	The strictly conserved oxyanion hole Gly47NH stabilizing the negatively charged intermediate is illustrated as a semicircle.	FIG
37	42	Gly47	residue_name_number	The strictly conserved oxyanion hole Gly47NH stabilizing the negatively charged intermediate is illustrated as a semicircle.	FIG
43	47	Thr1	residue_name_number	Collapse of the transition state frees the Thr1 N terminus (by completing an N-to-O acyl shift of the propeptide), which is subsequently protonated by Asp166OH via Ser129OH.	FIG
102	112	propeptide	structure_element	Collapse of the transition state frees the Thr1 N terminus (by completing an N-to-O acyl shift of the propeptide), which is subsequently protonated by Asp166OH via Ser129OH.	FIG
151	157	Asp166	residue_name_number	Collapse of the transition state frees the Thr1 N terminus (by completing an N-to-O acyl shift of the propeptide), which is subsequently protonated by Asp166OH via Ser129OH.	FIG
164	170	Ser129	residue_name_number	Collapse of the transition state frees the Thr1 N terminus (by completing an N-to-O acyl shift of the propeptide), which is subsequently protonated by Asp166OH via Ser129OH.	FIG
6	10	Thr1	residue_name_number	Next, Thr1NH2 polarizes a water molecule for the nucleophilic attack of the acyl-enzyme intermediate.	FIG
26	31	water	chemical	Next, Thr1NH2 polarizes a water molecule for the nucleophilic attack of the acyl-enzyme intermediate.	FIG
33	44	active-site	site	On hydrolysis of the latter, the active-site Thr1 is ready for catalysis (right set of structures).	FIG
45	49	Thr1	residue_name_number	On hydrolysis of the latter, the active-site Thr1 is ready for catalysis (right set of structures).	FIG
12	16	Thr1	residue_name_number	The charged Thr1 N terminus may engage in the orientation of the amide moiety and donate a proton to the emerging N terminus of the C-terminal cleavage product.	FIG
27	31	Thr1	residue_name_number	The resulting deprotonated Thr1NH2 finally activates a water molecule for hydrolysis of the acyl-enzyme.	FIG
55	60	water	chemical	The resulting deprotonated Thr1NH2 finally activates a water molecule for hydrolysis of the acyl-enzyme.	FIG
4	14	proteasome	complex_assembly	The proteasome favours threonine as the active-site nucleophile.	FIG
23	32	threonine	residue_name	The proteasome favours threonine as the active-site nucleophile.	FIG
4	35	Growth tests by serial dilution	experimental_method	(a) Growth tests by serial dilution of WT and pre2 (β5) mutant yeast cultures reveal growth defects of the active-site mutants under the indicated conditions after 2 days (2 d) of incubation.	FIG
39	41	WT	protein_state	(a) Growth tests by serial dilution of WT and pre2 (β5) mutant yeast cultures reveal growth defects of the active-site mutants under the indicated conditions after 2 days (2 d) of incubation.	FIG
52	54	β5	protein	(a) Growth tests by serial dilution of WT and pre2 (β5) mutant yeast cultures reveal growth defects of the active-site mutants under the indicated conditions after 2 days (2 d) of incubation.	FIG
56	62	mutant	protein_state	(a) Growth tests by serial dilution of WT and pre2 (β5) mutant yeast cultures reveal growth defects of the active-site mutants under the indicated conditions after 2 days (2 d) of incubation.	FIG
63	68	yeast	taxonomy_domain	(a) Growth tests by serial dilution of WT and pre2 (β5) mutant yeast cultures reveal growth defects of the active-site mutants under the indicated conditions after 2 days (2 d) of incubation.	FIG
107	118	active-site	site	(a) Growth tests by serial dilution of WT and pre2 (β5) mutant yeast cultures reveal growth defects of the active-site mutants under the indicated conditions after 2 days (2 d) of incubation.	FIG
119	126	mutants	experimental_method	(a) Growth tests by serial dilution of WT and pre2 (β5) mutant yeast cultures reveal growth defects of the active-site mutants under the indicated conditions after 2 days (2 d) of incubation.	FIG
13	15	WT	protein_state	(b) Purified WT and mutant proteasomes were tested for their chymotrypsin-like activity (β5) using the substrate Suc-LLVY-AMC.	FIG
20	26	mutant	protein_state	(b) Purified WT and mutant proteasomes were tested for their chymotrypsin-like activity (β5) using the substrate Suc-LLVY-AMC.	FIG
27	38	proteasomes	complex_assembly	(b) Purified WT and mutant proteasomes were tested for their chymotrypsin-like activity (β5) using the substrate Suc-LLVY-AMC.	FIG
89	91	β5	protein	(b) Purified WT and mutant proteasomes were tested for their chymotrypsin-like activity (β5) using the substrate Suc-LLVY-AMC.	FIG
113	125	Suc-LLVY-AMC	chemical	(b) Purified WT and mutant proteasomes were tested for their chymotrypsin-like activity (β5) using the substrate Suc-LLVY-AMC.	FIG
24	51	2FO–FC electron-density map	evidence	(c) Illustration of the 2FO–FC electron-density map (blue mesh contoured at 1σ) for the β5-T1C propeptide fragment.	FIG
88	94	β5-T1C	mutant	(c) Illustration of the 2FO–FC electron-density map (blue mesh contoured at 1σ) for the β5-T1C propeptide fragment.	FIG
95	105	propeptide	structure_element	(c) Illustration of the 2FO–FC electron-density map (blue mesh contoured at 1σ) for the β5-T1C propeptide fragment.	FIG
4	14	prosegment	structure_element	The prosegment is cleaved but still bound in the substrate-binding channel.	FIG
18	25	cleaved	protein_state	The prosegment is cleaved but still bound in the substrate-binding channel.	FIG
30	41	still bound	protein_state	The prosegment is cleaved but still bound in the substrate-binding channel.	FIG
49	74	substrate-binding channel	site	The prosegment is cleaved but still bound in the substrate-binding channel.	FIG
9	16	His(-2)	residue_name_number	Notably, His(-2) does not occupy the S1 pocket formed by Met45, similar to what was observed for the β5-T1A-K81R mutant.	FIG
37	46	S1 pocket	site	Notably, His(-2) does not occupy the S1 pocket formed by Met45, similar to what was observed for the β5-T1A-K81R mutant.	FIG
57	62	Met45	residue_name_number	Notably, His(-2) does not occupy the S1 pocket formed by Met45, similar to what was observed for the β5-T1A-K81R mutant.	FIG
101	112	β5-T1A-K81R	mutant	Notably, His(-2) does not occupy the S1 pocket formed by Met45, similar to what was observed for the β5-T1A-K81R mutant.	FIG
113	119	mutant	protein_state	Notably, His(-2) does not occupy the S1 pocket formed by Met45, similar to what was observed for the β5-T1A-K81R mutant.	FIG
4	28	Structural superposition	experimental_method	(d) Structural superposition of the β5-T1A-K81R and the β5-T1C mutant subunits onto the WT β5 subunit.	FIG
36	47	β5-T1A-K81R	mutant	(d) Structural superposition of the β5-T1A-K81R and the β5-T1C mutant subunits onto the WT β5 subunit.	FIG
56	62	β5-T1C	mutant	(d) Structural superposition of the β5-T1A-K81R and the β5-T1C mutant subunits onto the WT β5 subunit.	FIG
63	69	mutant	protein_state	(d) Structural superposition of the β5-T1A-K81R and the β5-T1C mutant subunits onto the WT β5 subunit.	FIG
88	90	WT	protein_state	(d) Structural superposition of the β5-T1A-K81R and the β5-T1C mutant subunits onto the WT β5 subunit.	FIG
91	93	β5	protein	(d) Structural superposition of the β5-T1A-K81R and the β5-T1C mutant subunits onto the WT β5 subunit.	FIG
4	28	Structural superposition	experimental_method	(e) Structural superposition of the β5-T1C propeptide onto the β1-T1A active site (blue) and the WT β5 active site in complex with the proteasome inhibitor MG132 (ref.).	FIG
36	42	β5-T1C	mutant	(e) Structural superposition of the β5-T1C propeptide onto the β1-T1A active site (blue) and the WT β5 active site in complex with the proteasome inhibitor MG132 (ref.).	FIG
43	53	propeptide	structure_element	(e) Structural superposition of the β5-T1C propeptide onto the β1-T1A active site (blue) and the WT β5 active site in complex with the proteasome inhibitor MG132 (ref.).	FIG
63	69	β1-T1A	mutant	(e) Structural superposition of the β5-T1C propeptide onto the β1-T1A active site (blue) and the WT β5 active site in complex with the proteasome inhibitor MG132 (ref.).	FIG
70	81	active site	site	(e) Structural superposition of the β5-T1C propeptide onto the β1-T1A active site (blue) and the WT β5 active site in complex with the proteasome inhibitor MG132 (ref.).	FIG
97	99	WT	protein_state	(e) Structural superposition of the β5-T1C propeptide onto the β1-T1A active site (blue) and the WT β5 active site in complex with the proteasome inhibitor MG132 (ref.).	FIG
100	102	β5	protein	(e) Structural superposition of the β5-T1C propeptide onto the β1-T1A active site (blue) and the WT β5 active site in complex with the proteasome inhibitor MG132 (ref.).	FIG
103	114	active site	site	(e) Structural superposition of the β5-T1C propeptide onto the β1-T1A active site (blue) and the WT β5 active site in complex with the proteasome inhibitor MG132 (ref.).	FIG
115	130	in complex with	protein_state	(e) Structural superposition of the β5-T1C propeptide onto the β1-T1A active site (blue) and the WT β5 active site in complex with the proteasome inhibitor MG132 (ref.).	FIG
135	145	proteasome	complex_assembly	(e) Structural superposition of the β5-T1C propeptide onto the β1-T1A active site (blue) and the WT β5 active site in complex with the proteasome inhibitor MG132 (ref.).	FIG
156	161	MG132	chemical	(e) Structural superposition of the β5-T1C propeptide onto the β1-T1A active site (blue) and the WT β5 active site in complex with the proteasome inhibitor MG132 (ref.).	FIG
4	13	inhibitor	chemical	The inhibitor as well as the propeptides adopt similar conformations in the substrate-binding channel.	FIG
29	40	propeptides	structure_element	The inhibitor as well as the propeptides adopt similar conformations in the substrate-binding channel.	FIG
76	101	substrate-binding channel	site	The inhibitor as well as the propeptides adopt similar conformations in the substrate-binding channel.	FIG
4	28	Structural superposition	experimental_method	(f) Structural superposition of the WT β5 and β5-T1C mutant active sites illustrates the different orientations of the hydroxyl group of Thr1 and the thiol side chain of Cys1.	FIG
36	38	WT	protein_state	(f) Structural superposition of the WT β5 and β5-T1C mutant active sites illustrates the different orientations of the hydroxyl group of Thr1 and the thiol side chain of Cys1.	FIG
39	41	β5	protein	(f) Structural superposition of the WT β5 and β5-T1C mutant active sites illustrates the different orientations of the hydroxyl group of Thr1 and the thiol side chain of Cys1.	FIG
46	52	β5-T1C	mutant	(f) Structural superposition of the WT β5 and β5-T1C mutant active sites illustrates the different orientations of the hydroxyl group of Thr1 and the thiol side chain of Cys1.	FIG
53	59	mutant	protein_state	(f) Structural superposition of the WT β5 and β5-T1C mutant active sites illustrates the different orientations of the hydroxyl group of Thr1 and the thiol side chain of Cys1.	FIG
60	72	active sites	site	(f) Structural superposition of the WT β5 and β5-T1C mutant active sites illustrates the different orientations of the hydroxyl group of Thr1 and the thiol side chain of Cys1.	FIG
137	141	Thr1	residue_name_number	(f) Structural superposition of the WT β5 and β5-T1C mutant active sites illustrates the different orientations of the hydroxyl group of Thr1 and the thiol side chain of Cys1.	FIG
170	174	Cys1	residue_name_number	(f) Structural superposition of the WT β5 and β5-T1C mutant active sites illustrates the different orientations of the hydroxyl group of Thr1 and the thiol side chain of Cys1.	FIG
4	28	Structural superposition	experimental_method	(g) Structural superposition of the WT β5 and β5-T1S mutant active sites reveals different orientations of the hydroxyl groups of Thr1 and Ser1, respectively.	FIG
36	38	WT	protein_state	(g) Structural superposition of the WT β5 and β5-T1S mutant active sites reveals different orientations of the hydroxyl groups of Thr1 and Ser1, respectively.	FIG
39	41	β5	protein	(g) Structural superposition of the WT β5 and β5-T1S mutant active sites reveals different orientations of the hydroxyl groups of Thr1 and Ser1, respectively.	FIG
46	52	β5-T1S	mutant	(g) Structural superposition of the WT β5 and β5-T1S mutant active sites reveals different orientations of the hydroxyl groups of Thr1 and Ser1, respectively.	FIG
53	59	mutant	protein_state	(g) Structural superposition of the WT β5 and β5-T1S mutant active sites reveals different orientations of the hydroxyl groups of Thr1 and Ser1, respectively.	FIG
60	72	active sites	site	(g) Structural superposition of the WT β5 and β5-T1S mutant active sites reveals different orientations of the hydroxyl groups of Thr1 and Ser1, respectively.	FIG
130	134	Thr1	residue_name_number	(g) Structural superposition of the WT β5 and β5-T1S mutant active sites reveals different orientations of the hydroxyl groups of Thr1 and Ser1, respectively.	FIG
139	143	Ser1	residue_name_number	(g) Structural superposition of the WT β5 and β5-T1S mutant active sites reveals different orientations of the hydroxyl groups of Thr1 and Ser1, respectively.	FIG
4	31	2FO–FC electron-density map	evidence	The 2FO–FC electron-density map for Ser1 (blue mesh contoured at 1σ) is illustrated.	FIG
36	40	Ser1	residue_name_number	The 2FO–FC electron-density map for Ser1 (blue mesh contoured at 1σ) is illustrated.	FIG
24	28	Thr1	residue_name_number	(h) The methyl group of Thr1 is anchored by hydrophobic interactions with Ala46Cβ and Thr3Cγ.	FIG
74	79	Ala46	residue_name_number	(h) The methyl group of Thr1 is anchored by hydrophobic interactions with Ala46Cβ and Thr3Cγ.	FIG
86	90	Thr3	residue_name_number	(h) The methyl group of Thr1 is anchored by hydrophobic interactions with Ala46Cβ and Thr3Cγ.	FIG
5	10	lacks	protein_state	Ser1 lacks this stabilization and is therefore rotated by 60°.	FIG
14	16	WT	protein_state	Inhibition of WT and mutant β5-T1S proteasomes by bortezomib and carfilzomib.	FIG
21	27	mutant	protein_state	Inhibition of WT and mutant β5-T1S proteasomes by bortezomib and carfilzomib.	FIG
28	34	β5-T1S	mutant	Inhibition of WT and mutant β5-T1S proteasomes by bortezomib and carfilzomib.	FIG
35	46	proteasomes	complex_assembly	Inhibition of WT and mutant β5-T1S proteasomes by bortezomib and carfilzomib.	FIG
50	60	bortezomib	chemical	Inhibition of WT and mutant β5-T1S proteasomes by bortezomib and carfilzomib.	FIG
65	76	carfilzomib	chemical	Inhibition of WT and mutant β5-T1S proteasomes by bortezomib and carfilzomib.	FIG
0	17	Inhibition assays	experimental_method	Inhibition assays (left panel).	FIG
9	14	yeast	taxonomy_domain	Purified yeast proteasomes were tested for the susceptibility of their ChT-L (β5) activity to inhibition by bortezomib and carfilzomib using the substrate Suc-LLVY-AMC.	FIG
15	26	proteasomes	complex_assembly	Purified yeast proteasomes were tested for the susceptibility of their ChT-L (β5) activity to inhibition by bortezomib and carfilzomib using the substrate Suc-LLVY-AMC.	FIG
78	80	β5	protein	Purified yeast proteasomes were tested for the susceptibility of their ChT-L (β5) activity to inhibition by bortezomib and carfilzomib using the substrate Suc-LLVY-AMC.	FIG
108	118	bortezomib	chemical	Purified yeast proteasomes were tested for the susceptibility of their ChT-L (β5) activity to inhibition by bortezomib and carfilzomib using the substrate Suc-LLVY-AMC.	FIG
123	134	carfilzomib	chemical	Purified yeast proteasomes were tested for the susceptibility of their ChT-L (β5) activity to inhibition by bortezomib and carfilzomib using the substrate Suc-LLVY-AMC.	FIG
155	167	Suc-LLVY-AMC	chemical	Purified yeast proteasomes were tested for the susceptibility of their ChT-L (β5) activity to inhibition by bortezomib and carfilzomib using the substrate Suc-LLVY-AMC.	FIG
0	11	IC50 values	evidence	IC50 values were determined in triplicate; s.d.'s are indicated by error bars.	FIG
10	21	IC50 values	evidence	Note that IC50 values depend on time and enzyme concentration.	FIG
0	11	Proteasomes	complex_assembly	Proteasomes (final concentration: 66 nM) were incubated with inhibitor for 45 min before substrate addition (final concentration: 200 μM).	FIG
0	10	Structures	evidence	Structures of the β5-T1S mutant in complex with both ligands (green) prove the reactivity of Ser1 (right panel).	FIG
18	24	β5-T1S	mutant	Structures of the β5-T1S mutant in complex with both ligands (green) prove the reactivity of Ser1 (right panel).	FIG
25	31	mutant	protein_state	Structures of the β5-T1S mutant in complex with both ligands (green) prove the reactivity of Ser1 (right panel).	FIG
35	60	complex with both ligands	complex_assembly	Structures of the β5-T1S mutant in complex with both ligands (green) prove the reactivity of Ser1 (right panel).	FIG
93	97	Ser1	residue_name_number	Structures of the β5-T1S mutant in complex with both ligands (green) prove the reactivity of Ser1 (right panel).	FIG
4	32	2FO–FC electron-density maps	evidence	The 2FO–FC electron-density maps (blue mesh) for Ser1 (brown) and the covalently bound ligands (green; only the P1 site (Leu1) is shown) are contoured at 1σ.	FIG
49	53	Ser1	residue_name_number	The 2FO–FC electron-density maps (blue mesh) for Ser1 (brown) and the covalently bound ligands (green; only the P1 site (Leu1) is shown) are contoured at 1σ.	FIG
112	119	P1 site	site	The 2FO–FC electron-density maps (blue mesh) for Ser1 (brown) and the covalently bound ligands (green; only the P1 site (Leu1) is shown) are contoured at 1σ.	FIG
121	125	Leu1	residue_name_number	The 2FO–FC electron-density maps (blue mesh) for Ser1 (brown) and the covalently bound ligands (green; only the P1 site (Leu1) is shown) are contoured at 1σ.	FIG
4	6	WT	protein_state	The WT proteasome:inhibitor complex structures (inhibitor in grey; Thr1 in black) are superimposed and demonstrate that mutation of Thr1 to Ser does not affect the binding mode of bortezomib or carfilzomib.	FIG
7	35	proteasome:inhibitor complex	complex_assembly	The WT proteasome:inhibitor complex structures (inhibitor in grey; Thr1 in black) are superimposed and demonstrate that mutation of Thr1 to Ser does not affect the binding mode of bortezomib or carfilzomib.	FIG
36	46	structures	evidence	The WT proteasome:inhibitor complex structures (inhibitor in grey; Thr1 in black) are superimposed and demonstrate that mutation of Thr1 to Ser does not affect the binding mode of bortezomib or carfilzomib.	FIG
67	71	Thr1	residue_name_number	The WT proteasome:inhibitor complex structures (inhibitor in grey; Thr1 in black) are superimposed and demonstrate that mutation of Thr1 to Ser does not affect the binding mode of bortezomib or carfilzomib.	FIG
86	98	superimposed	experimental_method	The WT proteasome:inhibitor complex structures (inhibitor in grey; Thr1 in black) are superimposed and demonstrate that mutation of Thr1 to Ser does not affect the binding mode of bortezomib or carfilzomib.	FIG
120	128	mutation	experimental_method	The WT proteasome:inhibitor complex structures (inhibitor in grey; Thr1 in black) are superimposed and demonstrate that mutation of Thr1 to Ser does not affect the binding mode of bortezomib or carfilzomib.	FIG
132	136	Thr1	residue_name_number	The WT proteasome:inhibitor complex structures (inhibitor in grey; Thr1 in black) are superimposed and demonstrate that mutation of Thr1 to Ser does not affect the binding mode of bortezomib or carfilzomib.	FIG
140	143	Ser	residue_name	The WT proteasome:inhibitor complex structures (inhibitor in grey; Thr1 in black) are superimposed and demonstrate that mutation of Thr1 to Ser does not affect the binding mode of bortezomib or carfilzomib.	FIG
180	190	bortezomib	chemical	The WT proteasome:inhibitor complex structures (inhibitor in grey; Thr1 in black) are superimposed and demonstrate that mutation of Thr1 to Ser does not affect the binding mode of bortezomib or carfilzomib.	FIG
194	205	carfilzomib	chemical	The WT proteasome:inhibitor complex structures (inhibitor in grey; Thr1 in black) are superimposed and demonstrate that mutation of Thr1 to Ser does not affect the binding mode of bortezomib or carfilzomib.	FIG
